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Abstract 
 
  As new therapeutic targets and drugs are discovered for B-cell lymphoma and other 
cancers, companion diagnostics are also needed to determine target engagement, therapeutic 
efficacy, and patient segmentation for clinical trials. We first employed synthetic chemistry to 
build a platform for modifying small molecule drugs into imaging probes, using the poly(ADP-
ribose) polymerase 1 (PARP1) inhibitor AZD2281 (Olaparib) as a model for technology 
development. Our results show that small-molecule companion imaging drugs can be used for 
fluorescence imaging in cells, as well as for pharmacokinetic studies and positron emission 
tomography (PET) imaging in vivo, without significantly perturbing their target binding 
properties or cellular uptake. To apply this approach to B-cell lymphoma drugs currently in 
clinical trials, we modified an irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK), 
PCI-32765 (Ibrutinib), with the fluorophore Bodipy FL (BFL), and used it for imaging in cells 
and in a mouse window-chamber xenograft model. The excellent co-localization of our probe 
(Ibrutinib-BFL) with BTK demonstrated its utility for studying additional BTK inhibitors and as 
a companion imaging probe. In parallel, we hypothesized that central nervous system (CNS) 
lymphoma diagnosis from paucicellular cerebrospinal fluid (CSF) samples could be improved 
with molecular profiling of putative lymphoma cells trapped in a customized microfluidic chip. 
Following fabrication and characterization of a polydimethylsiloxane (PDMS) diagnostic device 
containing an array of affinity-free single-cell capture sites, we were able to efficiently recover  
                                                                                iii>90% of lymphocytes, perform immunostaining on chip, and apply an image-processing 
algorithm to group cells based on their molecular marker expression, such as kappa/lambda light 
chain restriction. Additionally, in combination with Ibrutinib-BFL or other imaging drugs, we 
demonstrated the potential for on-chip drug imaging for use in conjunction with drug 
development. Finally, we applied bioorthogonal conjugation chemistries on cellulose paper for 
potential applications in lowering the cost of drug screening. We anticipate that these approaches 
will enable direct, molecular information for personalized treatment decisions in B-cell 
lymphomas, as well as provide a roadmap for the development of companion diagnostic probes 
and devices for additional indications. 
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                                                                                  xChapter 1. 
 
Introduction 
 
 
1.1. Using Diagnostics to Inform Drug Development 
  How can drug development be improved to notice failures early or to turn those 
failures into cures? 
  Pharmaceutical drug development in the United States involves the progression of 
pre-clinical drug candidates (which have gone through cell and animal testing) through a 
series of costly human clinical trials: Phase I (safety, dosing, pharmacokinetics), Phase II 
(efficacy, dosing), and Phase III (safety and efficacy in a larger population; comparison to 
previously used treatments). Once past phase III, the Food and Drug Administration 
(FDA) will decide whether to approve a drug to be marketed. For oncology drugs, the 
success rates at each stage are 55%, 28%, and 45%, respectively, meaning that out of all 
the drug candidates that enter clinical development, only about 7% will be approved1.  
  Reasons for the failures vary. Sometimes there are safety issues in Phase I, for 
example unanticipated side effects from the drug or its metabolites interacting with the 
body in a way different from the intended mechanism-of-action. Others fail in Phase II 
due to the inability of the drug to engage with the target of interest (due to poor delivery 
or low potency), too low of a therapeutic index, or resistance mechanisms that can 
quickly reverse the efficacy of a drug. Particularly in Phase III trials, disease 
heterogeneity can greatly influence the statistical efficacy of a drug in a diverse 
population of patients, and conventional cancer diagnostics that rely on changes in cellular morphology (cytopathology, histopathology), tissue density (X-ray, CT, MRI), or 
tumor metabolism (18FDG positron emission tomography (PET)) do not give enough 
molecular information to separate patients into subgroups. 
  Recently, the motivation and ability to differentiate cancers by molecular pathway 
rather than tissue-of-origin has led to the advent of targeted therapeutics, and the search 
for biomarkers and molecular response criteria during drug discovery. This in turn has 
allowed us to improve preclinical studies, diagnostics, and monitoring during clinical 
trials using new technologies for a) directly establishing target engagement and drug 
effects in vivo and in vitro, and b) better diagnostics for each individual patient to predict 
drug efficacy and to monitor disease progression during treatment. Moreover, key 
challenges are to accomplish this in the least invasive manner possible, relatively cheaply, 
and at the point-of-care. Once these approaches are used to identify problems during drug 
development, solutions can be investigated, including screens for more specific drugs, 
nanoparticle-mediated drug delivery, combination drugs to combat resistance, and 
personalized medicine based on molecular-level disease profiling. 
 
1.2. Imaging Drug Pharmacokinetics, Pharmacodynamics, and Target Occupancy 
  To provide insights into both target and off-target engagement by therapeutics, we can 
use reporter ligands that directly bind to the therapeutic target2. These can be small 
molecule or antibody-based drugs, chemically modified into radioactive, fluorescent, or 
affinity probes, that are henceforth used to directly study biodistribution, 
pharmacokinetics, cellular and sub-cellular targeting specificity (i.e. with which other cell 
                                                                                 2types or proteins does the drug interact), cell-to-cell heterogeneity, drug occupancy, and 
pharmacodynamics3. Two approaches to making such probes are direct conjugation to a 
reporter or creating probes with a “clickable” chemical moiety. 
  In our group, bioorthogonal click chemistry using trans-cyclooctene (TCO) and 
tetrazine (Tz) groups was previously explored as a way to label antibodies and 
nanoparticles with fluorophores or 18F for targeted PET4-6. The application of TCO/Tz 
click chemistry had several important advantages: a) two-step delivery of the ligand and 
reporter could improve the kinetics with which the labeled component reaches the target 
(e.g. the reporter small-molecules have shorter circulation half-life than nanoparticles or 
antibodies), b) the very fast click reaction allows for a modular 18F-TCO labeling 
approach, whereas direct synthetic incorporation of radioactive fluorine may be too slow 
when considering 18F radiodecay, and c) the same drug conjugate can be easily adapted 
for either radio or fluorescent labeling. The radiolabeled ligands were used to image drug 
biodistribution and target occupancy by unlabeled drug using PET whole-animal 
imaging, while the fluorescently labeled probes were used in high-resolution intravital 
fluorescence imaging in a mouse tumor window chamber model7. 
  Later, we applied this strategy to turning small-molecules into imaging probes. The 
work in Chapter 2 describes starting with a drug candidate, AZD2281 (Olaparib, a 
PARP1 inhibitor), chemically modifying it for either fluorescence imaging or PET using 
click chemistry, and using in vitro and cell studies to validate the probe’s affinity to the 
drug target. It was then used as an in vivo tool to learn about the original drug, using both 
fluorescence imaging and PET imaging in mice. Interestingly, Olaparib development was 
                                                                                 3stopped after failed Phase II clinical trials in 2011, but was recently resurrected and is 
again in clinical trials for more precise indications – a misstep that perhaps could have 
been avoided by using imaging to properly characterize target protein expression levels 
and drug pharmacodynamics. 
 
1.3. Molecular In Vitro Diagnostics 
  Conventional cancer diagnosis from biopsies, cytopathology or histopathology, is 
based on changes in cellular morphology using non-specific H&E stain to visualize 
nuclei and cellular substructures. More recently, partial or whole cancer genome 
sequencing has been added to look for specific tumor mutations or predispositions. While 
the former approach lacks molecular specificity, the latter only points to an upstream 
identifier of malignancy or cancer target. For accurate, downstream criteria, it would be 
helpful to perform measurements at the biochemical, protein level, allowing for direct 
monitoring of drug binding and efficacy. Although it has been possible to gain some 
information using flow cytometry systems, improved approaches combine the ability to 
simultaneously interrogate at the morphological, protein, and genomic levels. 
  One such integrated method is to use microfluidic chips to capture and profile cancer 
cell populations. A notable innovation was the CTC Chip, used to capture rare (5-1000 
per mL) circulating tumor cells from blood8. In that work, anti-EpCAM antibodies were 
used to capture only those cells expressing that protein on their surface, allowing for the 
counting of EpCAM-positive circulating cells in patients, and their correlation to 
treatment response and course of disease8. To remove capture bias, our group has focused 
                                                                                 4on the design of chips with single-cell passive capture sites, followed by on-chip 
immunostaining and/or removal of the cells for further analysis9-11. 
  An additional benefit of using microfluidic chips is that analysis can be done on 
diverse tissue samples without extensive pre-processing. Searching for tumor cells in 
blood or discarded tissues such as ascites fluid10 add to the potential to monitor cancer 
cells during drug treatments without additional, invasive biopsies. We can then use 
specific, molecular criteria to track the patient subpopulations in whom a particular 
treatment is effective, as well as development of drug resistance to inform treatment 
regime changes. 
 
1.4. B-Cell Lymphoma 
  Lymphoma and leukemia are proliferative diseases of mature and immature 
lymphocytes, respectively, but in reality can be split up into many different entities on the 
cellular and molecular levels. Here, in Chapter 3 and Chapter 4, the work described 
focuses on taking the principles of imaging drugs and in vitro diagnostics and applying 
them broadly to these B-cell malignancies. 
  Within the last 15 years, there has been a revolution in the molecular understanding of 
B-cell cancers at the same time as new drugs – both small molecules and biologics – have 
been introduced to treat them12-14. One surprising finding that led to a paradigm shift was 
the stratification of Diffuse Large B-Cell Lymphoma (DLBCL), the most common type 
of lymphoma, into two subtypes, ABC and GCB, segmented based on the RNA 
expression using microarray data12,15,16. This clear heterogeneity beneath a veil of 
                                                                                 5cytological and morphological similarity revealed the need for approaches based on 
molecular expression markers for personalized characterization and treatment of 
disease13.  
  One particularly promising drug class in development, covalent inhibitors of Bruton’s 
Tyrosine Kinase (BTK), is thought to be more effective in the ABC subtype of 
DLBCL17,18, as well as in chronic lymphocytic leukemia, acute myeloid leukemia, and in 
mantle cell lymphoma19-22. One such drug, the irreversible BTK inhibitor PCI-32765 
(Ibrutinib, now marketed as Imbruvica), was already effectively modified with Bodipy 
FL dye into a drug occupancy assay probe that was used during preclinical and clinical 
development19,23. The method took advantage of the irreversible binding of Ibrutinib to 
visualize it bound to its target on a denaturing polyacrylamide gel using fluorescent gel 
scanning, and they determined that occupancy decreases only about 20% over a 24-hour 
period19. Chapter 3 describes work in which we created a similar probe and tested it for 
utility as an imaging probe, with potential applications in both cancer cell biology and as 
a targeted PET agent for lymphoma. 
  We then thought it would be interesting to focus in on a medical need where diagnosis 
is quite challenging and the disease is aggressive: CNS lymphoma, which can be a 
primary lymphoma tumor site (with increased risk in immunodeficient patients), or can 
occur due to a metastasis across the blood-brain barrier. The success of diagnosis at the 
site of disease – in cerebrospinal fluid (CSF) samples – is limited due to sample 
paucicellularity, as well as the poor specificity/sensitivity of the conventional approach, 
cytopathology; sophisticated imaging modalities such as CT/MRI do not perform any 
                                                                                 6better. For this clinical application, we custom-built a microfluidic chip platform with 
molecular imaging capability, and demonstrated our ability to process and analyze these 
types of samples. This work is described in Chapter 4. 
  
1.5. Lowering the Cost of Diagnostics 
  Many of the tools currently being developed for molecular diagnostics rely on costly 
equipment, for example fluorescence microscopes or sequencing machines, or at the very 
least a trip to the hospital. In order to minimize the costs for patients of monitoring drug 
targets and their occupancy and monitoring disease progression, drastically different 
approaches may be needed, especially for resource-limited settings. 
  To bring diagnostics truly to the “point-of-care” - the home or the field - one 
approach that some researchers and a non-profit (Diagnostics for All) are exploring has 
been coined “paper-based microfluidics”24. For example, a paper-based test was 
developed and field-tested to address the need to monitor occurrences of drug-related 
hepatotoxicty, common when combining drugs for multiple indications, such as HIV and 
tuberculosis25,26. In these tests, small-volume blood samples from finger pricks are 
wicked directly onto a paper device, about the size of a postage stamp, containing various 
detection points for multiplexed readouts. To provide additional functionality to these 
types of devices for their use in drug testing, I sought to combine paper-based detection 
with TCO-Tz click chemistry by synthesizing “clickable” paper. Chapter 5 provides 
further background on paper microfluidics, as well as the results from this work and some 
potential applications. 
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The PARP1 Inhibitor Olaparib as a Model System for Small-Molecule Drugs 
as Imaging Agents 
 
 
This work was previously published as: 
Thomas Reiner, Sarah Earley, Anna Turetsky, and Ralph Weissleder. Bioorthogonal 
Small-Molecule Ligands for PARP1 Imaging in Living Cells. ChemBioChem, 11: 2374–
2377 (2010). doi: 10.1002/cbic.201000477 
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T.R. and R.W. designed the research, and T.R. and A.T. performed experiments. T.R. 
performed chemical synthesis and characterization. S.E. prepared transgenic cell lines 
and provided guidance on immunofluorescence staining. T.R. and A.T. analyzed data and 
prepared figures. T.R. and R.W. wrote the manuscript. All authors reviewed and edited 
the manuscript. 
 
Due to recent successes in designing small molecule PARP1 inhibitors, we have 
synthesized imaging agents for PARP1 based on 1(2H)-phthalazinones. The 
intracellular distribution of AZD2281-TCO, a transcyclooctene-modified derivative, 
was visualized by selective reaction with a reactive fluorescent tetrazine. We show 
that AZD2281-TCO has an IC50 of 11.8 nm, assembles with Tz-fluorophores in the 
nucleus, and colocalizes with PARP1 in live cells. 
 2.1. Introduction 
  Poly(ADP-ribose) polymerase 1 (PARP1) is an important cellular protein that senses        
DNA damage and initiates the base excision repair pathway27. DNA damage (strand 
breaks) occurs during each cell cycle and must be repaired for a cell to survive. In the 
absence of functional BRCA (another class of complementary DNA repair enzymes), 
cells depend primarily on the PARP repair mechanism. Thus, PARP inhibitors (PARPi) 
are emerging as a useful option for cancer therapy, either as single agents or in 
combination with other DNA-damaging molecules28-30. In view of their encouraging 
results in breast cancer trials, there is now considerable interest in expanding PARPi to 
other primary tumors. However, despite the increasing body of literature on PARP, many 
questions remain unanswered, not only regarding its basic biology, regulation, 
heterogeneity, and role in individual tumor types, but also regarding the efficacy of new 
PARPi, optimum dosing, timing and combination of treatment, among other factors28,31. 
For example, PARP1 has a number of additional roles, including the restarting of stalled 
replication forks, the inhibition of nonhomologous end-joining repair, the regulation of 
transcription, the initiation of a unique cell death pathway, and the modulation of cellular 
bioenergetics28. Thus, to gain more insight into these additional roles and to better 
understand PARP1 regulation in vivo, it would be an enormous advantage to be able to 
image PARP1 in live cells and ultimately in whole living organisms. Whilst green 
fluorescent protein (GFP) fusion proteins remain valuable tools for imaging at the cellular 
level, labeled affinity ligands, which are cell permeable, will ultimately be required for 
whole-body preclinical and clinical imaging. 
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lead group 1(2H)-phthalazinones, such as AZD2281 (2.1) and its derivatives28,31,32. It has 
been shown that the 4-NH-piperazine of AZD2281 tolerates a diverse range of capping 
groups without significantly decreasing PARP1 binding affinity32. We therefore used this 
anchor point to attach bioorthogonally reactive groups and/or different fluorophores to 
the phthalazinone. We hypothesized that these modifications would still result in low 
nanomolar affinity ligands and that conjugates would retain their cell permeability, 
particularly with the use of bioorthogonal linkers. 
 
2.2. Results 
  As a precursor for the synthesized AZD2281 inhibitors (Figure 2.1), 4-[[4-Fluoro-3-       
(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (2.2) was obtained 
according to known literature procedures32. For the synthesis of the bioorthogonally 
reactive derivatives AZD2281-NOB (2.6) and AZD2281-TCO (2.7), compound 2.2 was 
first reacted with glutaric acid anhydride to produce the glutaric acid-modified 4-(5-
oxopentanamide)piperazine (2.3) in 72% yield. Subsequently, an ethylene diamine spacer 
was attached to precursor 2.3, yielding the amine-functionalized AZD2281 derivative 2.4. 
Norbornene-functionalized AZD2281-NOB (2.6) was obtained by amide-bond formation 
with 5-norbornene-2-carboxylic acid in the presence of polymer-supported 
dicyclohexylcarbodiimide (DCC) beads. In the case of AZD2281-trans-cyclooctene 
(AZD2281-TCO; 2.7), precursor 2.3 was reacted with (E)-cyclooct-4-enyl 2,5-
dioxopyrrolidin-1-yl carbonate (2.5) in the presence of triethylamine5. The identities of 
                                                                                11all 1(2H)-phthalazinone-based bioorthogonal probes and their precursors were confirmed 
using HPLC-MS, high-resolution MS and NMR spectroscopy. 
  The fast reaction kinetics of trans-cyclooctenes (TCO) and tetrazines (Tz) make        
AZD2281-TCO (2.7) a potential candidate for live-cell imaging using fluorophore-
tetrazine derivatives5,33,34. Cycloaddition of both AZD2281-TCO (2.7) and Texas Red-Tz 
(2.8) was detected by mixing the two compounds (0.3 mM), agitating for several minutes, 
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Figure 2.1. Synthesis of bifunctional 1(2H)-phthalazinone-based targeted probes. 
Reagents and conditions: a) Polystyrene-bound DCC, Et3N, CH2Cl2, RT, overnight; b) 
Et3N, CH2Cl2, RT, overnight; for detailed synthetic descriptions, see section 2.3. 
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[a]
Poly(ADP-ribose) polymerase 1 (PARP1) is an important cellular
protein that senses DNA damage and initiates the base exci-
sion repair pathway.
[1] DNA damage (strand breaks) occurs
during each cell cycle and must be repaired for a cell to sur-
vive. In the absence of functional BRCA (another class of com-
plementary DNA repair enzymes), cells depend primarily on
the PARP repair mechanism. Thus, PARP inhibitors
(PARPi) are emerging as a useful option for cancer
therapy, either as single agents or in combination
with other DNA-damaging molecules.
[2,3,4] In view of
their encouraging results in breast cancer trials, there
is now considerable interest in expanding PARPi to
other primary tumors. However, despite the increas-
ing body of literature on PARP, many questions
remain unanswered, not only regarding its basic biol-
ogy, regulation, heterogeneity, and role in individual
tumor types, but also regarding the efficacy of new
PARPi, optimum dosing, timing and combination of
treatment, among other factors.
[2,5] For example,
PARP1 has a number of additional roles,
[2] including
the restarting of stalled replication forks, the inhibi-
tion of nonhomologous end-joining repair, the regu-
lation of transcription, the initiation of a unique cell-
death pathway, and the modulation of cellular bio-
energetics.
[2] Thus, to gain more insight into these ad-
ditional roles and to better understand PARP1 regula-
tion in vivo, it would be an enormous advantage to
be able to image PARP1 in live cells and ultimately in
whole living organisms. Whilst green fluorescent pro-
tein (GFP) fusion proteins remain valuable tools for
imaging at the cellular level, labeled affinity ligands,
which are cell permeable, will ultimately be required
for whole-body preclinical and clinical imaging.
To date, a variety of small-molecule PARPi have been devel-
oped. These include the lead group 1(2H)-phthalazinones, such
as AZD2281 (1) and its derivatives.
[2,5,6] It has been shown that
the 4-NH-piperazine of AZD2281 tolerates a diverse range of
capping groups without significantly decreasing PARP1 bind-
ing affinity.
[6] We therefore used this anchor point to attach
bioorthogonally reactive groups and/or different fluorophores
to the phthalazinone. We hypothesized that these modifica-
tions would still result in low nanomolar affinity ligands and
that conjugates would retain their cell permeability, particularly
with the use of bioorthogonal linkers.
As a precursor for the synthesized AZD2281 inhibitors
(Scheme 1), 4-[[4-Fluoro-3-(piperazine-1-carbonyl)phenyl]meth-
yl]-2H-phthalazin-1-one (2) was obtained according to known
literature procedures.
[6] For the synthesis of the bioorthogonal-
ly reactive derivatives AZD2281-NOB (6) and AZD2281-TCO (7),
compound 2 was first reacted with glutaric acid anhydride to
produce the glutaric acid-modified 4-(5-oxopentanamide)piper-
azine (3) in 72% yield. Subsequently, an ethylene diamine
spacer was attached to precursor 3, yielding the amine-func-
tionalized AZD2281 derivative 4. Norbornene-functionalized
AZD2281-NOB (6) was obtained by amide-bond formation with
5-norbornene-2-carboxylic acid in the presence of polymer-
supported dicyclohexylcarbodiimide (DCC) beads. In the case
of AZD2281-trans-cyclooctene (AZD2281-TCO; 7), precursor 3
was reacted with (E)-cyclooct-4-enyl 2,5-dioxopyrrolidin-1-yl
carbonate (5) in the presence of triethylamine.
[7] The identities
of all 1(2H)-phthalazinone-based bioorthogonal probes and
their precursors were confirmed using HPLC-MS, high-resolu-
tion MS and NMR spectroscopy.
The fast reaction kinetics of trans-cyclooctenes (TCO) and
tetrazines (Tz)
[7–10] make AZD2281-TCO (7) a potential candi-
date for live-cell imaging using fluorophore-tetrazine deriva-
Scheme 1. Synthesis of bifunctional 1(2H)-phthalazinone-based targeted probes. Re-
agents and conditions: a) Polystyrene-bound DCC, Et3N, CH2Cl2, RT, overnight; b) Et3N,
CH2Cl2, RT, overnight; For detailed synthetic descriptions, see the Supporting Informa-
tion.
[a] Dr. T. Reiner, Dr. S. Earley, A. Turetsky, Prof. R. Weissleder
Center for Systems Biology, Massachusetts General Hospital, Richard B.
Simches Research Center
185 Cambridge Street, Suite 5.210, Boston, MA 02114 (USA)
Fax: (+1)617-643-6133
E-mail: rweissleder@mgh.harvard.edu
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/cbic.201000477.
2374   2010 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2010, 11, 2374–2377
2.1; AZD2281 2.4
2.4
2.4
2.6
2.7                                                                                13
tives. Cycloaddition of both AZD2281-TCO (7) and Texas Red-
Tz (8) was detected by mixing the two compounds (0.3 mm),
agitating for several minutes, and analyzing the products by
HPLC-MS (Figure 1A shows the HPLC trace for the AZD2281-
Texas Red (9) crude reaction mixture). LC-MS spectra confirmed
the quantitative conversion of Texas Red-Tz (8). Multiple peaks
were identified with a molecular mass corresponding to
AZD2281-Texas Red (9; Figure 1B, m/z 1536.0 [M+H]
+). These
were the result of different isomers formed in the tetrazine
trans-cyclooctene cycloaddition.
[7,9,10] The fast and selective
conversion of AZD2281-TCO (7) to AZD2281-Texas Red (9) in
the presence of Texas Red-Tz (8) indicates that these small
molecules also have potential applicability to in vivo experi-
ments. The inhibitory potentials of AZD2281 derivatives 6 and
7, and of pre-reacted AZD2281-Texas Red (9), were tested
using a PARP1 activity assay (see the Supporting Information
for details). Analysis of the AZD2281 derivatives 6 and 7 result-
ed in IC50 values of 10.1 1.3 nm and 11.8 1.4 nm, respective-
ly. Thus, modification and conjugation of linkers and fluoro-
phores to the 4-NH-piperazine group of AZD2281 precursor 2
appear to be tolerated by the enzyme, and allow the design of
bifunctional derivatives. The IC50 value of pre-reacted
AZD2281-Texas Red (9; 15.4 1.2 nm) demonstrates that the
trans-cyclooctene/tetrazine cycloaddition only minimally re-
duces binding of the 1(2H)-phthalazinone to PARP1, which
confirms its possible application as an imaging probe.
Due to their fast reaction kinetics compared to AZD2281-
NOB (6),
[7] the trans-cyclooctene conjugated AZD2281
(AZD2281-TCO; 7) and Texas Red-Tz (8) were tested under in
vivo conditions in live cells. MDA-MB436 cells, a well character-
ized BRCA1-mutant breast cancer cell line, were incubated
with Texas Red-Tz (8;1 mm in growth medium, 0.1% DMSO)
for 20 min, before the compound-containing medium was re-
moved. AZD2281-TCO (7) was then added (3 mm in growth
medium, 0.1% DMSO) and the mixture was incubated for
another 20 min. Texas Red-Tz (8) cleared out of the cells very
quickly, allowing the identification of AZD2281-Texas Red (9),
which stayed with its target for long periods of time. After
washing, fixing and permeabiliz-
ing the MDA-MB436 cells, PARP1
was visualized using monoclonal
antibodies (Mabs; Figure 2B).
Staining patterns for the Texas
Red dye (Figure 2A) showed that
it not only localized in the nu-
cleus, but also accumulated in
the nucleolus. Whilst anti-PARP1
Mabs showed similar nuclear lo-
calization (Figure 2B), there was
an absence of Mab signal in the
nucleoli. This was presumably
due to steric hindrance and not
to the absence of PARP in the
nucleolus, as earlier reports have
indicated.
[11,12] The results in Fig-
ure 2C confirm that there was
excellent spatial correlation be-
tween the small molecules
(AZD2281-TCO (7)/Texas Red-Tz
(8)). We also constructed a
PARP1-GFP fusion protein and
expressed it in MDA-MB436 cells
as an independent confirmation
of probe localization. In the
PARP1-GFP expressing cells, GFP
expression was clearly observed,
primarily in the nucleoli but also
in the nucleus. This pattern was
identical to that seen with the
AZD2281-TCO/Texas Red-Tz pair.
(Table 1, Figure 3)
Interestingly, incubation of live
cells with Texas Red-Tz (8) with-
out AZD2281-TCO (7) did not
lead to nuclear localization of
the dye. Instead, there was non-
Figure 1. A) An HPLC trace of AZD2281-TCO (7); Texas Red-tetrazine (8; one isolated stereoisomer shown); and
AZD2281-Texas Red (9; crude reaction mixture); B) LC-MS spectrum of AD2281-Texas Red (9; LC-MS of major prod-
uct peak shown).
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reaction mixture was filtered and volatiles removed in vacuo. The crude material was 
purified via HPLC, yielding the title compound as a clear solid (11.3 mg, 17 µmol, 44%). 
1H NMR (400 MHz,  CD3OD, * indicates rotamer peak) δ = 8.39-8.36 (m, 2H, CaromH, 
NH), 8.02-8.00 (m, 1H, NH), 7.98-7.94 (m, 1H, CaromH), 7.91-7.82 (m, 2H, CaromH), 
7.51-7.48 (m, 1H, CaromH), 7.40-7.37 (m, 1H, CaromH), 7.17 (t, 1H, 3JHH = 9.0, CaromH), 
6.77-6.76 (m, 1H, NH), 5.65-5.55 (m, 1H, CH), 5.50-5.40 (m, 1H, CH), 4.39 (s, 2H, 
CH2), 4.31-4.27 (m, 1H, CH), 3.82-3.13 (m, 8H, CH2), 2.46 (t, 2H, 3JHH = 7.4, CH2), 2.39 
(t, 2H, 3JHH = 7.4, *CH2), 2.33-1.53 (m, 14H, CH2, *CH2); 19F NMR (376 MHz, CD3OD) δ 
= -121.20; LC-ESI-MS(-) m/z = 673.3 [M-H+]-; LC-ESI-MS(+) m/z = 675.4 [M+H+]+; 
HRMS-ESI [M+H]+ m/z calcd. for [C36H43FN6O6]+ 675.3301, found 675.3301.  
HPLC Characterization of reaction between TexasRed-tetrazine (8) and AZD2281-
TCO (7)
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Figure S1: Synthesis of AZD2281-Texas Red (9) from AZD2281-TCO (7) and Texas Red-tetrazine (8) 
using tetrazine/trans-cyclooctene cycloadditions. 
AZD2281-TCO (7) and Texas Red-tetrazine (8) were combined in 40 µL of DMSO/PBS 
at a final concentration of 0.3 mM for each reagent.  The solution was stirred for several 
minutes at room temperature, yielding AZD2281-Texas Red (9). 
PARP-1 IC50 determination
A commercially available colorimetric assay (Trevigen, Gaithersburg, MD) was used to 
measure PARP activity in vitro in the presence of inhibitors. Ten-fold dilutions of 
AZD2281-derivatives (6) (final concentration 400 nM to 0.04 nM); and (7), (9) (4 µM to 
0.04 nM) were incubated with 0.5 units PARP HSA for 10 minutes in histone-coated 96-
well plates. All experiments were carried out in triplicate. Control samples did not 
contain inhibitor and background measurement samples did not contain PARP-1. All 
b) 
c) 
a) 
Figure 2.2. Synthesis and characterization of AZD2281-Texas Red. a) Synthesis of 
AZD2281-Texas Red (2.9) from AZD2281-TCO (2.7) and Texas Red-tetrazine (2.8) 
using tetrazine/trans-cyclooctene cycloadditions. b) An HPLC trace of AZD2281-TCO 
(2.7); Texas Red-tetrazine (2.8; one isolated stereoisomer shown); and AZD2281-Texas 
Red (2.9; crude reaction mixture). c) LC-MS spectrum of AZD2281-Texas Red (2.9; 
LC-MS of major product peak shown). 
2.7 2.9
2.8
AZD2281-Texas Red (2.9)
AZD2281-TCO (2.7)
Texas Red-Tz (2.8)and analyzing the products by HPLC-MS (Figure 2.2a; Figure 2.2b shows the HPLC 
trace for the AZD2281-Texas Red (2.9) crude reaction mixture). LC-MS spectra 
confirmed the quantitative conversion of Texas Red-Tz (2.8). Multiple peaks were 
identified with a molecular mass corresponding to AZD2281-Texas Red (2.9; Figure 2.2c, 
m/z 1536.0 [M+H]+). These were the result of different isomers formed in the tetrazine 
trans-cyclooctene cycloaddition5,34,35. The fast and selective conversion of AZD2281-
TCO (2.7) to AZD2281-Texas Red (2.9) in the presence of Texas Red-Tz (2.8) indicates 
that these small molecules also have potential applicability to in vivo experiments. The 
inhibitory potentials of AZD2281 derivatives 2.6 and 2.7, and of pre-reacted AZD2281-
Texas Red (2.9), were tested using a PARP1 activity assay (see section 2.3 for details). 
Analysis of the AZD2281 derivatives 2.6 and 2.7 resulted in IC50 values of 10.1 ± 1.3 nM 
and 11.8 ± 1.4 nM, respectively (Figure 2.3). Thus, modification and conjugation of 
linkers and fluorophores to the 4-NH-piperazine group of AZD2281 precursor 2.2 appear 
to be tolerated by the enzyme, and allow the design of bifunctional derivatives. The IC50 
value of pre-reacted AZD2281-Texas Red (2.9; 15.4 ± 1.2 nM) demonstrates that the 
trans-cyclooctene/tetrazine cycloaddition only minimally reduces binding of the 1(2H)-
phthalazinone to PARP1, which confirms its possible application as an imaging probe 
(Figure 2.3). 
  Due to their fast reaction kinetics compared to AZD2281-NOB (2.6), the trans-       
cyclooctene conjugated AZD2281 (AZD2281-TCO; 2.7) and Texas Red-Tz (2.8) were 
tested under in vivo conditions in live cells5. MDA-MB-436 cells, a well characterized 
BRCA1-mutant breast cancer cell line, were incubated with Texas Red-Tz (2.8; 1 µM in 
                                                                                14growth medium, 0.1% DMSO) for 20 minutes, before the compound-containing medium 
was removed. AZD2281-TCO (2.7) was then added (3 µM in growth medium, 0.1% 
DMSO) and the mixture was incubated for another 20 minutes. Texas Red-Tz (2.8) 
cleared out of the cells very quickly, allowing the identification of AZD2281-Texas Red 
(2.9), which stayed with its target for long periods of time. After washing, fixing and 
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Figure 2.3. Inhibition of PARP1 by AZD2281 derivatives. Top, table of IC50 values of 
PARP1 inhibition; Bottom, IC50 curves for the bifunctional 1(2H)-phthalazinone-based 
targeted probes. 
preferential distribution of fluorescence in the perinuclear cyto-
plasmic region, as well as in the nucleus (ratio=0.95:1). When
incubated with different concentrations of the trans-cyclooc-
tene probe (7; 3–10 nm), the nuclear/cytoplasmic signal ratios
gradually increased (Figure 2D, not blocked). This concentra-
tion-dependent binding of AZD2281-TCO (7) to PARP1 can be
inhibited with 30-fold excess of AZD2281 (1). This prevents nu-
clear localization and therefore binding of probe 7 to PARP1.
With different concentrations of 7, the nuclear/cytoplasmic
signal ratio remains unchanged (Figure 2D, blocked).
Like its two building blocks 7 and 8, pre-reacted AZD2281-
Texas Red (9) is able to penetrate the nuclear membranes in
live cells, although incubation of MDA-MB436 with 9 leads to
lower nuclear/cytoplasmic locali-
zation ratios (modest increase of
38 2%). The superior results of
sequential treatment of MDA-
MB436 cells with AZD2281-TCO
(7) and Texas Red-Tz (8) demon-
strates the advantages of a bio-
orthogonal in vivo reaction,
since both partners (the target-
ing molecule 7 as well as the
fluorophore 8) are small in size
(7: 674.76 gmol
 1; 8:
889.05 gmol
 1), and this contrib-
utes to easier permeation. Once
assembled, however, penetration
is less efficient leading to trap-
ping of the conjugate and high
target-to-background ratios.
In this report, we present
potential small-molecule-based
PARP1 imaging agents and con-
firm their utility for cell imaging.
We found that AZD2281-based
bifunctional small molecules
were most suited to bioorthogo-
nal in vivo target assembly. All
bioorthogonal and imaging
probes had IC50 values ranging
between 10.1 nm and 15.4 nm.
In particular, the TCO-modified
derivative was not only success-
fully reacted using a bioorthogo-
nal cycloaddition in cells, but
was found to colocalize with
anti-PARP1 Mabs. In turn, this co-
localization could be prevented
by blocking the targeted fluores-
cent probe with AZD2281. The
design strategy employed here,
as well as the specific com-
pounds investigated, should
prove useful for the future study
of PARP1 biology in live cells. It
is also highly likely that similar
strategies could be used for the design of positron emission
tomography (PET) imaging agents for whole-body imaging of
PARP1 and its inhibition by PARPi. Such agents would be par-
ticularly useful in drug development and clinical trials.
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2.9
AZD-NOB (2.6) 
AZD-TCO (2.7) 
AZD-Texas Red (2.9) permeabilizing the MDA-MB-436 cells, PARP1 was visualized using monoclonal 
antibodies (Mabs; Figure 2.4b). Staining patterns for the Texas Red dye (Figure 2.4a) 
showed that it not only localized in the nucleus, but also accumulated in the nucleolus. 
Whilst anti-PARP1 Mabs showed similar nuclear localization (Figure 2.4b), there was an 
absence of Mab signal in the nucleoli. This was presumably due to steric hindrance and 
not to the absence of PARP in the nucleolus, as earlier reports have indicated36,37. The 
results in Figure 2.4c confirm that there was excellent spatial correlation between the 
small molecules (AZD2281-TCO (2.7)/Texas Red-Tz (2.8)). We also constructed a 
PARP1-GFP fusion protein and expressed it in MDA-MB-436 cells as an independent 
confirmation of probe localization. In the PARP1-GFP expressing cells, GFP expression 
was clearly observed, primarily in the nucleoli but also in the nucleus (Figure 2.5). This 
pattern was identical to that seen with the AZD2281-TCO/Texas Red-Tz pair. 
  Interestingly, incubation of live cells with Texas Red-Tz (2.8) without AZD2281-       
TCO (2.7) did not lead to nuclear localization of the dye. Instead, there was non-
preferential distribution of fluorescence in the perinuclear cytoplasmic region, as well as 
in the nucleus (ratio = 0.95:1). When incubated with different concentrations of the trans-
cyclooctene probe (2.7; 3–10 nM), the nuclear/cytoplasmic signal ratios gradually 
increased (Figure 2.4d, not blocked). This concentration-dependent binding of AZD2281-
TCO (2.7) to PARP1 can be inhibited with 30-fold excess of AZD2281 (2.1). This 
prevents nuclear localization and therefore binding of probe 2.7 to PARP1. With different 
concentrations of 2.7, the nuclear/cytoplasmic signal ratio remains unchanged (Figure 
2.4d, blocked). 
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preferential distribution of fluorescence in the perinuclear cyto-
plasmic region, as well as in the nucleus (ratio=0.95:1). When
incubated with different concentrations of the trans-cyclooc-
tene probe (7; 3–10 nm), the nuclear/cytoplasmic signal ratios
gradually increased (Figure 2D, not blocked). This concentra-
tion-dependent binding of AZD2281-TCO (7) to PARP1 can be
inhibited with 30-fold excess of AZD2281 (1). This prevents nu-
clear localization and therefore binding of probe 7 to PARP1.
With different concentrations of 7, the nuclear/cytoplasmic
signal ratio remains unchanged (Figure 2D, blocked).
Like its two building blocks 7 and 8, pre-reacted AZD2281-
Texas Red (9) is able to penetrate the nuclear membranes in
live cells, although incubation of MDA-MB436 with 9 leads to
lower nuclear/cytoplasmic locali-
zation ratios (modest increase of
38 2%). The superior results of
sequential treatment of MDA-
MB436 cells with AZD2281-TCO
(7) and Texas Red-Tz (8) demon-
strates the advantages of a bio-
orthogonal in vivo reaction,
since both partners (the target-
ing molecule 7 as well as the
fluorophore 8) are small in size
(7: 674.76 gmol
 1; 8:
889.05 gmol
 1), and this contrib-
utes to easier permeation. Once
assembled, however, penetration
is less efficient leading to trap-
ping of the conjugate and high
target-to-background ratios.
In this report, we present
potential small-molecule-based
PARP1 imaging agents and con-
firm their utility for cell imaging.
We found that AZD2281-based
bifunctional small molecules
were most suited to bioorthogo-
nal in vivo target assembly. All
bioorthogonal and imaging
probes had IC50 values ranging
between 10.1 nm and 15.4 nm.
In particular, the TCO-modified
derivative was not only success-
fully reacted using a bioorthogo-
nal cycloaddition in cells, but
was found to colocalize with
anti-PARP1 Mabs. In turn, this co-
localization could be prevented
by blocking the targeted fluores-
cent probe with AZD2281. The
design strategy employed here,
as well as the specific com-
pounds investigated, should
prove useful for the future study
of PARP1 biology in live cells. It
is also highly likely that similar
strategies could be used for the design of positron emission
tomography (PET) imaging agents for whole-body imaging of
PARP1 and its inhibition by PARPi. Such agents would be par-
ticularly useful in drug development and clinical trials.
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Figure 2. The reaction of AZD2281-TCO (7) and Texas Red-Tz (8) in MDA-MB436 cells. A) AZD2281-TCO reacted
with Texas Red-Tz; speckles outside the cells, presumably resulting from precipitated Texas Red-Tz (8), were re-
moved; B) anti-PARP1 monoclonal antibody staining; C) a composite overlay on phase contrast D) the ratio of nu-
clear/cytoplasmic signal for AZD2281-TCO/Texas Red-Tz in the absence (not blocked: *) and presence (blocked:
&) of blocking reagent AZD2281. Scale Bar: 20 mm.
Table 1. IC50 values for the bifunctional 1(2H)-phthalazinone-based targeted probes and for AZD2281-Texas
Red.
Compound Name # MW [gmol
 1] IC50
[nm]
Reactive with
Reactive
AZD2281-NOB 6 642.7 10.1 1.3 Tz-fluorochromes
inhibitorAZD2281-TCO 7 674.8 11.8 1.4 Tz-fluorochromes
Fluorescent AZD2281-Texas Red 9 1535.6 15.4 1.2 NA
inhibitor
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Figure 2.4. Two-step imaging with AZD2281-TCO/TR-Tz in cells. The reaction of 
AZD2281-TCO (2.7) and Texas Red-Tz (2.8) in MDA-MB436 cells. a) AZD2281-TCO 
reacted with Texas Red-Tz; speckles outside the cells, presumably resulting from 
precipitated Texas Red-Tz (2.8), were removed. b) anti-PARP1 monoclonal antibody 
staining. c) a composite overlay on phase contrast. d) the ratio of nuclear/cytoplasmic 
signal for AZD2281-TCO/Texas Red-Tz in the absence (not blocked: blue squares) and 
presence (blocked: green circles) of blocking reagent AZD2281. Scale bar: 20 µm. 
a) b)
c) d)  Like its two building blocks 2.7 and 2.8, pre-reacted AZD2281-Texas Red (2.9) is        
able to penetrate the nuclear membranes in live cells, although incubation of MDA-
MB-436 with 2.9 leads to lower nuclear/cytoplasmic localization ratios (modest increase 
of 38 ± 2%). The superior results of sequential treatment of MDA-MB-436 cells with 
AZD2281-TCO (2.7) and Texas Red-Tz (2.8) demonstrates the advantages of a bio-
orthogonal in vivo reaction, since both partners (the targeting molecule 2.7 as well as the 
fluorophore 2.8) are small in size (2.7: 674.76 g mol-1; 2.8: 889.05 g mol-1), and this 
contributes to easier permeation. Once assembled, however, penetration is less efficient 
leading to trapping of the conjugate and high target-to-background ratios. 
 
2.3. Materials and Methods 
  Unless otherwise noted, all reagents were purchased from Sigma-Aldrich (St. Louis,        
MO, USA) and used without further purification. Texas Red-X, succinimidyl ester was 
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diminished and energetic processes do not function 
perfectly. Second, the poly(ADP-ribosyl)ation of vari-
ous proteins by over-activated PARP can also set the 
stage for unexpected biochemical processes (for exam-
ple, the inhibition of GAPDH)38. Third, mitochondrial 
injury promotes the release of mitochondrial cell-death 
factors (such as the release of apoptosis-inducing factor 
(AIF))72–74. The AIF-related mechanisms have received 
much attention recently. AIF released from a mitochon-
drion shuttles to the nucleus and induces peripheral 
chromatin condensation, large-scale fragmentation of 
DNA and, ultimately, cytotoxicity. Neutralization of 
AIF has been shown to exert neuroprotective effects 
in neuro-injury models in vitro72–74. The exact mecha-
nisms by which PARP activation triggers AIF release 
have not yet been delineated.
Both the release of AIF and the poly(ADP-ribo-
syl)ation of GAPDH might be triggered by free PAR 
oligomers that have been split off from poly(ADP-
ribosyl)ated proteins through the action of PARG38,74. 
Some of the above processes must also be re-evaluated 
in the context of recent observations concerning the 
functional role of an intramitochondrial version of 
PARP75–77.
TABLE 1 summarizes some of the diseases in which 
PARP inhibition or deficiency provides therapeutic 
benefit in vivo. Comprehensive reviews of previous 
pharmacological studies showing the cytoprotective 
effects of PARP inhibitors of various structural classes 
in vitro and the therapeutic effects of PARP inhibitors 
in vivo are presented in REFS 4,78 and the tables therein. 
In addition to various reperfusion diseases of isolated 
organs, recent preclinical data point to a role of PARP 
in systemic ischaemia–reperfusion (haemorrhagic 
shock)79 in reperfusion injury and systemic inflam-
mation that is induced by thoraco-abdominal aor-
tic aneurysm repair80, as well as in an experimental 
model of cavernous nerve injury which models the 
consequences of radical prostate surgery81.
Moderate PARP activation decreases the cellular 
NAD+ content and impairs cellular functions with-
out killing the cells. At this stage (which, in conjunc-
tion with septic shock and systemic inflammatory 
responses, is referred to as ‘pre-necrosis’ or ‘cytopathic 
hypoxia’), reversible suppression of cellular oxygen use 
and reversible cellular dysfunction is observed82. By 
restoring cellular energetics the pharmacological inhi-
bition of PARP facilitates the recovery of cells from 
this dysfunctional state. Examples of such restorative 
responses were found in endothelial cells that pro-
duced high levels of endogenous oxidants83 and in 
intestinal epithelial cells from colitic guts84.
In vivo, the role of PARP in regulating apoptosis 
and necrosis in disease is more complex, because 
certain cell types undergo apoptosis whereas others 
undergo necrosis. PARP inhibition can differentially 
affect these processes; for example, in autoimmune 
diabetes, PARP inhibition prevents oxidant-mediated 
β-cell necrosis, but promotes the apoptosis of islet-
infiltrating lymphocytes85.
Regulation of cell survival and death by PARP 
For a long time, there was controversy over the role 
of PARP in DNA-damage signalling and, especially, in 
DNA-damage-induced cell death. The two sides of the 
argument viewed PARP1 either as an indispensable 
cellular survival factor or as an active mediator of cell 
Figure 3 | Pathways involved in promoting cellular necrosis in response to massive 
poly(ADP-ribose) polymerase (PARP) activation in oxidatively/nitrosatively injured 
cells. a | The metabolic transformation of glyceraldehyde-3-phosphate (GAP) into 1,3-
diphosphoglycerate (1,3-DPG) requires NAD+ and fuels the ATP-producing part of anaerobic 
glycolysis, which leads to the synthesis of pyruvate. In the presence of NAD+ and pyruvate, 
the Krebs cycle supplies NADH to the respiratory chain, which triggers electron flux among 
respiratory complexes. Mitochondrial respiration generates a proton gradient across the inner 
membrane that is used by ATP synthase. b | When PARP1 is activated on a large scale, it 
metabolizes NAD+ into polymers of ADP-ribose and nicotinamide, with the consequent depletion 
of the pyridine nucleotide pool. Therefore, NAD+-dependent cellular metabolic pathways, such 
as anaerobic glycolysis and mitochondrial respiration, are impaired. NAD+ resynthesis uses 
additional cellular energy: nicotinamide is converted to nicotinamide mononucleotide (NMN) 
by phosphoribosyl transferase (PRT), which uses phosphoribosyl pyrophosphate (PRPP) that 
is obtained from ATP. ATP is also necessary to convert NMN into NAD+ by mononucleotide 
adenylyl transferase (NMNAT). Overall, the cellular energetic depletion leads to a loss of cellular 
functions, dissipation of membrane potential (∆ψ) and cell death through the necrotic route. 
Adapted, with permission, from REF. 69 © (2002) Elsevier Science.
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preferential distribution of fluorescence in the perinuclear cyto-
plasmic region, as well as in the nucleus (ratio=0.95:1). When
incubated with different concentrations of the trans-cyclooc-
tene probe (7; 3–10 nm), the nuclear/cytoplasmic signal ratios
gradually increased (Figure 2D, not blocked). This concentra-
tion-dependent binding of AZD2281-TCO (7) to PARP1 can be
inhibited with 30-fold excess of AZD2281 (1). This prevents nu-
clear localization and therefore binding of probe 7 to PARP1.
With different concentrations of 7, the nuclear/cytoplasmic
signal ratio remains unchanged (Figure 2D, blocked).
Like its two building blocks 7 and 8, pre-reacted AZD2281-
Texas Red (9) is able to penetrate the nuclear membranes in
live cells, although incubation of MDA-MB436 with 9 leads to
lower nuclear/cytoplasmic locali-
zation ratios (modest increase of
38 2%). The superior results of
sequential treatment of MDA-
MB436 cells with AZD2281-TCO
(7) and Texas Red-Tz (8) demon-
strates the advantages of a bio-
orthogonal in vivo reaction,
since both partners (the target-
ing molecule 7 as well as the
fluorophore 8) are small in size
(7: 674.76 gmol
 1; 8:
889.05 gmol
 1), and this contrib-
utes to easier permeation. Once
assembled, however, penetration
is less efficient leading to trap-
ping of the conjugate and high
target-to-background ratios.
In this report, we present
potential small-molecule-based
PARP1 imaging agents and con-
firm their utility for cell imaging.
We found that AZD2281-based
bifunctional small molecules
were most suited to bioorthogo-
nal in vivo target assembly. All
bioorthogonal and imaging
probes had IC50 values ranging
between 10.1 nm and 15.4 nm.
In particular, the TCO-modified
derivative was not only success-
fully reacted using a bioorthogo-
nal cycloaddition in cells, but
was found to colocalize with
anti-PARP1 Mabs. In turn, this co-
localization could be prevented
by blocking the targeted fluores-
cent probe with AZD2281. The
design strategy employed here,
as well as the specific com-
pounds investigated, should
prove useful for the future study
of PARP1 biology in live cells. It
is also highly likely that similar
strategies could be used for the design of positron emission
tomography (PET) imaging agents for whole-body imaging of
PARP1 and its inhibition by PARPi. Such agents would be par-
ticularly useful in drug development and clinical trials.
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Figure 2. The reaction of AZD2281-TCO (7) and Texas Red-Tz (8) in MDA-MB436 cells. A) AZD2281-TCO reacted
with Texas Red-Tz; speckles outside the cells, presumably resulting from precipitated Texas Red-Tz (8), were re-
moved; B) anti-PARP1 monoclonal antibody staining; C) a composite overlay on phase contrast D) the ratio of nu-
clear/cytoplasmic signal for AZD2281-TCO/Texas Red-Tz in the absence (not blocked: *) and presence (blocked:
&) of blocking reagent AZD2281. Scale Bar: 20 mm.
Table 1. IC50 values for the bifunctional 1(2H)-phthalazinone-based targeted probes and for AZD2281-Texas
Red.
Compound Name # MW [gmol
 1] IC50
[nm]
Reactive with
Reactive
AZD2281-NOB 6 642.7 10.1 1.3 Tz-fluorochromes
inhibitorAZD2281-TCO 7 674.8 11.8 1.4 Tz-fluorochromes
Fluorescent AZD2281-Texas Red 9 1535.6 15.4 1.2 NA
inhibitor
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PARP1-MAB
PARP1-GFP
A) Cells incubated with AZD2281-TCO, 
washed, and then incubated with TexasRed-
Tz. Then ﬁxed for imaging.
B) Cell were ﬁxed and permeablized, stained 
with anti-PARP monoclonal antibody, and 
imaged.
C) Overlay shows that AZD2281 can stain 
nucleoli, while the antibody is too large.
D) Dose-response curve of increase in 
nuclear staining with increasing 
concentrations of AZD2281-TCO and 
TexasRed-Tz
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cells, which correlates with protein expression of PARP1 in
the respective cell lines (see the Supporting Information for
details).
In subsequent in vivo experiments, 30 mCi of
18F-
AZD2281 were injected into Nu/Nu mice and imaged by
PET/CT over a period of 2 h. Figure 3A displays the
distribution of the PET probe at 10, 30, and 50 min. The
images clearly show initial localization of the probe to be
mainly in liver, gall bladder, and intestines, consistent with
hepatobiliary excretion. After 50 min (Figure 3A), the major-
ity of the probe had left the bloodstream (t1/2=6 min) and was
excreted through the large intestines.
Tumor-bearing mice were obtained by injection of MDA-
MB-436 cells (5 10
6 cells in matrigel) into the flanks of Nu/
Nu mice, and the tumors were allowed to grow and
vascularize for 7 days. Figure 3B shows a three-dimensional
reconstruction of a tumor-bearing mouse injected with 30 mCi
of
18F-AZD2281. Uptake in the tumors is clearly visible.
Immediately after imaging, the mice were injected with 1 mg
AZD2281 BID. Re-injection of 30 mCi of
18F-AZD2281
confirmed inhibition of the probe s uptake into the tumors
(Figure 3B and C). Therefore, owing to the rapid decay rate
of
18F, each mouse serves as its own control on subsequent
days of imaging, facilitating direct comparisons of SUVs.
In summary, we have showed a) that
18F-AZD2281
accumulates in PARP1-overexpressing cancer cells (e.g.
MDA-MB-436), b) the cellular accumulation can be inhibited
by nonlabeled AZD2281, c)
18F-AZD2281 accumulates in
PARP1 mouse models of cancer in vivo, and d) PARP1
inhibition can be quantitated by PET imaging in vivo. The
imaging agent was developed in relatively short time usingthe
above described chemically orthogonal scavenger-assisted
high-performance method. Scavenger beads for alternative
conjugation methods could also be developed and applied in
similar ways. However, we believe that the described method
is particularly appealing for development of PET imaging
agents because of the extremely fast kinetics of the tetrazine/
trans-cyclooctene inverse-electron-demand Diels–Alder reac-
tion at room temperature, its independence of catalysts, and
high selectivity. The technology described can be readily
expanded to other drugs, biomolecules, and molecular targets
and should facilitate the development of PET imaging agents
for drug testing.
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Figure 2. Competitive in vitro inhibition assays with
18F-AZD2281. Cells
containing either a high (MDA-MB-436) or a low amount of PARP1
(MDA-MB-231) were treated with 5 mCi of
18F-AZD2281 in the presence
of different concentrations of AZD2281 (10 mm–0.01 nm). After the
cells were washed, cell-associated activity was determined by measure-
ment of the g-radiation. For the control measurement, no unlabeled
AZD2281 was added.
Figure 3. In vivo evaluation of
18F-AZD2281. A) Combined PET/CT
scans of a nontumor-bearing mouse injected with
18F-AZD2281
recorded 10, 30, and 50 min after injection. B) Three-dimensional
reconstruction of a tumor-bearing animal injected with
18F-AZD2281
with and without pre-injection of AZD2281 (bladder segmented out for
clarity). C) Quantification of uptake through the tumor in hind legs
with and without intraperitoneal pre-injection of unlabeled AZD2281
SUV: standardized uptake value
3 Angew. Chem. Int. Ed. 2011, 50,1–5   2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
These are not the final page numbers!  
 
cells, which correlates with protein expression of PARP1 in
the respective cell lines (see the Supporting Information for
details).
In subsequent in vivo experiments, 30 mCi of
18F-
AZD2281 were injected into Nu/Nu mice and imaged by
PET/CT over a period of 2 h. Figure 3A displays the
distribution of the PET probe at 10, 30, and 50 min. The
images clearly show initial localization of the probe to be
mainly in liver, gall bladder, and intestines, consistent with
hepatobiliary excretion. After 50 min (Figure 3A), the major-
ity of the probe had left the bloodstream (t1/2=6 min) and was
excreted through the large intestines.
Tumor-bearing mice were obtained by injection of MDA-
MB-436 cells (5 10
6 cells in matrigel) into the flanks of Nu/
Nu mice, and the tumors were allowed to grow and
vascularize for 7 days. Figure 3B shows a three-dimensional
reconstruction of a tumor-bearing mouse injected with 30 mCi
of
18F-AZD2281. Uptake in the tumors is clearly visible.
Immediately after imaging, the mice were injected with 1 mg
AZD2281 BID. Re-injection of 30 mCi of
18F-AZD2281
confirmed inhibition of the probe s uptake into the tumors
(Figure 3B and C). Therefore, owing to the rapid decay rate
of
18F, each mouse serves as its own control on subsequent
days of imaging, facilitating direct comparisons of SUVs.
In summary, we have showed a) that
18F-AZD2281
accumulates in PARP1-overexpressing cancer cells (e.g.
MDA-MB-436), b) the cellular accumulation can be inhibited
by nonlabeled AZD2281, c)
18F-AZD2281 accumulates in
PARP1 mouse models of cancer in vivo, and d) PARP1
inhibition can be quantitated by PET imaging in vivo. The
imaging agent was developed in relatively short time usingthe
above described chemically orthogonal scavenger-assisted
high-performance method. Scavenger beads for alternative
conjugation methods could also be developed and applied in
similar ways. However, we believe that the described method
is particularly appealing for development of PET imaging
agents because of the extremely fast kinetics of the tetrazine/
trans-cyclooctene inverse-electron-demand Diels–Alder reac-
tion at room temperature, its independence of catalysts, and
high selectivity. The technology described can be readily
expanded to other drugs, biomolecules, and molecular targets
and should facilitate the development of PET imaging agents
for drug testing.
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AZD2281 was added.
Figure 3. In vivo evaluation of
18F-AZD2281. A) Combined PET/CT
scans of a nontumor-bearing mouse injected with
18F-AZD2281
recorded 10, 30, and 50 min after injection. B) Three-dimensional
reconstruction of a tumor-bearing animal injected with
18F-AZD2281
with and without pre-injection of AZD2281 (bladder segmented out for
clarity). C) Quantification of uptake through the tumor in hind legs
with and without intraperitoneal pre-injection of unlabeled AZD2281
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Poly(ADP-ribose) polymerase 1 (PARP1) has gained interest in recent 
years as the primary DNA-damage response enzyme in the absence of 
functional BRCA. Since this nuclear protein is overexpressed in BRCA -/- 
breast cancers, helping the cells to survive conventional cisplatin 
treatment, it has become an important complementary drug target for 
these tumors. 
We hypothesized that the most potent of these small molecule drugs, 
AZD2281, a nanomolar afﬁnity binder currently in clinical trials, could be 
used as a novel PARP1 imaging agent. For optimum modularity and 
efﬁcient nuclear targeting, AZD2281 was chemically modiﬁed with either a 
tetrazine or trans-cyclooctene moiety, which together react quickly in a 
biologically orthogonal “click” reaction. Probes were modiﬁed with the 
corresponding reactive group.
First, we developed and tested in cells a ﬂuorescent probe applicable for 
gaining insight into the cellular biology and localization of PARP1. We went 
on to create an 18F-labeled probe, which was was shown to be a 
potentially useful ligand for PET imaging of tumors in vivo.
Nuclear target, DNA damage 
response
Nanomolar affinity ligand, 
AZD2281
In clinical trials as combination 
drug for BRCA-/- cancers
Figure 2.5. PARP1-GFP expression is visible in the nucleoli of MDA-MB-436 cells. purchased from Invitrogen (Carlsbad, CA, USA). Cyclohexylcarbodiimide polystyrene 
resin was purchased from EMD biosciences (Gibbstown, NJ, USA). LC-ESI-MS analysis 
and HPLC purifications were performed on a Waters (Milford, MA, USA) LC-MS 
system. For LC-ESI-MS analyses, a Waters XTerra® C18 5 µm column was used. For 
preparative runs, an Atlantis® Prep T3 OBDTM 5 µM column was used. High-resolution 
electrospray ionization (ESI) mass spectra were obtained on a Bruker Daltonics APEXIV 
4.7 Tesla Fourier Transform mass spectrometer (FT-ICR-MS) in the Department of 
Chemistry Instrumentation Facility (Massachusetts Institute of Technology, Cambridge, 
MA, USA). Cellular images were taken on a Nikon (Tokyo, Japan) Eclipse 80i 
microscope with either a Nikon Plan Apo 40X/0.95 air or a Nikon Plan Apo 60X/1.45 oil 
immersion objective. IC50 assays were analyzed using a Tecan (Männedorf, Switzerland) 
Safire2 microplate system. All kinetic data were analyzed using Prism 4 (GraphPad, La 
Jolla, CA, USA) for Mac. 
 
2.3.1. Synthesis 
  Texas Red-Tz (2.8) was synthesized similar to methods described earlier5,33,34.        
(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1- 
one (2.1)32, 4-[[4-Fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one 
(2.2)32 and (E)-cyclooct-4-enyl 2,5-dioxopyrrolidin-1-yl carbonate (2.5)5 were 
synthesized as described earlier.  
         
                                                                                194-[[4-Fluoro-3-(4-(5-oxopentanamide)piperazine-1-carbonyl)phenyl]methyl]-2H-
phthalazin-1-one (2.3).  
  Glutaric anhydride (0.50 g, 4.37 mmol) and N,N- diisopropylethylamine (2.28 mL,        
13.11 mmol) were added to a solution of 4-[[4-Fluoro-3-(piperazine-1-carbonyl)phenyl] 
methyl]-2H-phthalazin-1-one (2.2) (1.60 g, 4.37 mmol) in dichloromethane (50 mL) and 
the reaction mixture and stirred for 30 min. Water (50 mL) was then added and the 
reaction mixture stirred for another 30 min. The reaction mixture was acidified with HCl 
to pH 2, the organic phase separated and the aqueous phase extracted with 
dichloromethane (3x 30 mL). The combined organic phases were dried over MgSO4 and 
volatiles removed in vacuo. The resulting crude material was purified using silica 
chromatography (0%-30% MeOH/DCM), yielding the pure product as an off-white solid 
(1.52 g, 3.16 mmol, 72%). 1H NMR (400 MHz, CD3OD, * indicates rotamer peak) δ = 
8.35 (d, 1H, 3JHH = 7.7, CaromH), 8.25 (s, 1H, 3JHH), 7.94 (d, 1H, 3JHH = 7.7, CaromH), 
7.90-7.78 (m, 2H, CaromH), 7.49-7.46 (m, 1H, CaromH), 7.39-7.36 (m, 1H, CaromH), 7.15 (t, 
1H, 3JHH = 9.0, CaromH), 4.37 (s, 2H, CH2), 3.81-3.71 (m, 2H, CH2), 3.68-3.62 (m, 2H, 
CH2), 3.54-3.46 (m, 2H, CH2), 3.36-3.26 (m, 2H, CH2), 2.50 (t, 2H, 3JHH = 7.4, CH2), 
2.43 (t, 2H, 3JHH = 7.4, *CH2), 2.38 (t, 2H, 3JHH = 7.0, CH2), 2.36 (t, 2H, 3JHH = 7.0, 
*CH2), 1.92-1.83 (m, 2H, CH2, *CH2); 19F NMR (376 MHz, CD3OD) δ = -121.14; LC-
ESI-MS(-) m/z = 479.2 [M-H+]-, 959.3 [2M-H+]-; LC-ESI-MS(+) m/z = 481.3 [M+H+]+, 
961.5 [2M+H+]+. HRMS-ESI [M+H]+ m/z calcd. for [C25H25FN4O5]+ 481.1882, found 
481.1862. 
 
                                                                                204-[[4-Fluoro-3-(4-(N-(2-aminoethyl)-5-oxo-pentanamide)piperazine-1-
carbonyl)phenyl]methyl]-2H-phthalazin-1-one (2.4).  
  Cyclohexylcarbodiimide polystyrene resin (634 mg, 2.3 mmol/g) was added to a        
solution of 4-[[4-Fluoro-3-(4-(5-oxopentanamide)piperazine-1-
carbonyl)phenyl]methyl]-2H-phthalazin-1-one (2.3) (350 mg, 0.73 mmol) in 
dichloromethane (20 mL) and the resulting mixture stirred gently for 7 h at room 
temperature. Subsequently, ethylenediamine (976 µL, 14.6 mmol) was added and the 
reaction mixture stirred for another 60 min, before the reaction mixture was filtered and 
volatiles removed in vacuo. The crude material was purified via HPLC, yielding the title 
compound as a clear solid (62 mg, 0.12 mmol, 16%). 1H NMR (400 MHz, CD3OD, * 
indicates rotamer peak) δ = 8.37 (d, 1H, 3JHH = 7.7, CaromH), 7.97 (d, 1H, 3JHH = 6.6, 
CaromH), 7.91-7.82 (m, 2H, CaromH), 7.53-7.48 (m, 1H, CaromH), 7.40-7.36 (m, 1H, 
CaromH), 7.17 (t, 1H, 3JHH = 8.9, CaromH), 4.39 (s, 2H, CH2), 3.82-3.72 (m, 2H, CH2), 
3.68-3.64 (m, 2H, CH2), 3.53-3.48 (m, 2H, CH2), 3.46 (t, 2H, 3JHH = 5.7, CH2), 3.38-3.28 
(m, 2H, CH2), 3.06 (t, 2H, 3JHH = 5.7, CH2), 2.52 (t, 2H, 3JHH = 7.2, CH2), 2.45 (t, 2H, 
3JHH = 7.1, *CH2), 2.32 (t, 2H, 3JHH = 7.1, CH2), 2.31 (t, 2H, 3JHH = 6.9, *CH2), 1.96-1.86 
(m, 2H, CH2, *CH2); 19F NMR (376 MHz, CD3OD) δ = -121.19; LC-ESI-MS(-) m/z = 
521.3 [M-H+]- (100); LC-ESI-MS(+) m/z = 523.4 [M+H+]+. HRMS-ESI [M+H]+ m/z 
calcd. for [C27H31FN6O4]+ 523.2464, found 523.2464. 
 
 
 
                                                                                21AZD2281-NOB (2.6).  
  Cyclohexylcarbodiimide polystyrene resin (33 mg, 2.3 mmol/g) and triethylamine (16        
µL, 0.11 mmol) were added to a solution of 4-[[4-Fluoro-3-(4-(N-(2-aminoethyl)-5-oxo-
pentanamide)piperazine-1-carbonyl)phenyl] methyl]-2H-phthalazin-1-one (2.4) (20 mg, 
38 µmol) and 5-norbornene-2-carboxylic acid (11 mg, 77 µmol) in dichloromethane (1 
mL) and the resulting mixture stirred gently over night at room temperature. 
Subsequently, the reaction mixture was filtered and volatiles removed in vacuo. The 
crude material was purified via HPLC, yielding the title compound as a clear solid (5.9 
mg, 9 µmol, 24%). 1H NMR (400 MHz, CD3OD, * indicates rotamer peak, not all peaks 
integrated due to endo/exo-mixture) δ = 8.37 (d, 1H, 3JHH = 7.4, CaromH), 7.80-7.82 (m, 
3H, CaromH), 7.51-7.48 (m, 1H, CaromH), 7.40-7.36 (m, 1H, CaromH), 7.17 (m, 1H, 
CaromH), 6.18-6.09 (m), 5.92-5.86 (m), 4.39 (s, 2H, CH2), 3.80-3.21 (m), 3.13 (m), 3.01 
(s), 2.87-2.81 (m), 2.47 (t, 2H, 3JHH = 7.2, CH2), 2.40 (t, 2H, 3JHH = 7.1, *CH2), 2.27-1.80 
(m), 1.68-1.22 (m); 19F NMR (376 MHz, CD3OD) δ = -121.20; LC-ESI-MS(-) m/z = 
641.3 [M-H+]-; LC-ESI-MS(+) m/z = 643.5 [M+H+]+. HRMS-ESI [M+H]+ m/z calcd. for 
[C35H39FN6O5]+ 643.3039, found 643.3022. 
 
AZD2281-TCO (2.7).  
  Triethylamine (16 µL, 0.11 mmol) was added to a solution of 4-[[4-Fluoro-3-(4-(N-       
(2-aminoethyl)-5-oxo-pentanamide) piperazine-1-carbonyl)phenyl] methyl]-2H-
phthalazin-1-one (2.4) (20 mg, 38 µmol) and (E)-cyclooct-4-enyl-2,5-dioxopyrrolidin-1-
yl carbonate (2.5) (12 mg, 46 µmol) in dichloromethane (1 mL) and the resulting mixture 
                                                                                22stirred gently over night at room temperature. Subsequently, the reaction mixture was 
filtered and volatiles removed in vacuo. The crude material was purified via HPLC, 
yielding the title compound as a clear solid (11.3 mg, 17 µmol, 44%). 1H NMR (400 
MHz, CD3OD, * indicates rotamer peak) δ = 8.39-8.36 (m, 2H, CaromH, NH), 8.02-8.00 
(m, 1H, NH), 7.98-7.94 (m, 1H, CaromH), 7.91-7.82 (m, 2H, CaromH), 7.51-7.48 (m, 1H, 
CaromH), 7.40-7.37 (m, 1H, CaromH), 7.17 (t, 1H, 3JHH = 9.0, CaromH), 6.77-6.76 (m, 1H, 
NH), 5.65-5.55 (m, 1H, CH), 5.50-5.40 (m, 1H, CH), 4.39 (s, 2H, CH2), 4.31-4.27 (m, 
1H, CH), 3.82-3.13 (m, 8H, CH2), 2.46 (t, 2H, 3JHH = 7.4, CH2), 2.39 (t, 2H, 3JHH = 7.4, 
*CH2), 2.33-1.53 (m, 14H, CH2, *CH2); 19F NMR (376 MHz, CD3OD) δ = -121.20; LC-
ESI-MS(-) m/z = 673.3 [M-H+]-; LC-ESI-MS(+) m/z = 675.4 [M+H+]+; HRMS-ESI [M
+H]+ m/z calcd. for [C36H43FN6O6]+ 675.3301, found 675.3301. 
 
2.3.2. HPLC characterization of reaction between Texas Red-tetrazine (2.8) and 
AZD2281-TCO (2.7)	

	
 AZD2281-TCO (2.7) and Texas Red-tetrazine (2.8) were combined in 40 μL of        
DMSO/PBS at a ﬁnal concentration of 0.3 mM for each reagent. The solution was stirred 
for several minutes at room temperature, yielding AZD2281-Texas Red (2.9).	

 
2.3.3. PARP1 IC50 determination	

	
 A commercially available colorimetric assay (Trevigen, Gaithersburg, MD, USA) was        
used to measure PARP activity in vitro in the presence of inhibitors. Ten-fold dilutions of 
AZD2281-derivatives (2.6) (ﬁnal concentration 400 nM to 0.04 nM); and (2.7), (2.9) (4 
                                                                                23μM to 0.04 nM) were incubated with 0.5 units PARP HSA for 10 minutes in histone-
coated 96-well plates. All experiments were carried out in triplicate. Control samples did 
not contain inhibitor and background measurement samples did not contain PARP1. All	

reaction mixtures were adjusted to a ﬁnal volume of 50 uL and a maximum ﬁnal 
concentration 0.4% DMSO in assay buffer. The remainder of the assay was performed 
according to the manufacturer’s instructions. PARP1 activity was measured by 
absorbance at 450 nm in each well using a Saﬁre2 microplate reader (Tecan Group, 
Mannedorf, Switzerland). IC50 values were calculated using Prism software (GraphPad, 
La Jolla, CA, USA).	

 
2.3.4. Cell Culture	

	
 MDA-MB-231 and MDA-MB-436 cells were obtained from the ATCC and cultured        
in RPMI 1640 supplemented with 10% fetal bovine serum, L-glutamine, and penicillin/ 
streptomycin. MDA-MB-231 and MDA-MD-436 cells stably expressing PARP-GFP 
were derived by transfection with Lipofectamine 2000 (Invitrogen) and isolation of 
individual G418-resistant clones. Cells were maintained in growth medium containing 1 
mg/mL G418. Expression of PARP-GFP in MDA-MB-436 cells was veriﬁed using 
immunoﬂuorescence microscopy to show nuclear localization of PARP-GFP, and western 
blotting for PARP-GFP.	

 
2.3.5. In vitro cell assays	

	
 For AZD2281-TCO IC50 assays, MDA-MB-436 cells (500 μL, 80.000 cells/mL) were        
seeded into glycerine-treated 8-well chamber slides (Lab TekTM, Thermo Scientiﬁc, 
                                                                                24Rochester, NY, USA), and allowed to attach over night. Cells were then incubated with 
Texas Red-Tz (2.8) (25 μL, 20 μM) for 20 minutes (37°C) before the medium was 
removed and cells were washed (1x, medium, 500 μL). Subsequently, 500 μL medium, 
Hoechst 33258 (10 μL , 100x in PBS) and AZD2281-TCO (2.7) (25 μL, in PBS, 3% 
DMSO, 30 μM-100 nM) were added and incubated at 37°C for 20 min. Cells were 
washed with PBS (3x 500 μL), ﬁxed with paraformaldehyde (4% in PBS) and washed 
with PBS (3x 500 μL, time between each wash = 5 min). PBS was removed and cells 
mounted using Prolong Gold (Invitrogen, Carlsbad, CA, USA) before imaging. For 
AZD2281-TCO blocking experiments, MDA-MB-436 cells (500 μL, 80,000 cells/mL) 
were seeded into glycerine-treated 8-well chamber slides (Lab TekTM, Thermo 
Scientiﬁc, Rochester, NY, USA), and allowed to attach over night. Cells were then 
incubated with Texas Red-Tz (2.8) (25 μL, 20 μM) for 20 minutes (37°C) before the 
medium was removed and cells were washed (1x, medium, 500 μL). Subsequently, 500 
μL medium, Hoechst 33258 (10 μL , 100x in PBS), AZD2281 (2.1) (5 μL in DMSO, 10 
mM) and AZD2281-TCO (2.7) (25 μL, in PBS, 3% DMSO, 30 μM-100 nM) were added 
and incubated at 37°C for 20 min. Cells were washed with PBS (3x 500 μL), ﬁxed with 
paraformaldehyde (4% in PBS) and washed with PBS (3x 500 μL, time between each 
wash = 5 min). PBS was removed and cells mounted using Prolong Gold (Invitrogen, 
Carlsbad, CA, USA) before imaging.	

 
2.3.6. Image analysis	

	
 Cells were observed on a Nikon 80i (Nikon, Tokyo, Japan) microscope equipped with        
an ImagEM camera (Hammamatsu Photonics, Tokyo, Japan). Images detailing distinct 
                                                                                25and separate cellular regions were obtained with the following ﬁlters: (Dapi, excitation 
350 ± 50 nm, emission 460 ± 50 nm, dichroic 400LP; IgG Pab, excitation 480 ± 20 nm, 
emission 535 ± 25 nm, dichroic 505LP; Texas Red-Tz (2.8), excitation 560 ± 20 nm, 
emission 630 ± 30 nm, dichroic 595DCLP; Chroma Technology, Bellows Falls, VT, 
USA) Images in each channel were captured using identical acquisition parameters. For 
each image, both cell structures and nuclei structures have been obtained using the 
appropriate ﬂuorescence ﬁlters and appropriate excitation signal levels to avoid collecting 
auto-ﬂuorescence. The collected data was then pre-processed with Cellproﬁler38 and 
statistics collected using Matlab (The Mathworks, Waltham, MA, USA). Cell structures 
were then identiﬁed using Otsu's method39 and binary masks were generated matching 
the boundary of each cell structure. Within each image and for each cell, the ﬂuorescence 
signal for the total cell and the signal in the nuclear area was calculated using the 
corresponding mask as a spatial ﬁlter. The two signals were then normalized for their 
total areas. The ratio of the ﬂuorescent signal in the cytosol region over the signal in the 
nuclear region was then calculated. Background subtraction was performed on the 
normalized signal using the cell’s negative masks. For all cells we chose an optimal ratio 
between 0.35 and 0.48 for the cytosol area over the nucleus area.	

 
2.3.7. MDA-MB436 cellular imaging	

	
 MDA-MB-436 cells (500 μL, 80.000 cells/mL) were seeded into glycerine-treated 8-       
well chamber slides (Lab TekTM, Thermo Scientiﬁc, Rochester, NY, USA), and allowed 
to attach over night. They were incubated with Texas Red-Tz (2.8) (25 μL, 20 μM) for 20 
minutes (37°C) before the medium was removed and cells were washed (1x, medium, 
                                                                                26500 μL). Subsequently, 500 μL medium and AZD2281-TCO (2.7) (25 μL, in PBS, 3% 
DMSO, 30 μM) were added and incubated at 37°C for 20 min. Cells were washed with 
PBS (3x 500 μL), ﬁxed with paraformaldehyde (4% in PBS) and washed with PBS (3x 
500 μL, time between each wash = 5 min). Cells were permeabilized using Triton-X-100 
(2% in PBS, 10 min) and incubated with anti-PARP-1 Mab (EMD biosciences, 
Gibbstown, NJ, USA) for 3h, before stained with secondary IgG-GFP Pab (EMD 
biosciences, Gibbstown, NJ, USA). PBS was removed and cells mounted using Prolong 
Gold (Invitrogen, Carlsbad, CA, USA) before imaging.	

 
2.3.8. PARP1-GFP reporter construct	

	
 PARP-GFP was constructed by PCR of human PARP-1 from Open Biosystems clone        
5193735 from the NIH_MGC_114 cDNA library, and cloning into pAcGFP-N1 between 
XhoI and XmaI restriction sites. The PARP-GFP construct was veriﬁed by DNA 
sequencing.	

 
2.3.9. PARP-1-GFP MDA-MB-436 cellular imaging	

	
 PARP-1-GFP expressing MDA-MB-436 cells (500 μL, 80,000 cells/mL) were seeded        
into glycerine-treated 8-well chamber slides (Lab Tek, Thermo Scientiﬁc, Rochester, NY, 
USA), and allowed to attach over night. They were washed with PBS (3x 500 μL), ﬁxed 
with paraformaldehyde (4% in PBS) and washed with PBS (3x 500 μL, time between 
each wash = 5 min). Cells were permeabilized using Triton-X-100 (0.5% in PBS, 10 min) 
and incubated with anti-PARP1 Mab (EMD biosciences, Gibbstown, NJ, USA) for 3h, 
                                                                                27before stained with secondary IgG-GFP Pab (EMD biosciences). PBS was removed and 
cells mounted using Prolong Gold (Invitrogen) before imaging.	

 
2.4. Discussion 
  In this report, we present potential small-molecule-based PARP1 imaging agents and        
confirm their utility for cell imaging. We found that AZD2281-based bifunctional small 
molecules were most suited to bioorthogonal in vivo target assembly. All bioorthogonal 
and imaging probes had IC50 values ranging between 10.1 nM and 15.4 nM. In particular, 
the TCO-modified derivative was not only successfully reacted using a bioorthogonal 
cycloaddition in cells, but was found to colocalize with anti-PARP1 Mabs. In turn, this 
colocalization could be prevented by blocking the targeted fluorescent probe with 
AZD2281. The design strategy employed here, as well as the specific compounds 
investigated, should prove useful for the future study of PARP1 biology in live cells. It is 
also highly likely that similar strategies could be used for the design of positron emission 
tomography (PET) imaging agents for whole-body imaging of PARP1 and its inhibition 
by PARPi. Such agents would be particularly useful in drug development and clinical 
trials. 
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2.6. 18F-PARP1 Inhibitors 
  Two subsequent publications from our group demonstrated chemical synthesis and        
PET imaging using 18F-PARP1 inhibitors. By using two-step 18F labeling via the [4+2] 
Diels-Alder cycloaddition described above, any tetrazine-modified small-molecule can be 
modified into a PET imaging agent for in vivo use, with higher yields as compared to 
direct fluorination. 
 
An 18F-labeled PARP1 imaging agent, based on AZD2281, was prepared via an 
inverse electron demand Diels–Alder cycloaddition in high radiochemical yield for 
positron emission tomography (PET) imaging. This strain-promoted ‘bioorthogonal’ 
reaction is envisioned to be a widely applicable 18F-labeling strategy for repeat and 
on-demand synthesis of small molecules for PET imaging. 
 
Adapted from: 
Edmund J. Keliher*, Thomas Reiner*, Anna Turetsky, Scott A. Hilderbrand, and Ralph 
Weissleder. High-Yielding, Two-Step 18F Labeling Strategy for 18F-PARP1 inhibitors. 
ChemMedChem, 6: 424–427 (2011). doi: 10.1002/cmdc.201000426. *Equal contribution 
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characterization. E.J.K., T.R., and R.W. designed the study, prepared figures and wrote 
the manuscript. A.T. performed PARP1 inhibition assays and analyzed resulting data. All 
authors reviewed and edited the manuscript. 
 
See Appendix A for detailed synthetic methods. 
 
  Positron emission tomography (PET) of labeled metabolites, drugs, proteins and 
nanomaterials is rapidly emerging as a powerful imaging tool to detect and monitor the 
stages of disease, to study human biology, to investigate pharmacokinetics and 
pharmacodynamics of new drugs, or to measure treatment efficacy in clinical trials40-46. 
18F is one of the most commonly used isotopes for clinical imaging given its half-life, 
ease of production, wide availability, and compatibility with microfluidic syntheses47. 
Despite extensive use and well-established procedures of labeling some small molecules, 
facile 18F platform-type universally adaptable labeling strategies are still largely missing. 
This is especially true for rapid labeling of small molecules that emerge from high-
throughput screens or for optimizing hybrid and modular imaging agents. Bioorthogonal 
chemistries represent one avenue to develop such generic labeling platforms. 
  To date, several bioorthogonal reactions have been described35,48-52 but only a few 
have been adapted for isotope labeling. The most popular reaction is the 1,3-dipolar 
cycloaddition, “click” reaction, between azides and alkynes47,53. These reactions were 
found to be particularly useful for in vitro 18F-fluorination of biomolecules and are now 
                                                                                30commonly used4,54,55. Our search for alternative, more rapid, selective, and chemically 
accessible coupling reactions without need for a catalyst led us to investigate the [4+2] 
inverse electron demand Diels–Alder cycloaddition using trans-cyclooctenes (TCO) and 
tetrazines (Tz)5,33,34. Advantages of the TCO/Tz labeling strategy include : a) fast reaction 
times in excess of 6,000 m-1 s-1; b) high selectivity ; c) no need for elevated temperatures 
or catalysts ; d) bio-compatible reaction conditions; and e) activatable tetrazines34. 
  Here, we extend our previous work on TCO and Tz chemistry5,33,34,56 and show that 
the Diels–Alder cycloaddition can be used for rapid 18F labeling of drugs. This strategy 
allows one to piggy-back onto the development of the vast number of small-molecule 
affinity ligands, peptides, and antibodies with various protein targets. Using PARP1 as a 
model target and AZD2281 as a well-developed nanomolar affinity ligand28,57, we show 
that the TCO/Tz strategy can be used to efficiently label the drug scaffold in very short 
times and at exceptionally high yields. This contrasts to conventional synthesis of directly 
18F-fluorinated AZD2281 derivatives where yields are much lower. We show the 
successful fully automated synthesis of a 18F-labeled TCO, its conjugation with a 
tetrazine-modified AZD2281, and compare affinities of the parent drugs and 
intermediates. The described platform-based methodology is modular and could easily be 
adapted to other molecularly targeted drug scaffolds of interest. 
  There are three generic 18F labeling strategies for AZD2281: a) de novo synthesis of 
the native compound substituting 18F for the aryl fluorine atom; b) conventional 
tosylation and subsequent fluorination of hydroxy-AZD2281 derivatives ; and c) 
prosthetic group labeling followed by conjugation to the parent compound. The first 
                                                                                31choice would result in a chemically identical drug but synthetic steps would be lengthy, 
requiring purification of intermediates, which may not be feasible given the short half-life 
of 18F, and it would be impractical for repetition for on-demand synthesis in a clinical 
setting. We therefore focused on the prosthetic group approach using the TCO/Tz 
chemistry. While 18F labeling of either TCO or Tz is conceivable, preliminary 
experiments demonstrated the substituted 1,2,4,5-tetrazine moiety was not stable to 
commonly used mild nucleophilic fluorination conditions: tetrabutyl ammonium 
bicarbonate, potassium fluoride, pH 8.5, 40°C. Therefore, focus was turned to the design 
and synthesis of an 18F-labeled TCO in which labeling would take place away from the 
cyclooctenyl ring due to susceptibility of that system to isomerization to 
bicyclo[3.3.0]octenes58. (Z)-2-(Cyclooct-4-enyloxy)acetic acid (2.11) was prepared in 
63% yield over two steps from commercially available (Z)-cyclooct-4-enol (2.10; Figure 
2.6). Carboxylic acid 2.11 was converted to (E)-2-(cyclooct-4-enyloxy)ethanol (2.13) 
first by lithium aluminum hydride (LiAlH4) reduction to give (Z)-2-(cyclooct-4-
enyloxy)ethanol (2.12) in 78% yield, followed by photochemical cis/trans isomerization 
and isolation of the (E)-isomers by the previously described cycle/trap method35. The 
major (E)-cyclooctyl stereoisomer was isolated by column chromatography and 
converted to the corresponding tosylate 2.14 in 84% yield. (E)-5-(2-
Fluoroethoxy)cyclooct-1-ene (2.1519F) was prepared in 91% yield by the treatment of 
2.14 with tetrabutylammonium fluoride (TBAF) in THF. All previously unknown 
compounds were fully characterized by 1H, 13C, and 19F NMR. 
                                                                                32  As a precursor for the chemoselective reactive PARP1 inhibitor AZD2281-Tz (2.17), 
4-[[4-fluoro-3-(4-(5-oxopentanamide)piperazine-1-carbonyl)phenyl]methyl]-2H-
phthalazin-1-one (2.3) was generated according to known literature procedures56. This 
precursor was reacted with 2.1633 in the presence of polymer-supported N,N’-
dicyclohexylcarbodiimide (DCC) beads to yield 2.17 as a pink solid. Cycloadduct 
2.1819F was prepared by the addition of dimethyl sulfoxide (DMSO) solutions of 2.17 
and 2.1519F at room temperature and subsequent high-pressure liquid chromatography 
(HPLC) purification (Figure 2.7). 
  Radiofluorination of 2.14 was performed following a modified procedure previously 
described for the 18F labeling of 1-azido-2-(2-(2-18F-fluoroethoxy)ethoxy)ethane6. In 
brief, no carrier added (n.c.a.) 18F-fluoride (18F-) in 18O-enriched H2O obtained from 
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Figure 2.6. Synthetic scheme for the synthesis of radiolabeled 18F-TCO (2.1518F). 
Reagents and conditions: a) NaH, ICH2CO2H, THF, reflux, 4 h, 66%; b) LiAlH4, Et2O, 
0°C, RT, 24 h, 78%; c) Et2O/hexanes (9 :1), hv, RT, 8 h, 37%; d) TsCl, Et3N, CH3CN, 
RT, 2 h, 84 ; e) TBAF, THF, RT, 2 h, 91%. 
 
pared in 91% yield by the treatment of 5 with tetrabutylam-
monium fluoride (TBAF) in THF. All previously unknown com-
pounds were fully characterized by
1H,
13C, and
19FN M R .
As a precursor for the chemoselective reactive PARP1 inhibi-
tor AZD2281-Tz (9), 4-[[4-fluoro-3-(4-(5-oxopentanamide) piper-
azine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (7) was
generated according to known literature procedures
(Scheme 2).
[24] This precursor was reacted with 8
[21] in the pres-
ence of polymer-supported N,N’-dicyclohexylcarbodiimide
(DCC) beads to yield 9 as a pink solid. Cycloadduct 10
19F was
prepared by the addition of dimethyl sulfoxide (DMSO) solu-
tions of 9 and 6
19F at room temperature and subsequent high-
pressure liquid chromatography (HPLC) purification.
Radiofluorination of 5 was performed following a modified
procedure previously described for the
18F labeling of 1-azido-
2-(2-(2-
18F-fluoroethoxy)ethoxy)ethane.
[33] In brief, no carrier
added (n.c.a.)
18F-fluoride (
18F
 ) in
18O-enriched H2O obtained
from PETNET Solutions and tetrabutylammonium bicarbonate
(nBu4NHCO3) were dried by azeotropic distillation of the aceto-
nitrile/water mixture under reduced pressure and a
stream of argon. Tosylate 5 in DMSO was added to
the dried
18F
 (n.c.a.)/nBu4NHCO3 and heated to 908C
for 10 min. Filtration of the reaction mixture through
alumina-N removed unreacted
18F
  prior to HPLC pu-
rification. Having a low UV absorbance, identification
of the desired 6
18F product was confirmed in a sepa-
rate experiment by HPLC injection of 6
19F, fraction
collection at the same elution as observed for radio-
active 6
18F, and NMR analysis of the non-radioactive
concentrate. HPLC purified 6
18F was isolated from the
collected HPLC solvents by C18 solid phase extrac-
tion (SPE) and eluted with dichloromethane to give
7.7 3.4 mCi (n=16) 6
18F in 44.7 7.8% decay-cor-
rected radiochemical yield (dcRCY) in an average
time of 41 min from the start of drying of [
18F]-F
 
(n.c.a.). Analytical HPLC demonstrated >93% radiochemical
purity of 6
18F. Tetrazine 9 in DMSO was added to the 6
18F/
CH2Cl2 solution, stirred for 3 min and subjected to HPLC purifi-
cation (Scheme 2). C18 SPE provided 10
18F in 59.6 5.0% iso-
lated dcRCY (n=3) with >96% radiochemical purity.
Compound 9 and AZD2281-Tz/trans-cyclooctene inverse
electron demand Diels–Alder products 10
19F, 10
16O and 10
18O
were analyzed using HPLC–mass spectrometry (MS-ESI)
(Figure 1). Under the reaction
conditions for this cycloaddition,
it was found that the initial dihy-
dropyridazine products under-
went aromatization to the corre-
sponding pyridazines. LC/MS
data confirmed the aromatiza-
tion of the formed heterocycle,
giving m/z values of 792.6, 790.5
and 792.6, respectively (calcd:
792.4, 790.4 and 792.4). To verify
their elemental composition,
compounds 9, 10
19F, 10
16O and
10
18O were also subjected to
high-resolution mass spectrome-
try (HRMS). All measured values
reflected the calculated masses.
Furthermore, HRMS allowed the
distinction between 10
19F and
10
18O, whose masses differ by
0.0085 gmol
 1, confirming the
radioactive decay of 10
18F to
10
18O (Figure 1).
In addition to the above-described cycloadducts, we also
prepared fluorinated AZD2281 analogues (Scheme 3) using nu-
cleophilic substitution. Two candidates were designed and syn-
thesized based on known literature procedures.
[34] 4-[[4-Fluoro-
3-(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one
was acylated with 6-hydroxyhexanoic acid or hydroxyacetic
acid to give derivatives 12 and 15. These hydroxy-AZD2281 de-
rivatives were converted to the corresponding tosylates 13
and 16. Attempts to fluorinate 13 resulted in decomposition of
starting material, while the reaction of tosylate 16 with sodium
Scheme 1. Synthetic scheme for the synthesis of radiolabeled
18F-TCO (6
18F). Reagents
and conditions: a) NaH, ICH2CO2H, THF, reflux, 4 h, 66%; b) LiAlH4, Et2O, 08C!RT, 24 h,
78%; c) Et2O/hexanes (9:1), hn, RT, 8 h, 37%; d) TsCl, Et3N, CH3CN, RT, 2 h, 84%; e) TBAF,
THF, RT, 2 h, 91%.
Scheme 2. Synthetic scheme for the synthesis of radiolabeled AZD2281-
18F( 10
18F). Reagents and conditions:
a) polystyrene-bound DCC, Et3N, CH2Cl2, RT, 7 h, 25%; b) CH2Cl2, RT, 3 min, 60%.
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OHPETNET Solutions and tetrabutylammonium bicarbonate (nBu4NHCO3) were dried by 
azeotropic distillation of the acetonitrile/water mixture under reduced pressure and a 
stream of argon. Tosylate 2.14 in DMSO was added to the dried 18F-(n.c.a.)/nBu4NHCO3 
and heated to 90°C for 10 min. Filtration of the reaction mixture through alumina-N 
removed unreacted 18F- prior to HPLC purification. Having a low UV absorbance, 
identification of the desired 2.1518F product was confirmed in a separate experiment by 
HPLC injection of 2.1519F, fraction collection at the same elution as observed for radio- 
active 2.1518F, and NMR analysis of the non-radioactive concentrate. HPLC purified 
2.1518F was isolated from the collected HPLC solvents by C18 solid phase extraction 
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pared in 91% yield by the treatment of 5 with tetrabutylam-
monium fluoride (TBAF) in THF. All previously unknown com-
pounds were fully characterized by
1H,
13C, and
19FN M R .
As a precursor for the chemoselective reactive PARP1 inhibi-
tor AZD2281-Tz (9), 4-[[4-fluoro-3-(4-(5-oxopentanamide) piper-
azine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (7) was
generated according to known literature procedures
(Scheme 2).
[24] This precursor was reacted with 8
[21] in the pres-
ence of polymer-supported N,N’-dicyclohexylcarbodiimide
(DCC) beads to yield 9 as a pink solid. Cycloadduct 10
19F was
prepared by the addition of dimethyl sulfoxide (DMSO) solu-
tions of 9 and 6
19F at room temperature and subsequent high-
pressure liquid chromatography (HPLC) purification.
Radiofluorination of 5 was performed following a modified
procedure previously described for the
18F labeling of 1-azido-
2-(2-(2-
18F-fluoroethoxy)ethoxy)ethane.
[33] In brief, no carrier
added (n.c.a.)
18F-fluoride (
18F
 ) in
18O-enriched H2O obtained
from PETNET Solutions and tetrabutylammonium bicarbonate
(nBu4NHCO3) were dried by azeotropic distillation of the aceto-
nitrile/water mixture under reduced pressure and a
stream of argon. Tosylate 5 in DMSO was added to
the dried
18F
 (n.c.a.)/nBu4NHCO3 and heated to 908C
for 10 min. Filtration of the reaction mixture through
alumina-N removed unreacted
18F
  prior to HPLC pu-
rification. Having a low UV absorbance, identification
of the desired 6
18F product was confirmed in a sepa-
rate experiment by HPLC injection of 6
19F, fraction
collection at the same elution as observed for radio-
active 6
18F, and NMR analysis of the non-radioactive
concentrate. HPLC purified 6
18F was isolated from the
collected HPLC solvents by C18 solid phase extrac-
tion (SPE) and eluted with dichloromethane to give
7.7 3.4 mCi (n=16) 6
18F in 44.7 7.8% decay-cor-
rected radiochemical yield (dcRCY) in an average
time of 41 min from the start of drying of [
18F]-F
 
(n.c.a.). Analytical HPLC demonstrated >93% radiochemical
purity of 6
18F. Tetrazine 9 in DMSO was added to the 6
18F/
CH2Cl2 solution, stirred for 3 min and subjected to HPLC purifi-
cation (Scheme 2). C18 SPE provided 10
18F in 59.6 5.0% iso-
lated dcRCY (n=3) with >96% radiochemical purity.
Compound 9 and AZD2281-Tz/trans-cyclooctene inverse
electron demand Diels–Alder products 10
19F, 10
16O and 10
18O
were analyzed using HPLC–mass spectrometry (MS-ESI)
(Figure 1). Under the reaction
conditions for this cycloaddition,
it was found that the initial dihy-
dropyridazine products under-
went aromatization to the corre-
sponding pyridazines. LC/MS
data confirmed the aromatiza-
tion of the formed heterocycle,
giving m/z values of 792.6, 790.5
and 792.6, respectively (calcd:
792.4, 790.4 and 792.4). To verify
their elemental composition,
compounds 9, 10
19F, 10
16O and
10
18O were also subjected to
high-resolution mass spectrome-
try (HRMS). All measured values
reflected the calculated masses.
Furthermore, HRMS allowed the
distinction between 10
19F and
10
18O, whose masses differ by
0.0085 gmol
 1, confirming the
radioactive decay of 10
18F to
10
18O (Figure 1).
In addition to the above-described cycloadducts, we also
prepared fluorinated AZD2281 analogues (Scheme 3) using nu-
cleophilic substitution. Two candidates were designed and syn-
thesized based on known literature procedures.
[34] 4-[[4-Fluoro-
3-(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one
was acylated with 6-hydroxyhexanoic acid or hydroxyacetic
acid to give derivatives 12 and 15. These hydroxy-AZD2281 de-
rivatives were converted to the corresponding tosylates 13
and 16. Attempts to fluorinate 13 resulted in decomposition of
starting material, while the reaction of tosylate 16 with sodium
Scheme 1. Synthetic scheme for the synthesis of radiolabeled
18F-TCO (6
18F). Reagents
and conditions: a) NaH, ICH2CO2H, THF, reflux, 4 h, 66%; b) LiAlH4, Et2O, 08C!RT, 24 h,
78%; c) Et2O/hexanes (9:1), hn, RT, 8 h, 37%; d) TsCl, Et3N, CH3CN, RT, 2 h, 84%; e) TBAF,
THF, RT, 2 h, 91%.
Scheme 2. Synthetic scheme for the synthesis of radiolabeled AZD2281-
18F( 10
18F). Reagents and conditions:
a) polystyrene-bound DCC, Et3N, CH2Cl2, RT, 7 h, 25%; b) CH2Cl2, RT, 3 min, 60%.
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Figure 2.7. Synthetic scheme for the synthesis of radiolabeled AZD2281-18F (2.1818F). 
Reagents and conditions: a) polystyrene-bound DCC, Et3N, CH2Cl2, RT, 7 h, 25%; b) 
CH2Cl2, RT, 3 min, 60%. 
2.3
2.16
2.17
2.17
2.1518F
2.1818F(SPE) and eluted with dichloromethane to give 7.7 ± 3.4 mCi (n = 16) 2.1518F in 44.7 ± 
7.8% decay-corrected radiochemical yield (dcRCY) in an average time of 41 min from 
the start of drying of [18F]-F- (n.c.a.). Analytical HPLC demonstrated >93% 
radiochemical purity of 2.1518F. Tetrazine 2.17 in DMSO was added to the 2.1518F/ 
CH2Cl2 solution, stirred for 3 min and subjected to HPLC purification (Figure 2.8). C18 
SPE provided 2.1818F in 59.6 ± 5.0% isolated dcRCY (n = 3) with >96% radiochemical 
purity.  
  Compound 2.17 and AZD2281-Tz/trans-cyclooctene inverse electron demand Diels–
Alder products 2.1819F, 2.1816O, and 2.1818O were analyzed using HPLC–mass 
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Figure 2.8. Characterization of radiolabeled compounds. a) LC/MS-ESI traces ; b) 
HRMS spectra of AZD2281-derivatives 2.17, 2.1819F, 2.1816O and 2.1818O ; c) HPLC 
radiotraces of 18F-labeled compounds 2.1518F and 2.1818F. 
fluoride provided 17
19F in 14% yield. Standard
18F radiolabeling
conditions (Kryptofix-222 (K222), K2CO3), even at low tempera-
tures (408C), resulted in decomposition of the starting sulfo-
nate ester 16. Experiments were conducted to test the use of
microwave heating at short time intervals with no positive re-
sults. Attempts to use the less alkaline tetrabutyl ammonium
bicarbonate (nBu4NHCO3) as a phase-transfer catalyst also re-
sulted in decomposition of the starting materials, and <1% ra-
diochemical yields (RCY) of 17
18F.
The above results show that the chemoselective approach
resulted in significantly higher yields of
18F-labeled AZD2281
analogues and in much shorter time. The next question was
therefore how the TCO/Tz ligand would affect target affinity.
To assess this, a colorimetric assay was employed to measure
PARP1 activity (Figure 2). The published value for AZD2281 is
5n m,
[34,35] identical to what we observed in our assay. Conven-
tionally fluorinated 17
19F had an
IC50 value of 5.2 1.1 nm, consis-
tent with the small side group.
Compound 9 showed an IC50
value of 8.4 1.3 nm, quite re-
markable given the bulkier side
chain. Cycloaddition fluorinated
10
19F had an IC50 value of 17.9 
1.1 nm (Figure 2), still in the low
double-digit nanomolar range
and likely sufficient for imaging
purposes. These findings are also
in agreement with previous re-
sults showing that modification of AZD2281 at the piperazine
position only minimally perturbs the ability to bind PARP1.
[24]
In summary, these results show that the cycloaddition ap-
proach can achieve rapid and high-yield fluorination under
mild conditions. Introduction of the hexahydrocycloocta[d]pyri-
dazine group seems to only minimally affect the affinity of
AZD2281 for PARP1. While this retention of binding affinity
may not be achieved by all targeted small molecules due to
the relative size of the hyzahydrocycloocta[d]pyridazine linker,
further research of modified linkers to distance the binding
moiety and pyrazine may be warranted. It is envisioned that
this labeling strategy will also have particular utility for the ra-
diofluorination of peptides, antibodies and nanomaterials
where the size of the hexahydrocycloocta[d]pyridazine linker
will be of lesser importance.
Figure 1. a) LC/MS-ESI traces; b) HRMS spectra of AZD2281-derivatives 9, 10
19F, 10
16O and 10
18O; c) HPLC radiotraces of
18F-labeled compounds 6
18F and 10
18F.
Scheme 3. Synthetic scheme for the synthesis of conventionally fluorinated AZD2281 derivatives. Reagents and
conditions: a) TsCl, Et3N, CH2Cl2, RT, overnight, 24% for 13 and 32% for 16; b) NaF, CH3CN, 408C, 6 h, 16%.
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2.17; AZD2281-Tz
2.1819F; AZD2281-19F
2.1816O; AZD2281-16O
2.1818O; AZD2281-18O
2.17 
2.1819F 
2.1816O 
2.1818Ospectrometry (MS-ESI) (Figure 2.8). Under the reaction conditions for this cycloaddition, 
it was found that the initial dihydropyridazine products underwent aromatization to the 
corresponding pyridazines. LC/MS data confirmed the aromatization of the formed 
heterocycle, giving m/z values of 792.6, 790.5 and 792.6, respectively (calcd : 792.4, 
790.4 and 792.4). To verify their elemental composition, compounds 2.17, 2.1819F, 
2.1816O and 2.1818O were also subjected to high-resolution mass spectrometry (HRMS). 
All measured values reflected the calculated masses. Furthermore, HRMS allowed the 
distinction between 2.1819F and 2.1818O, whose masses differ by 0.0085 g mol-1, 
confirming the radioactive decay of 2.1818F to 2.1818O (Figure 2.8). 
  In addition to the above-described cycloadducts, we also prepared fluorinated 
AZD2281 analogues (Figure 2.9) using nucleophilic substitution. Two candidates were 
designed and synthesized based on known literature procedures32. 4-[[4-Fluoro- 3-
(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one was acylated with 6-
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fluoride provided 17
19F in 14% yield. Standard
18F radiolabeling
conditions (Kryptofix-222 (K222), K2CO3), even at low tempera-
tures (408C), resulted in decomposition of the starting sulfo-
nate ester 16. Experiments were conducted to test the use of
microwave heating at short time intervals with no positive re-
sults. Attempts to use the less alkaline tetrabutyl ammonium
bicarbonate (nBu4NHCO3) as a phase-transfer catalyst also re-
sulted in decomposition of the starting materials, and <1% ra-
diochemical yields (RCY) of 17
18F.
The above results show that the chemoselective approach
resulted in significantly higher yields of
18F-labeled AZD2281
analogues and in much shorter time. The next question was
therefore how the TCO/Tz ligand would affect target affinity.
To assess this, a colorimetric assay was employed to measure
PARP1 activity (Figure 2). The published value for AZD2281 is
5n m,
[34,35] identical to what we observed in our assay. Conven-
tionally fluorinated 17
19F had an
IC50 value of 5.2 1.1 nm, consis-
tent with the small side group.
Compound 9 showed an IC50
value of 8.4 1.3 nm, quite re-
markable given the bulkier side
chain. Cycloaddition fluorinated
10
19F had an IC50 value of 17.9 
1.1 nm (Figure 2), still in the low
double-digit nanomolar range
and likely sufficient for imaging
purposes. These findings are also
in agreement with previous re-
sults showing that modification of AZD2281 at the piperazine
position only minimally perturbs the ability to bind PARP1.
[24]
In summary, these results show that the cycloaddition ap-
proach can achieve rapid and high-yield fluorination under
mild conditions. Introduction of the hexahydrocycloocta[d]pyri-
dazine group seems to only minimally affect the affinity of
AZD2281 for PARP1. While this retention of binding affinity
may not be achieved by all targeted small molecules due to
the relative size of the hyzahydrocycloocta[d]pyridazine linker,
further research of modified linkers to distance the binding
moiety and pyrazine may be warranted. It is envisioned that
this labeling strategy will also have particular utility for the ra-
diofluorination of peptides, antibodies and nanomaterials
where the size of the hexahydrocycloocta[d]pyridazine linker
will be of lesser importance.
Figure 1. a) LC/MS-ESI traces; b) HRMS spectra of AZD2281-derivatives 9, 10
19F, 10
16O and 10
18O; c) HPLC radiotraces of
18F-labeled compounds 6
18F and 10
18F.
Scheme 3. Synthetic scheme for the synthesis of conventionally fluorinated AZD2281 derivatives. Reagents and
conditions: a) TsCl, Et3N, CH2Cl2, RT, overnight, 24% for 13 and 32% for 16; b) NaF, CH3CN, 408C, 6 h, 16%.
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Figure 2.9. Synthetic scheme for the synthesis of conventionally fluorinated AZD2281 
derivatives. Reagents and conditions : a) TsCl, Et3N, CH2Cl2, RT, overnight, 24% for 13 
and 32% for 16 ; b) NaF, CH3CN, 40°C, 6 h, 16%. 
n = 5; 2.20 
      1; 2.23
n = 5; 2.21 
      1; 2.24
n = 1; 2.2519Fhydroxyhexanoic acid or hydroxyacetic acid to give derivatives 2.20 and 2.23. These 
hydroxy-AZD2281 derivatives were converted to the corresponding tosylates 2.21 and 
2.24. Attempts to fluorinate 2.21 resulted in decomposition of starting material, while the 
reaction of tosylate 2.24 with sodium fluoride provided 2.2519F in 14% yield. Standard 
18F radiolabeling conditions (Kryptofix-222 (K222), K2CO3), even at low temperatures 
(40°C), resulted in decomposition of the starting sulfonate ester 2.24. Experiments were 
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Figure 2.10. Inhibition of PARP1 by fluorinated AZD2281 derivatives. a) IC50 values 
and radiochemical yields (RCY) for derivatives 2.17, 2.1819F, 2.1919F and 2.1519F; b) 
IC50 curves for PARP1 inhibitors 2.17 (circles), 2.1819F (squares), 2.1919F (upside-down 
pyramids) and trans-cyclooctene 2.1519F (pyramids). 
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Figure 2. a) IC50 values and radiochemical yields (RCY) for derivatives 9, 10
19F, 17
19F and
6
19F; b) IC50 curves for PARP1 inhibitors 9 (*), 10
19F (&), 17
19F (!) and trans-cyclooctene
6
19F (~).
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2.17 
2.1819F 
2.1919F
2.1519Fconducted to test the use of microwave heating at short time intervals with no positive 
results. Attempts to use the less alkaline tetrabutyl ammonium bicarbonate (nBu4NHCO3) 
as a phase-transfer catalyst also resulted in decomposition of the starting materials, and 
<1% radiochemical yields (RCY) of 2.2518F. 
  The above results show that the chemoselective approach resulted in significantly 
higher yields of 18F-labeled AZD2281 analogues and in much shorter time. The next 
question was therefore how the TCO/Tz ligand would affect target affinity. To assess this, 
a colorimetric assay (as described in 2.3.3) was employed to measure PARP1 activity 
(Figure 2.10). The published value for AZD2281 is 5 nm31,32, identical to what we 
observed in our assay. Conventionally fluorinated 2.2519F had an IC50 value of 5.2 ± 1.1 
nm, consistent with the small side group. Compound 9 showed an IC50 value of 8.4 ± 
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Figure 2.1159. Imaging of radioactivity in PARP1-high and PARP1-low cells following 
incubation with 18F-AZD2281. MDA-MB-436 (PARP1 high) and MDA-MD-321 
(PARP1 low) cells in a plate were incubated with various concentration of cold 
AZD2281 (listed bottom of image) and 5 µCi of 18F-AZD2281. Radioactivity was 
determined by γ emission. 1.3nm, quite remarkable given the bulkier side chain. Cycloaddition fluorinated 2.1819F 
had an IC50 value of 17.9 ± 1.1 nm, still in the low double-digit nanomolar range and 
sufficient for imaging purposes following removal of excess 2.17 by a scavenger-assisted 
method (Figures 2.11 and 2.12, see Reiner et al., Angew. Chem. Int. Ed., 2011)59. 
 
2.7. Reflections and Follow-on Work 
  There were two important conclusions moving forward that were drawn from this        
technology development work: a) novel, targeted small molecule ligands can be modified 
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cells, which correlates with protein expression of PARP1 in
the respective cell lines (see the Supporting Information for
details).
In subsequent in vivo experiments, 30 mCi of
18F-
AZD2281 were injected into Nu/Nu mice and imaged by
PET/CT over a period of 2 h. Figure 3A displays the
distribution of the PET probe at 10, 30, and 50 min. The
images clearly show initial localization of the probe to be
mainly in liver, gall bladder, and intestines, consistent with
hepatobiliary excretion. After 50 min (Figure 3A), the major-
ity of the probe had left the bloodstream (t1/2=6 min) and was
excreted through the large intestines.
Tumor-bearing mice were obtained by injection of MDA-
MB-436 cells (5 10
6 cells in matrigel) into the flanks of Nu/
Nu mice, and the tumors were allowed to grow and
vascularize for 7 days. Figure 3B shows a three-dimensional
reconstruction of a tumor-bearing mouse injected with 30 mCi
of
18F-AZD2281. Uptake in the tumors is clearly visible.
Immediately after imaging, the mice were injected with 1 mg
AZD2281 BID. Re-injection of 30 mCi of
18F-AZD2281
confirmed inhibition of the probe s uptake into the tumors
(Figure 3B and C). Therefore, owing to the rapid decay rate
of
18F, each mouse serves as its own control on subsequent
days of imaging, facilitating direct comparisons of SUVs.
In summary, we have showed a) that
18F-AZD2281
accumulates in PARP1-overexpressing cancer cells (e.g.
MDA-MB-436), b) the cellular accumulation can be inhibited
by nonlabeled AZD2281, c)
18F-AZD2281 accumulates in
PARP1 mouse models of cancer in vivo, and d) PARP1
inhibition can be quantitated by PET imaging in vivo. The
imaging agent was developed in relatively short time usingthe
above described chemically orthogonal scavenger-assisted
high-performance method. Scavenger beads for alternative
conjugation methods could also be developed and applied in
similar ways. However, we believe that the described method
is particularly appealing for development of PET imaging
agents because of the extremely fast kinetics of the tetrazine/
trans-cyclooctene inverse-electron-demand Diels–Alder reac-
tion at room temperature, its independence of catalysts, and
high selectivity. The technology described can be readily
expanded to other drugs, biomolecules, and molecular targets
and should facilitate the development of PET imaging agents
for drug testing.
Received: October 20, 2010
Published online: January 21, 2011
. Keywords: cancer therapy · chemically orthogonal conjugation ·
invivoimaging·positronemissiontomography·scavengerresin
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Figure 2. Competitive in vitro inhibition assays with
18F-AZD2281. Cells
containing either a high (MDA-MB-436) or a low amount of PARP1
(MDA-MB-231) were treated with 5 mCi of
18F-AZD2281 in the presence
of different concentrations of AZD2281 (10 mm–0.01 nm). After the
cells were washed, cell-associated activity was determined by measure-
ment of the g-radiation. For the control measurement, no unlabeled
AZD2281 was added.
Figure 3. In vivo evaluation of
18F-AZD2281. A) Combined PET/CT
scans of a nontumor-bearing mouse injected with
18F-AZD2281
recorded 10, 30, and 50 min after injection. B) Three-dimensional
reconstruction of a tumor-bearing animal injected with
18F-AZD2281
with and without pre-injection of AZD2281 (bladder segmented out for
clarity). C) Quantification of uptake through the tumor in hind legs
with and without intraperitoneal pre-injection of unlabeled AZD2281
SUV: standardized uptake value
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Figure 2.1259. PET imaging in a mouse using 18F-AZD2281. a) PET imaging of 18F-
AZD2281 pharmacokinetics in a mouse. b) PET imaging and quantification of 
accumulation of 30 µCi 18F-AZD2281 in MDA-MB-436 mouse flank tumors, and 
blocking of accumulation with 1 mg cold AZD2281 administered 12 hours prior (with 
bladder segmented out).
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a. b.to be imaging probes without significantly altering their affinity, as long as the design is 
such that the modification is away from the part of the molecule that interacts with the 
target binding pocket, and b) in fact, it turned out that the click chemistry strategy is not 
the best for small-molecule imaging, especially in vivo, since the kinetics become 
complicated. For a time, the two-step click chemistry approach seemed as though it was 
the most suitable 18F labeling platform, but the development of newer fluorination 
strategies have allowed for complementary approaches. 
  Follow-on intravital fluorescence imaging studies were done using AZD2281 directly        
conjugated to a fluorochrome, Bodipy FL60,61. Direct labeling improved the kinetics of 
PARP1 binding in vivo, allowing for experimental modeling of the pharmacokinetics of 
leakage into the tumor interstitium from the mouse vasculature, uptake into cells, and 
clearance of non-specific binding. At the same time, we expect the recently advances in 
efficient and fast synthesis of 18F-Bodipy FL62,63 to open doors for PET imaging using 
such small-molecule drug-18F-Bodipy FL conjugates. Thus, as described in Chapter 3, we 
chose to use Bodipy FL to directly modify the drug Ibrutinib when exploring its use as a 
potential lymphoma companion imaging agent. 
  Finally, in ongoing work, the pharmacodynamic effects of AZD2281 are being        
studied by introducing a DNA damage reporter to ovarian and breast cancer cells, among 
others. The efficacy of the drug in causing cell death is being correlated against DNA 
damage, as well as PARP1 expression (via imaging drug uptake), and BRCA status. This 
may help discern how to best predict PARP1 inhibitor efficacy in patients. 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A number of Bruton’s tyrosine kinase (BTK) inhibitors are currently in 
development, yet it has been difficult to visualize BTK expression and 
pharmacological inhibition in vivo in real time. We synthesized a fluorescent, 
irreversible BTK binder based on the drug Ibrutinib and characterized its behavior 
in cells and in vivo. We show a 200 nM affinity of the imaging agent, high selectivity, 
and irreversible binding to its target following initial washout, resulting in surprisingly high target-to-background ratios. In vivo, the imaging agent rapidly 
distributed to BTK expressing tumor cells, but also to BTK-positive tumor-
associated host cells.  
 
3.1. Introduction   
  Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase with restricted        
cellular expression largely limited to B lymphocytes, macrophages/monocytes, and 
certain cancer cells64-67. As a critical component of the B cell receptor (BCR) signaling 
network, BTK is crucial for B cell development68,69 and acts in multiple anti-apoptotic 
signaling pathways, including the PI3K-AKT70, STAT571 and NF-κB72,73 pathways. BTK 
is thus intimately involved in regulating cell survival, proliferation, and differentiation. In 
human haematological malignancies, BTK is abundantly expressed and activated in 
malignant cells from patients with B-cell multiple myeloma74, acute myeloid leukemia 
(AML)20, chronic lymphocytic leukemia (CLL)75, and non-Hodgkin’s lymphoma 
(NHL)17,76. It is thus estimated that there are about 80,000 new BTK-positive 
haematologic malignancies in the US per year. 
  Several BTK inhibitors are under development and have shown remarkable efficacy        
in early clinical trials19,21,22,77,78. Ibrutinib (PCI-32765) is one example of a selective, 
irreversible BTK inhibitor, whose covalent binding results in long-lasting target 
occupancy, retaining inhibitory effect until new protein is synthesized23,79. The 
irreversible inhibitory effect of Ibrutinib is attributed to an electrophilic group on the 
molecule binding covalently to Cys 481 in the active site of BTK80. Most clinical trials to 
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such as computed tomography (CT), to image drug effects, while a denaturing gel 
electrophoresis assay has been used when tissue is available in Ibrutinib trials13,23. In the 
latter assay, a fluorescent probe binds any unoccupied BTK in tissue biopsy or blood to 
produce a fluorescent band; the lighter the band, the more BTK is occupied by drug. 
Even in co-clinical trials using mouse models, drug efficacy is largely tested by 
volumetrics or cell counts, while little is known about the kinetics of drug distribution in 
vivo, accumulation across cell types, and their respective heterogeneities or drug effects. 
There is therefore a need for imaging tools to study BTK inhibitor distribution at the 
single cell level in vivo. Such tools could be valuable to better understand kinetics, 
selectivity, drug action, inform on dose ranging studies, and allow in vitro testing of 
harvested cells from patients. Furthermore, imaging would be especially useful in the 
development of next generation BTK inhibitors78,81,82. 
  We hypothesized that an Ibrutinib-like scaffold could be converted into a companion        
diagnostic imaging agent by modification with a fluorescent tag while preserving 
irreversible target binding. The goal of the current study was to explore whether terminal 
modification of Ibrutinib could generate a BTK-selective imaging agent for in vivo use. 
Given the irreversible nature of target binding, one would expect improved target-to-
background ratios following the clearance of unbound fractions. We indeed show 
remarkable target localization, specificity, and the ability to measure drug distribution and 
target inhibition in vivo. As more attention is paid to cell-to-cell heterogeneity in drug 
                                                                                43response and its importance on efficacy, we believe this will be a useful tool to study 
BTK expression and inhibition83. 
 
3.2. Results 
  We sought to design a bright, fluorescent derivative of an irreversible BTK inhibitor        
that would preserve the selectivity of the parent drug. As such a model agent, Ibrutinib 
fits tightly into the ATP binding pocket of BTK, forms an irreversible bond with Cys481, 
and has a suitable modification point for fluorochrome attachment (PDB: 3GEN, Figure 
3.1a). A Bodipy-FL modified Ibrutinib (Ibrutinib-BFL) was designed and synthesized de 
novo in seven steps (Figure 3.1b). Briefly, iodination of commercially available 
pyrazolopyrimidine compound with N-Iodosuccinimide, followed by Suzuki coupling of 
the product with 4-phenyloxybenzene boronic acid, resulted in compound 3.2. Mitsunobu 
reaction of compound 3.2 with N-Boc-3-hydroxypiperidine resulted in compound 3.3. 
After deprotection of the Boc protecting group in acidic conditions, the crude product 
was coupled with the linker (compound 3.5) to introduce a Michael acceptor for the 
irreversible binding affinity. Coupling of the crude Boc-deprotected compound 3.6 with 
Bodipy-FL-NHS finalized the synthetic steps to produce Ibrutinib-BFL (3.7) at an overall 
yield of ~11%. 
  To confirm the effect of BFL modification on the inhibition efficacy of the drug, half-
maximal inhibitory concentration (IC50) of Ibrutinib and Ibrutinib-BFL were determined 
against purified BTK enzyme. Ibrutinib-BFL had an IC50 of ~200 nM, which is less 
potent than the parent drug (~2 nM IC50; Figure 3.2). Although it may be possible to 
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Figure 3.1. Structure and Synthetic Scheme of Ibrutinib-BFL (3.7). a. Crystal structure 
prediction of Ibrutinib-BFL (3.7) in its binding pocket of BTK. The reactive cysteine is 
highlighted in yellow inside the box. Hydrogen bonds are shown as purple dotted lines. 
3D models were rendered using PyMol. b. Synthetic scheme of Ibrutinib-BFL (3.7). 
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2. 3.5, PyBOP, TEA / DMFfurther optimize the affinity of Ibrutinib-BFL by testing various linkers, we found the 
current generation probe to be quite acceptable for imaging, as shown in subsequent 
experiments. We next determined whether Ibrutinib-BFL would bind to purified BTK in 
vitro, endogenous BTK in live cells, and ultimately in vivo. Purified BTK was incubated 
with varying concentrations of the imaging probe for one hour at room temperature, 
denatured at 70°C for 10 minutes and then processed for SDS-PAGE gel analysis. There 
was a clear dose-response increase of the fluorescent signal around 80 kDa (BTK 
molecular weight is 76 kDa), as well as at the bottom of the gel (unbound fraction of 
Ibrutinib-BFL) (Figure 3.3a). Additionally, binding could be blocked by pre-incubation 
with the parent compound and silver staining of the gel showed equal loading of BTK 
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3.  Gel electrophoresis of Ibrutinib-BFL bound to BTK. 
To visualize the specificity and covalent binding of our probe, Ibrutinib-BFL, in 2-
fold dilutions, was incubated for two hours with purified BTK, and the mixture was 
separated by polyacrylamide gel electrophoresis (similar to the method in Honigberg 
et  al.,  mentioned  in  background).  The  gel  was  then  imaged  using  a  Typhoon 
fluorescent gel scanner with 488-nm excitation. The BTK-Ibrutinib-BFL complex, 
forming a band at 76 kD, could clearly be visualized, showing a similar IC50 as in the 
enzymatic inhibition assay (Figure 3a). We could also see excess Ibrutinib-BFL at the 
bottom of the gel, showing that we were saturating the enzyme. Silver staining was 
used as a control for equal enzyme loading in all lanes (Figure 3b). We then wanted 
to  test  the  cell-permeability  and  BTK  selectivity  of  Ibrutinib-BFL.  First,  four 
lymphoma  cell  lines,  Daudi  (Burkitt’s  lymphoma),  DB,  Toledo,  and  RC-K8 
Figure 2. 
Figure 3.2. Inhibition of BTK by Ibrutinib-BFL. protein (Figure 3.4a,c). These results clearly confirmed the covalent binding property of 
Ibrutinib-BFL toward purified BTK. 
  We next performed a similar experiment in lymphoma cells. We first determined BTK 
expression in several lymphoma cell lines (Daudi Burkitt’s Lymphoma line, and DB, 
Toledo, and RC-K8 Diffuse Large B-Cell Lymphoma (DLBCL) lines) and one T-cell 
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Figure 3.3. Characterization of Ibrutinib-BFL. a. Target binding. Denaturing gel 
electrophoresis of decreasing concentrations of Ibrutinib-BFL incubated with 0.1 µg 
purified BTK for one hour, imaged with 488 nm excitation / 520 nm emission. Note the 
dose dependent binding of Ibrutinib-BFL. Size marker on the far left. b. Denaturing gel 
electrophoresis of cell lysates following incubation of decreasing concentrations of 
Ibrutinib-BFL with Toledo (BTK+, left half of gel) or Jurkat (BTK-, right half of gel) 
cells at 37°C for two hours. Note the superb specificity of the probe.                                                                                 48
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Diego,  CA,  USA)  ranging  from  500  nM  to  0.8  nM  in  final  2%  DMSO  at  37°C  for  1.5  hours. 
Without washout, Ibrutinib-BFL was then added to each well for 50 nM final concentration and 
4% final DMSO, and incubated at 37°C for two hours. A positive control sample contained no 
Ibrutinib,  while  a  negative  control  for  autofluorescence  contained  no  Ibrutinib-BFL.  After  two 
hours, Ibrutinib-BFL-containing media was removed by centrifugation, and cells were incubated 
in fresh media at 37°C for 24 hours prior to analysis by flow cytometry. Cells collected for flow 
cytometry were centrifuged and resuspended in 200 µL PBS containing 0.5% BSA, and filtered 
through 35 µM Cell Strainer tubes (BD). Flow cytometry in the FITC channel was performed on 
an  LSRII  flow  cytometer  (BD)  and  subsequent  data  analysis  was  done  using  FlowJo  software 
(TreeStar, Ashland, OR, USA). 
 
 
Supplementary Figures 
 
Supplementary Fig. S1. Gel electrophoresis experiments. a. Competition. After pre-incubation 
of BTK with concentrations of Ibrutinib ranging from 80 to 2.5 nM for one hour, Ibrutinib-BFL is 
blocked from binding to the BTK. Loading of Ibrutinib-BFL can be seen at the bottom of the gel. 
Extent of blocking seems to depend more on time than on concentration of Ibrutinib. b. Western 
blot of lymphoma cell lines, blotted with anti-BTK antibody (left) or stimulated and blotted with 
an antibody with cross-reactivity for pBTK and pITK, expressed in T cells. Orange dotted line 
indicates 80 kDa size marker; BTK is reported as having molecular weight of 76 kDa. c. Silver 
stain of purified BTK loading in Figure 2a. d. Silver stain of cell lysate loading in Figure 2b. 
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Figure 3.4. Additional gel electrophoresis experiments. a. Competition. After pre-
incubation of BTK with concentrations of Ibrutinib ranging from 80 to 2.5 nM for one 
hour, Ibrutinib-BFL is blocked from binding to the BTK. Loading of Ibrutinib-BFL can 
be seen at the bottom of the gel. Extent of blocking seems to depend more on time than 
on concentration of Ibrutinib. b. Western blot of lymphoma cell lines, blotted with anti-
BTK antibody (left) or stimulated and blotted with an antibody with cross-reactivity for 
pBTK and pITK, expressed in T cells. Orange dotted line indicates 80 kDa size marker; 
BTK is reported as having molecular weight of 76 kDa. c. Silver stain of purified BTK 
loading in Figure 3.3a. d. Silver stain of cell lysate loading in Figure 3.3b.                                                                                 49
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Supplementary Fig. S2. Optimization of BTK imaging and blocking experiment. a. Staining cells 
with Ibrutinib-BFL. Toledo and Jurkat cells were incubated with 0 nM (top) or 50 nM (bottom) 
Ibrutinib-BFL  for  two  hours,  followed  by  a  24-hour  washout  period  in  probe-free  media. 
Ibrutinib-BFL  only  remains  bound  to  Toledo  cells,  as  shown  by  clear  separation  of  cell 
populations  by  flow  cytometry.  b.  Blocking  with  Ibrutinib.  (Top)  Difference  in  fluorescence 
between Toledo cells stained with 100 nM Ibrutinib-BFL and unstained Toledo cells. Unstained 
cells  provide  a  benchmark  for  100%  blocking.  (Bottom)  Blocking  of  BTK  staining  by  pre-
incubation  of  Toledo  cells  with  varying  concentrations  of  unmodified  Ibrutinib  for  1.5  hours, 
followed by staining with Ibrutinib-BFL. Greater than 90% blocking at all concentrations above 
the Ibrutinib IC50 (~1 nM) confirms that Ibrutinib-BFL binds the same target as Ibrutinib. 
 
 
 
 
 
   
Figure 3.5. Optimization of BTK imaging and blocking experiment. a. Staining cells 
with Ibrutinib-BFL. Toledo and Jurkat cells were incubated with 0 nM (top) or 50 nM 
(bottom) Ibrutinib-BFL for two hours, followed by a 24-hour washout period in probe-
free media. Ibrutinib-BFL only remains bound to Toledo cells, as shown by clear 
separation of cell populations by flow cytometry. b. Blocking with Ibrutinib. (Top) 
Difference in fluorescence between Toledo cells stained with 100 nM Ibrutinib-BFL and 
unstained Toledo cells. Unstained cells provide a benchmark for 100% blocking. 
(Bottom) Blocking of BTK staining by pre-incubation of Toledo cells with varying 
concentrations of unmodified Ibrutinib for 1.5 hours, followed by staining with 
Ibrutinib-BFL. Greater than 90% blocking at all concentrations above the Ibrutinib IC50 
(~1 nM) confirms that Ibrutinib-BFL binds the same target as Ibrutinib. leukemia line (Jurkat) by Western blot (Figure 3.4b). As expected, T cells did not express 
BTK. We found high BTK expression in Daudi and Toledo cell lines, and henceforth used 
Toledo as model BTK-positive cells and Jurkat as negative control cells. Toledo and 
Jurkat cells were incubated with different doses of Ibrutinib-BFL, and cell lysates were 
processed for SDS-PAGE and analyzed by fluorescent gel scanning. The imaging probe 
showed remarkable specificity, with binding observed only at a single band (Figure 3.3b). 
The specificity was further confirmed by the absence of a band in BTK-negative Jurkat 
cells, even at the highest concentration of probe (Figure 3.3b), as well as by silver 
staining of the gel (Figure 3.4d). 
  We next performed live cell imaging experiments using an imaging flow cytometry 
system. To prepare Toledo and Jurkat cells, we incubated them with 100 nM Ibrutinib-
BFL for two hours, followed by washing. Figure 3.5 and Figure 3.6 summarize some of 
the results confirming target binding, specificity via blocking, and the ability to perform 
live cell imaging. To quantify co-localization between the imaging probe and BTK at the 
subcellular level, we created a stable transgenic cell line expressing a BTK-mCherry 
fusion protein in HT1080 human fibrosarcoma cells. In vitro cell experiments showed 
excellent co-localization and blocking (r2 = 0.9851; Figure 3.7). 
  We next performed in vivo experiments using three-color (blue: vasculature, green: 
Ibrutinib-BFL, red: BTK-mCherry-HT1080 cells) time-lapse intravital imaging. The 
intravascular half-life of Ibrutinib-BFL was ~10 minutes (Figure 3.8). Within an hour 
after systemic administration, there was extensive leakage of the compound into the  
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Figure 3.6. Cellular imaging of lymphoma cells. Representative images of 
T
oledo (BTK-positive; left) and Jurkat (BTK-
negative; right) cells incubated with 100 nM Ibrutinib-BFL
 at 37°C for 2 hours, then in probe-free media at 37°C for 24 hours. 
Cells were co-stained with Hoechst (nucleus) and CD45 (cell membrane) to show Ibrutinib-BFL
 localization in the cytoplasm of 
BTK-positive cells. Note the specificity
. Images were obtained with an 
Amnis ImageStream flow cytometry system. tumor interstitium and other organs as shown by intravital imaging and in a 
biodistribution experiment (Figures 3.9, 3.10). At later time points, cellular uptake 
became apparent, presumably due to interstitial washout and/or intracellular 
accumulation. The ability to image in multiple channels allowed us to ask whether 
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Figure 3.7. Imaging of adherent BTK-mCherry cells to determine co-localization with 
Ibrutinib-BFL. a. Imaging co-localization between 500 nM Ibrutinib-BFL (green) and 
HT1080 cells stably transfected with BTK-mCherry (red), following a 2-hour incubation 
with Ibrutinib-BFL and then a 24-hour incubation in probe-free media (top). Center: 
competitive inhibition with 1 µM Ibrutinib prior to Ibrutinib-BFL addition. Bottom: 
Ibrutinib-BFL incubated with non-BTK expressing parent HT1080 cells. b. Note the 
exquisite co-localization. Scale bar: 50 µm                                                                                 53
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Supplementary Fig. S3. Vascular half-life. 75 nmol Ibrutinib-BFL was injected into the tail vein 
of C57BL/6 mice and serial imaging was performed in the mouse ear to determine vascular half-
life of the IV injected probe. Imaging was performed using a customized Olympus IV110 laser-
scanning  microscope  equipped  with  a  10x  objective.  a.  Images  of  vasculature  (red)  and 
Ibrutinib-BFL  (green)  over  60  minutes  post  injection.  b.  Fluorescence  in  the  mouse  ear 
vasculature was used to calculate an initial blood half-life of ~11.25 minutes by fitting a one-
phase exponential decay. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Vascular half-life. 75 nmol Ibrutinib-BFL was injected into the tail vein of 
C57BL/6 mice and serial imaging was performed in the mouse ear to determine vascular 
half- life of the IV injected probe. Imaging was performed using a customized Olympus 
IV110 laser- scanning microscope equipped with a 10x objective. a. Images of 
vasculature (red) and Ibrutinib-BFL (green) over 60 minutes post injection. b. 
Fluorescence in the mouse ear vasculature was used to calculate an initial blood half-life 
of ~11.25 minutes by fitting a one- phase exponential decay.                                                                                 54
Figure 3.9. In vivo tumor imaging. Serial imaging before, and at 2, 5, and 24 hours after 
intravenous administration of Ibrutinib-BFL to a representative mouse harboring a BTK-
positive HT1080 tumor (red; first column). Note extensive drug accumulation in all 
cells, persisting even at the 24-hour time point. * Indicates accumulation in non-tumor 
cells (see Figure 3.11). Scale bar: 50 µm Ibrutinib specifically localized in tumor cells. We show that greater than 99% of all BTK-
mCherry-HT1080 cells had achieved therapeutic drug concentrations within one hour. 
This effective intracellular dose persisted for prolonged periods of time and the 
compound was still detectable inside cancer cells 24 hours after administration (Figure 
3.9). Interestingly, there was also accumulation of Ibrutinib-BFL in non-tumor cells even 
at late time points. Given the exquisite specificity of the drug (see Figure 3.3), we 
hypothesized that these non-target cells also contain BTK. We thus performed correlative 
immunohistochemistry using anti-BTK antibody. Our data indicates that Ibrutinib-BTK 
also accumulates in tumor-associated macrophages and lymphocytes (Figure 3.11). 
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Figure 3.10. Ex vivo fluorescence imaging with DMSO control or Ibrutinib-BFL. (top 
and bottom, respectively, of individual organ figures). 
 
-6- 
Supplementary Fig. S4. Ex vivo fluorescence imaging with DMSO control or Ibrutinib-BFL (top 
and bottom of individual organ figures). C57BL/6 mice were IV injected with 150 µL of Ibrutinib-
BFL  solution  [7.5  µL  of  10  mM  Ibrutinib-BFL  solution  in  DMSO  was  diluted  with  142.5  µL  of 
DMAc:solutol:PBS  (v:v:v = 1:1:7.5) mixture (final concentration = 50 µM)] or DMSO control. 
One  hour  after  injection,  animals  are  euthanized  and  the  organs  were  collected.  Ex  vivo 
fluorescence images of organs were obtained using FMT 2500 system (Perkin Elmer). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
3.3. Materials and Methods 
3.3.1. Synthesis and characterization of the probe 
  All reagents were obtained from commercial sources and used without further 
purification. Dry THF, MeOH, DCM, and DMF were obtained from Sigma-Aldrich (St. 
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Figure 3.11. Histology. To corroborate intravital serial imaging, tumors were examined 
histologically. Anti-BTK staining showed BTK signal in HT-1080-BTK-mCherry cells 
as expected, but also in tumor-associated macrophages (white). These regions of drug 
accumulation correspond to those seen by intravital imaging (* in Figure 3.9). Scale bar: 
10 µm Louis, MO). 1H and 13C NMR spectra were recorded at 23°C on a Bruker 400 MHz 
spectrometer. Recorded shifts are reported in parts per million (δ) and calibrated using 
residual undeuterated solvent. Data are represented as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, br 
= broad), coupling constant (J, Hz), and integration. NMR spectra are shown in Appendix 
B. LC-ESI-MS analysis and HPLC-purifications were performed on a Waters (Milford, 
MA) LC-MS system. For LC-ESI-MS analyses, a Waters XTerra® C18 5 µm column was 
used. For preparative runs, an Atlantis® Prep T3 OBDTM 5 µm column was used 
[eluents 0.1% TFA (v/v) in water (solution A) and MeCN (solution B); gradient: 0-1.5 
min, 5-100% B; 1.5-2.0 min, 100% B for analysis and 0-0.75 min, 5% B; 0.75-9.0 min, 
5-100% B; 9.0-10.0 min, 100% B for prep.]. 
 
3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3.1).  
  A solution of 4-amino-1H-pyrazolo[3,4-d]pyrimidine (780 mg, 5.77 mmol) and N-
Iodo-succinimide (2.02 g, 8.98 mmol) in DMF (6 mL) was stirred at 80°C overnight. 
Resulting brown solution was filtered and sticky solid was washed with water and cold 
ethanol. Resulting light yellow solid was dried in vacuo to give compound 3.1 (1.50 g, 
99.6% yield). Crude product was used for the next reaction without further 
characterization. 
3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3.2).  
  A solution of compound 1 (200 mg, 0.77 mmol), tetrakis-(triphenylphosphine) 
palladium (124 mg, 0.11 mmol), potassium phosphate tribasic (488 mg, 2.3 mmol), and 
                                                                                574-phenoxyphenylboronic acid (492 mg, 2.3 mmol) in 1,4-dioxane (2.5 mL) in a 
microwave vial was heated to 180°C for 10 minutes under microwave irradiation. 
Resulting reaction mixture was diluted with water and organic material was extracted 
with EA three times. Combined organic material was dried over Na2SO4 and concentrated 
in vacuo. Resulting yellow solution was dissolved with DCM and resulting turbid 
solution was filtered to give compound 3.2 as a white solid (138 mg, 59.4% yield). 1H 
NMR (400 MHz, DMSO) δ 13.55 (s, 1H), 8.24 (s, 1H), 7.67 (d, J = 8.2 Hz, 2H), 7.44 (t, J 
= 7.8 Hz, 2H), 7.17 (m, 5H); 13C NMR (101 MHz, DMSO) δ 158.0, 157.0, 156.3, 156.0, 
155.7, 143.9, 130.1, 130.0, 128.4, 123.7, 119.0, 118.9, 96.9; LRMS (ESI) m/z calcd for 
C17H13N5O [M+H]+ 304.12, found 304.14. 
  
(R)-tert-butyl 3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-
yl)piperidine-1-carboxylate (3.3).  
  A solution of compound 3.2 (57 mg, 0.19 mmol), (S)-3-hydroxy-N-Boc-piperidine 
(80 mg, 0.40 mmol), DIAD (150 µL, 0.764 mmol), and polymer-TPP (0.5 g, 1.6 mmol) 
in THF (4 mL) was stirred at ambient temperature overnight. After reaction completion, 
polymer-TPP was removed by filtration, filtrate was concentrated in vacuo and purified 
with silica gel column chromatography (EA : Hex = 0 : 100 to EA only) to give 
compound 3.3 (45 mg, 48.7% yield) as a clear oil. 1H NMR (400 MHz, CDCl3) δ 8.37 (s, 
1H), 7.65 (d, J = 7.5 Hz, 2H), 7.38 (m, 2H), 7.19 – 7.12 (m, 3H), 7.08 (d, J = 8.6 Hz, 2H), 
5.49 (s, 2H), 4.84 (dq, J = 10.4, 5.1, 4.3 Hz, 1H), 4.35 – 4.23 (m, 1H), 4.16 – 4.06 (m, 
1H), 3.46 (t, J = 11.5 Hz, 1H), 2.88 (td, J = 12.3, 2.8 Hz, 1H), 2.34 – 2.14 (m, 2H), 1.96 – 
                                                                                581.85 (m, 1H), 1.78 – 1.65 (m, 1H), 1.45 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 158.5, 
157.8, 156.4, 155.7, 154.6, 154.2, 143.6, 130.0, 129.9, 127.9, 124.0, 119.5, 119.1, 98.6, 
79.8, 52.9, 48.2, 44.0, 30.2, 28.4, 24.5.; LRMS (ESI) m/z calcd for C27H30N6O3 [M+H]+ 
487.24, found 487.25. 
 
(E)-ethyl 4-((tert-butoxycarbonyl)amino)but-2-enoate (3.4).  
  To a solution of NaH (50 mg, 1.26 mmol) in THF (4 mL), stirred at 0°C, 
triethylphosphonoacetate (374 µL) was added dropwise. After warming up to ambient 
temperature, solution of N-Boc-2-aminoacetaldehyde (100 mg, 0.63 mmol) in THF (1 
mL) was added. Reaction mixture was stirred at ambient temperature. After reaction 
completion, reaction mixture was diluted with water and organic material was extracted 
with EA three times. Combined organic material was dried over Na2SO4 and concentrated 
in vacuo. Reaction mixture was purified with silica gel column chromatography (EA : 
Hex = 0 : 100 to EA only) to give compound 3.4 (110 mg, 76.4% yield) as a clear oil. 1H 
NMR (400 MHz, CDCl3) δ 6.88 (dt, J = 15.7, 4.9 Hz, 1H), 5.91 (dt, J = 15.6, 1.8 Hz, 1H), 
4.81 (s, 1H), 4.16 (q, J = 7.2 Hz, 2H), 3.89 (s, 2H), 1.42 (s, 9H), 1.26 (t, J = 7.1 Hz, 3H); 
13C NMR (101 MHz, CDCl3) δ 166.2, 155.7, 144.9, 121.4, 79.9, 60.5, 41.4, 28.4, 14.3; 
LRMS (ESI) m/z calcd for C11H19NO4 [M+H]+ 230.13, found 230.15. 
 
(E)-4-((tert-butoxycarbonyl)amino)but-2-enoic acid (3.5).  
  A solution of compound 3.4 (110 mg, 0.48 mmol) and LiOH (168 mg, 2.4 mmol) in 
THF (3 mL) and water (2 mL) was stirred at ambient temperature overnight. THF was 
                                                                                59evaporated and resulting yellow aqueous solution was acidified with 1N HCl to pH 3. 
Organic material was extracted with DCM three times. Combined organic material was 
dried over Na2SO4 and concentrated in vacuo. Reaction mixture was purified with silica 
gel column chromatography (MeOH : DCM = 0 : 100 to 1 : 10) to give compound 3.5 (80 
mg, 82.9% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 6.93 (dt, J = 15.9, 4.7 
Hz, 1H), 5.87 (dt, J = 15.7, 1.9 Hz, 1H), 4.73 (s, 1H), 3.88 (s, 2H), 1.39 (s, 9H); 13C NMR 
(101 MHz, CDCl3) δ 170.9, 155.8, 147.4, 120.8, 80.2, 41.5, 28.5; LRMS (ESI) m/z calcd 
for C9H15NO4 [M+H]+ 202.10, found 202.10. 
 
(R,E)-tert-butyl (4-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-
yl)piperidin-1-yl)-4-oxobut-2-en-1-yl)carbamate (3.6).  
  A solution of compound 3.3 (100 mg, 0.21 mmol) in 2 mL of TFA and DCM mixture 
(1 : 3 = v : v) was stirred at ambient temperature. After 30 minutes stirring, reaction 
mixture was concentrated in vacuo. After azeotropic distillation with DCM and ACN 
three times, crude product was concentrated in vacuo. Then crude product was diluted 
with DMF (2.1 mL) to make 0.1 M solution. 650 µL of crude product solution in DMF 
was mixed with compound 3.5 (16 mg, 0.078 mmol), HBTU (37 mg, 0.097 mmol), and 
TEA (45 µL) in DMF (200 µL) and reaction mixture was stirred at ambient temperature. 
After one hour, reaction mixture was directly loaded onto a C18 reverse phase column for 
purification (Water : ACN w/ 0.1% Formic acid = 95 : 5 to 0 : 100) to give compound 3.6 
(25 mg, 67.8% yield) as a sticky solid. 1H NMR (400 MHz, CDCl3) δ 8.36 (d, 1H), 7.72 – 
7.57 (m, 3H), 7.38 (t, J = 7.8 Hz, 2H), 7.21 – 7.02 (m, 5H), 6.65 (t, J = 9.8 Hz, 1H), 5.75 
                                                                                60(br s, 2H), 4.94 – 4.74 (m, 1H), 4.74 – 4.60 (m, 1H), 4.52 (d, J = 13.0 Hz, 0.5H), 4.10 – 
3.97 (m, 0.5H), 3.86 (d, J = 13.2 Hz, 0.5H), 3.66 (dd, J = 13.2, 10.4 Hz, 0.5H), 3.33 (t, J = 
12.0 Hz, 0.5H), 3.26 – 2.95 (m, 2H), 2.85 – 2.66 (m, 0.5H), 2.50 – 2.15 (m, 2H), 2.06 – 
1.86 (m, 1H), 1.80 – 1.58 (m, 1H), 1.46 (s, 9H); LRMS (ESI) m/z calcd for C31H35N7O4 
[M+H]+ 570.28, found 570.20. 
  (R,E)-3-(3-((4-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-
yl)piperidin-1-yl)-4-oxobut-2-en-1-yl)amino)-3-oxopropyl)-5,5-difluoro-7,9-
dimethyl-5H-dipyrrolo[1,2-c:2’,1'-f][1,3,2]diazaborinin-4-ium-5-uide (3.7). A solution of 
compound 3.6 (5 mg, 0.009 mmol) in 2 mL of TFA and DCM mixture (1 : 3 = v : v) was 
stirred at ambient temperature. After 30 minutes stirring, reaction mixture was 
concentrated in vacuo. After azeotropic distillation with DCM and ACN for three times, 
crude product was concentrated in vacuo. Then crude product was diluted with DMF 
(880 µL) to make 0.1 M solution. 390 µL of crude product solution in DMF was mixed 
with BODIPY-FL-NHS (1 mg, 0.0026 mmol) and TEA (2 µL, 0.013 mmol) in DMSO (1 
mL) and the resulting reaction mixture was stirred at ambient temperature for one hour 
and was then purified using standard HPLC techniques to give compound 3.7 (1.1 mg, 
57.6% yield) as a greenish solid. 1H NMR (400 MHz, CDCl3) δ 8.45 (br s, 1H), 8.23 (d, J 
= 9.9 Hz, 1H), 7.63 (dd, J = 32.3, 8.2 Hz, 2H), 7.48 - 7.21 (m, 3H), 7.21 - 7.06 (m, 2H), 
7.04 - 6.86 (m, 2H), 6.66 (dt, J = 4.9, 4.9, 15.3 Hz, 1H), 6.52 - 6.28 (m, 2H), 6.18 (d, J = 
22.1 Hz, 1H), 4.56 (d, J = 12.3 Hz, 1H), 4.24 (dd, J = 13.3, 39.5 Hz, 2H), 4.03 - 3.78 (m, 
3H), 3.54 - 3.44 (m, 1H), 3.27 - 3.07 (m, 3H), 2.74 - 2.62 (m, 1H), 2.60 - 2.30 (m, 5H), 
                                                                                612.29 - 2.17 (m, 3H), 2.09 - 1.99 (m, 1H), 1.74 - 1.60 (m, 1H); LRMS (ESI) m/z calcd for 
C40H40BF2N9O3 [M+H]+ 744.34, found 744.30. 
 
3.3.2. Kinase inhibition assay 
  The Z’-LYTE Kinase Assay Kit - Tyrosine 1 Peptide (Invitrogen, Grand Island, NY, 
USA) was used according to the manufacturer’s instructions and tested against purified 
BTK enzyme (Promega, Madison, WI, USA) and ATP. The assay was then performed in 
the presence of inhibitors Ibrutinib and Ibrutinib-BFL using 1 µg/mL BTK and 50 µM 
ATP, without pre-incubation of inhibitors with the enzyme. Concentrations of Ibrutinib 
were 4-fold serial dilutions ranging from 33 nM to 0.01 nM, while concentrations of 
Ibrutinib-BFL were 4-fold serial dilutions ranging from 8000 nM to 1.95 nM. Negative 
control samples did not contain ATP, and positive controls contained the pre- 
phosphorylated peptide included in the assay kit. Kinase reaction buffer contained 0.67% 
DMSO. Experiments were performed in quadruplicate in 384-well plates. Fluorescence 
resulting from peptide phosphorylation was measured on a TECAN plate reader system 
(Zurich, Switzerland). Background fluorescence from the fluorescent probe was 
subtracted from the final measurements. Prism (GraphPad Software, La Jolla, CA, USA) 
was used to plot dose-response curves and to calculate IC50 values. 
 
3.3.3. Cell lines 
  The diffuse large B-cell lymphoma (DLBCL) cell lines DB and Toledo were 
generously provided by Dr. Anthony Letai (Dana Farber Cancer Institute, Boston, MA, 
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(Boston University, Boston, MA, USA). Daudi Burkitt’s lymphoma cell line and Jurkat T-
cell leukemia line were from ATCC (Manassas, VA, USA). Lymphoma cell lines were 
cultured in RPMI 1640 media supplemented with 10% fetal bovine serum at 37°C and 
5% CO2. To test the BTK inhibitor in adherent cells, we used HT1080 human 
fibrosarcoma cells, which have previously been shown to be ideal for intravital imaging 
studies84. HT1080 cells were from ATCC, grown in DMEM supplemented with 10% fetal 
bovine serum and 2% glutamine-penicillin-streptomycin at 37°C and 5% CO2. HT1080-
BTK-mCherry cells were prepared by viral infection of HT1080 cells. Virus generated 
from pMSCVpuro-mCherry-BTK retroviral vector85 was a generous gift from Dr. Hidde 
Ploegh (Massachusetts Institute of Technology, Cambridge, MA, USA). Viral supernatant 
was added directly to HT1080 cells for 48 hours, and BTK-mCherry-expressing cells 
were then selected with RPMI media containing 2 µg/mL puromycin for 96 hours. 
Following selection, HT1080-BTK-mCherry cells were cultured under the same 
conditions as the original HT1080 cells. 
 
3.3.4. Western blot 
  Cell lysates were prepared from B-cell lymphoma (Daudi, DB, Toledo, RC-K8) and 
control T cell (Jurkat) lines by lysis in RIPA buffer, and total protein concentrations were 
measured using the TECAN plate reader after performing the Pierce BCA protein assay 
(Thermo Fisher Scientific) according to the manufacturer’s instructions in a 96-well plate 
format. 17.5 µg of each cell line was diluted with H2O to 20 µL, and samples were then 
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for final 25% and 10% concentrations, respectively, and samples were heated to 70°C for 
10 minutes. Samples were loaded onto a 12-well NuPAGE Novex 4-12% Bis-Tris Gel 
(Invitrogen). Using Novex Sharp Pre-stained Protein Standard (Invitrogen) as a size 
marker, the gel was run in MES buffer at 200 V for 35 minutes. An iBlot blotting system 
(Invitrogen) was used for transfer to a PVDF membrane. Membranes were blocked in 
Pierce SuperBlock blocking buffer (Thermo Fisher Scientific) for one hour, then stained 
overnight at 4°C in 1:500 mouse anti-human-BTK antibody (Clone 53/BTK, BD, 
Franklin Lakes, NJ, USA) in TBST buffer containing 10% SuperBlock. Blots were then 
washed in TBST three times for 20 minutes and incubated in 1:1000 Peroxidase 
Affinipure goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, 
PA, USA) in TBST buffer containing 10% SuperBlock for one hour at room temperature. 
After washing three times for 20 minutes each, blots were incubated with SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Fisher Scientific), exposed on film, and 
developed with a Kodak X-OMAT 2000A processor (Rochester, NY, USA). 
 
3.3.5. Gel electrophoresis 
  To test the covalent binding of Ibrutinib-BFL to BTK, 0.1 µg (1 µL) purified BTK 
was combined with 0.4 µL Ibrutinib-BFL (prepared in advance in 2-fold dilutions ranging 
from 200 µM to 0.19 µM, 33% DMSO in PBS) and 18.6 µL PBS, and incubated in the 
dark at room temperature for one hour. In the second experiment, Toledo and Jurkat cells 
(2.2x106 per well in culture media) were incubated in growth media containing 5-fold 
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37°C for two hours. Control samples were incubated in growth media containing 2% 
DMSO. Cells were washed once with ice cold PBS, then lysed in 150 µL 1X RIPA buffer 
(Cell Signaling Technology, Beverly, MA, USA) containing protease inhibitors. To the 
purified enzyme samples or cell lysates, NuPAGE LDS sample buffer and NuPAGE 
reducing agent (Invitrogen) were added for final 25% and 10% concentrations, 
respectively, and samples were heated to 70°C for 10-12 minutes in a Mastercycler 
thermal cycler (Eppendorf, Hamburg, Germany). 25 µL per lane was loaded into 12-well 
NuPAGE Novex 4-12% Bis-Tris gels (Invitrogen). Using 10 µL of Novex Sharp Pre-
stained Protein Standard (Invitrogen) as a size marker, the gels were run in NuPAGE 
MES SDS running buffer (Invitrogen) at 200 V for 35 minutes in the XCell SureLock 
Mini-Electrophoresis system (Invitrogen). The gels were removed from the cassette and 
imaged using a Typhoon 9410 fluorescence scanner (GE Healthcare, Pittsburgh, PA, 
USA) using 488 nm excitation and a 520 nm emission filter. To show total protein 
loading, gels were silver-stained using the Pierce Silver Stain for Mass Spectrometry kit 
(Thermo Fisher Scientific, Rockford, IL, USA). 
 
3.3.6. Flow cytometry 
  Jurkat and Toledo cells were incubated in growth media containing 5-fold serial 
dilutions of Ibrutinib-BFL, ranging from 8 µM to 12.8 nM in final 2% DMSO at 37°C for 
two hours. Control samples contained cells in media containing 2% DMSO. Cells were 
centrifuged and resuspended in growth media at time-points of 1, 14, 24, and 72 hours. At 
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remaining cells were cultured at 37°C. 24 hours was found to be the optimal washout 
time-point and used in subsequent experiments. A separate, blocking experiment was 
performed in which Toledo cells were first incubated in growth media containing 5-fold 
serial dilutions of unmodified Ibrutinib (Cellagen Technology, San Diego, CA, USA) 
ranging from 500 nM to 0.8 nM in final 2% DMSO at 37°C for 1.5 hours. Without 
washout, Ibrutinib-BFL was then added to each well for 50 nM final concentration and 
4% final DMSO, and incubated at 37°C for two hours. A positive control sample 
contained no Ibrutinib, while a negative control for autofluorescence contained no 
Ibrutinib-BFL. After two hours, Ibrutinib-BFL-containing media was removed by 
centrifugation, and cells were incubated in fresh media at 37°C for 24 hours prior to 
analysis by flow cytometry. Cells collected for flow cytometry were centrifuged and 
resuspended in 200 µL PBS containing 0.5% BSA, and filtered through 35 µM Cell 
Strainer tubes (BD). Flow cytometry in the FITC channel was performed on an LSRII 
flow cytometer (BD) and subsequent data analysis was done using FlowJo software 
(TreeStar, Ashland, OR, USA). 
 
3.3.7. Imaging of non-adherent lymphoma cells by flow cytometry 
  Jurkat and Toledo cells were single- or triple-stained with the following, followed by 
washing: Ibrutinib-BFL (2 hours in growth media, 37°C), Hoechst 33342 nuclear dye 
(Invitrogen), or APC-conjugated anti-human-CD45 antibody (Clone HI30, BioLegend, 
San Diego, CA, USA)(both 30 minutes in PBS containing 2% BSA, 4°C). Stained cells 
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ImageStreamX Mark II imaging flow cytometry (Amnis Corporation, Seattle, WA, USA). 
Single-stained samples were used to create a compensation table, then 30,000 images 
from each triple-stained sample were collected using excitation lasers 405-nm, 488-nm, 
592-nm, and bright-field excitation, and 430-550-nm (Ch7), 480-560-nm (Ch2), 640-745-
nm (Ch11), and 430-480 (Ch1) emission filters. Representative images were manually 
selected from this data set. 
 
3.3.8. Imaging of adherent cells by microscopy 
  HT1080-BTK-mCherry cells were seeded into a 96-well plate at 20,000 cells per well 
and allowed to grow to confluence overnight. Cells were incubated in growth media 
containing 1 µM Ibrutinib in final 0.1% DMSO, or control 0.1% DMSO, at 37°C for 1.5 
hours. Without washout, a 50X stock of Ibrutinib-BFL in 5% DMSO was added for a 
final concentration of 500 nM. Control wells contained equivalent DMSO without 
Ibrutinib-BFL. Cells were incubated for one hour at 37°C and then washed once with 
media for five minutes. The media was then replaced and cells were incubated overnight 
at 37°C. The live cells were subsequently imaged on the DeltaVision imaging system 
(Applied Precision, a GE Healthcare Company). Images were processed with Fiji 
software, an open-source version of ImageJ. 
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  Nu/nu mice were implanted with 2x106 HT1080-BTK-mCherry cells into a dorsal 
skinfold window chamber (APJ Trading Company, Ventura, CA, USA) according to 
established protocols7 and according with guidelines from the Institutional Subcommittee 
on Research Animal Care. Tumors were allowed to grow and vascularize for two weeks. 
75 nmol Ibrutinib-BFL in 150 µL solution containing DMAc and solutol was injected via 
tail vein as reported previously61. Mice were anesthetized with 2% isoflurane in 2 L/min 
oxygen. Time-lapse microscopy was performed for two hours using a customized 
Olympus FV1000 confocal/multiphoton microscope equipped with a 20X objective (both 
Olympus America, Chelmsford, MA, USA). In addition, tumors were imaged before 
injection, and at 2, 5, and 24 hours post-injection. Images were processed with Fiji 
software. 
 
3.3.10. Histology 
  HT1080-BTK-mCherry tumors were harvested from nu/nu mice and embedded in 
O.C.T. compound (Sakura Finetek, Torrance, CA, USA). Serial 6 µm-thick frozen 
sections were prepared for histological analysis. Fluorescence immunohistochemistry 
staining was performed using Mac-3 (clone: M3/84, BD Biosciences, San Jose, CA, 
USA) and BTK (clone: D3H5, Cell Signaling Technology), followed by Alexa Fluor 647 
goat anti-rat IgG and Alexa Fluor 488 goat anti-rabbit IgG (both Invitrogen) secondary 
antibodies, respectively. Images were captured using a BX63 fluorescence microscope 
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UK) and processed with Fiji software. 
 
3.3.11. Ex vivo fluorescence imaging 
  C57BL/6 mice were IV injected with 150 µL of Ibrutinib-BFL solution [7.5 µL of 10 
mM Ibrutinib-BFL solution in DMSO was diluted with 142.5 µL of DMAc:solutol:PBS 
(v:v:v = 1:1:7.5) mixture (final concentration = 50 µM)] or DMSO control. One hour 
after injection, animals are euthanized and the organs were collected. Ex vivo 
fluorescence images of organs were obtained using an OV110 system (Olympus 
America) with 488 nm excitation. 
 
3.4. Discussion 
  Inhibition of BTK is emerging as a promising target for B-cell malignancies, other 
cancers with BTK over-expression, and certain autoimmune diseases where BTK is 
involved. Ibrutinib, an irreversible inhibitor, is approved for treatment of mantle cell 
lymphoma and chronic lymphocytic leukemia, and is currently undergoing late-stage 
efficacy studies in patients with various B-cell malignancies. Based on its covalent target 
binding, we hypothesized that the molecule could serve as a companion imaging agent. 
Here we show that this is indeed the case. Ibrutinib-BFL co-localized with BTK in BTK-
positive malignant cells and had low background accumulation in non-BTK cells, 
including those expressing structurally related interleukin-2-inducible T-cell kinase 
(ITK), which is expressed in T cells and Jurkat cells (see Figure 3.4). The companion 
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competitively inhibited, allowed drug concentrations to be quantitated in vivo, and 
enabled mapping of drug distributions at the single cell level. As such, we believe that 
Ibrutinib-BFL could have several applications, including use as a companion diagnostic 
for flow cytometry in haematologic malignancies, as an imaging agent to localize and 
map BTK-positive tumors, as a method to track subcellular localization of endogenous 
BTK, and as a tool to measure pharmacokinetics and pharmacodynamics in experimental 
settings during development of novel BTK-pathway inhibitors. 
  BTK is a cytoplasmic tyrosine kinase belonging to the Tec family. It is expressed in 
the B-cell lineage, plays a pivotal role in signaling and development, and is highly active 
in several haematological malignancies18,86. Some previous BTK imaging has been done 
with fluorescent protein tags (BTK-GFP and BTK-mCherry) to understand its activation 
and nucleocytoplasmic shuttling87-89, and its roles in myeloid cell chemotaxis90 and 
infection85,91. Alternative research methods have primarily involved fluorescently labeled 
antibodies for immunohistochemistry and flow cytometry applications. The former is 
limited to experimental models and requires protein over-expression, and the latter 
requires cell permeabilization and fixation. The approach developed here, utilizing a 
small molecule affinity ligand, is compatible with live cells, can be used in vivo, and has 
potential clinical applicability. Not only does Ibrutinib-BFL specifically bind to BTK, but 
also it remains bound until protein turnover due to the virtually nonexistent off-rate of 
covalent inhibitors. This feature will allow for long-term study of endogenous BTK in 
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heterogeneity in responses to drugs targeting the BCR signaling pathway13,83. 
  Beyond utilizing Ibrutinib-BFL in pharmacologic studies of next generation 
inhibitors, there are future diagnostic opportunities in which BTK-expressing lymphomas 
could be imaged in the clinic. While the current work focused on single cell imaging in 
vivo, we also anticipate whole body imaging applications. For example, the fluorine in 
BODIPY-FL could be exchanged for 18F for positron emission tomography (PET) 
imaging, or entirely replaced via bioorthogonal ligands or direct 18F attachment60,92-94. 
Alternatively, longer-lived isotopes such as Zirconium-89 could also be utilized in order 
to take full advantage of the probe’s irreversible binding kinetics95-99. Such molecules 
may be useful in clinical imaging-based tests for whole body distribution and inhibition 
of BTK. Other areas of interest are to use these molecules for imaging BTK in 
macrophages during infection, or to use them as a readout during gene therapy for the 
immunodeficiency disorder X-linked agammaglobulinemia, which results from loss of 
functional BTK100. Irrespective of the contemplated use, we believe that the developed 
agent should be useful in a number of different applications. As covalent inhibitors have 
gained interest, we anticipate covalent imaging agents to follow, and Ibrutinib-BFL can 
provide a roadmap for such development. 
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3.6. Reflections and Future Work 
  The decision to design an imaging agent with an irreversible inhibitor scaffold 
provided a window into how the roadmap for the development of companion imaging 
drugs might differ for covalent drugs, which is important as more are developed due to 
their specificity to their target and extremely slow off-rate79. However the kinetics and 
binding constants also become complicated, as IC50’s are time-dependent and covalent 
binding is relatively slower than reversible interactions. We found that relatively long 
washout times are required for high signal-to-noise in vitro, meaning that these probes are 
spectacular for labeling and tracking over time, but perhaps less useful for quick 
feedback. 
  To explore these issues further, follow-on experiments are being conducted in which 
binding is measured by anisotropy rather than by fluorescence signal. Bound and 
unbound Ibrutinib-BFL can therefore be differentiated based on the rotational freedom of 
the Bodipy FL fluorophore, which slows down when bound to protein101. This approach 
is being utilized to build binding curves of Ibrutinib according to both concentration and 
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inhibitors in development, including AVL-29278,102. Thus it will be possible to compare 
the binding kinetics and specificities of the various therapeutics, which are in parallel 
clinical trials. Additional follow-on work involves the synthesis of an AVL-292-BFL. 
  Another promising irreversible inhibitor in development is CO-1686 (Clovis 
Oncology), which specifically targets activating EGFR mutations and the T790M EGFR 
resistance mutation in non-small cell lung cancers, while sparing normal EGFR in 
healthy cells103. An imaging probe version of this drug could be useful in differentiating 
cancer cells from healthy cells in both targeted PET and in in vitro diagnostic tests, and is 
also being developed as a follow-on to this work. 
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Molecular profiling of central nervous system lymphomas in cerebrospinal fluid 
(CSF) samples can be challenging due to the paucicellular nature of the limited 
samples. We designed a microfluidic chip able to process the entire CSF sample 
volume, capture single lymphoid cells in sub-nanoliter traps, and then profile the 
cells on-chip by fluorescence image analysis or by response to chemotherapeutic 
agents, all in less than one hour. We show that the system can detect scant 
lymphoma cells and quantitate their kappa/lambda immunoglobulin light chain restriction patterns. The approach can be further customized for measurement of 
additional biomarkers, such as those for differential diagnosis of lymphoma 
subtypes or for prognosis, as well as for imaging exposure to experimental drugs. 
 
4.1. Introduction 
  Central nervous system (CNS) lymphoma is diagnosed in about 10,000 new patients        
per year in the US and is either primary (de novo lymphoma) or secondary (metastases 
from systemic disease). Primary CNS lymphoma (PCNSL) accounts for ~1,500-3,000 
patients in the US, but affects an estimated 2-6% of all AIDS patients and is thus more 
prevalent in low/middle income countries with high AIDS frequency104,105. With respect 
to secondary lymphoma, 25% of Diffuse Large B-Cell Lymphoma (DLBCL) and mantle 
cell lymphoma patients, and up to 50% of Burkitt Lymphoma patients will ultimately 
exhibit CNS involvement106-109. Importantly, secondary CNS lymphoma is often the 
cause of death in high-grade lymphomas unresponsive to treatment110. Clinical diagnosis 
of CNS lymphoma typically relies on conventional cytopathology of CSF or radiographic 
means (MRI). Recent molecular distinctions have been made between germinal (GCB) 
type DLBCL, activated (ABC) type DLBCL, and Burkitt’s lymphoma, and prognosis and 
treatment choices have been shown to depend on these cell-of-origin distinctions, 
highlighting the need for a diagnostic platform that can support molecular 
phenotyping12,15,111-113. 
  Lumbar puncture is used to collect small volumes of cerebrospinal fluid (CSF). CSF        
has a viscosity similar to water and contains distinct electrolytes, but also contains scant 
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monocytes, and 0-30 B lymphocytes, as well as other less common cell populations 
115,116. Table 4.1 summarizes the cell counts for the major cell populations. In patients 
with CNS lymphoma, lymphocyte populations increase in number and are often 
monoclonal. Conventional cytology (smear test) is only useful when lymphoma cells 
make up more than 5% of cells in a sample of CSF, and can be difficult to interpret due to 
similar morphology between benign and malignant lymphocytes117. Newer approaches 
such as flow cytometry have shown impressive sensitivity, but require sufficient numbers 
of cells for analysis 116,118. Thus, estimates of secondary CNS lymphoma prevalence have 
differed in the literature. 
  To address these unmet needs, we sought to design a microfluidic chip that allows        
analysis of all harvested cells (i.e. without the need of sample preparation which often 
loses cells and/or alters them) and which could potentially be used in resource limited 
settings where HIV is more prevalent119. Based on previous designs of chips 
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Table 4.1. Cell populations in CSF 
Normal CNS lymphoma Inflammation
B cells (per mL) 0-30 10-500,000 200-43,000
T cells (per mL) 150-2,000 250-180,000+ (max 97.2%) 9,000-460,000
Monocytes (per mL) 80-1,100 — —
Granulocytes (per mL) 20-430 — —
NK cells (per mL) 0-50 max 7.4% 1,500-50,000incorporating individual cell capture/analysis120, we designed and developed an 
integrated device that allows comprehensive staining, phenotyping, and drug response 
measurements. We expect that this approach will provide a flexible platform to profile 
lymphoma cells from paucicellular samples, thus enhancing the accuracy and ease of 
CNS lymphoma diagnosis, the potential for biomarker-based treatments, and the ability to 
track the efficacy of those treatments over time. 
 
4.2. Results 
  We designed a microfluidic chip which meets several criteria for processing CSF        
samples, including a) sites to capture a large number of lymphoid cells, such that if 
lymphoma cells make up 0.1% of the population, we could capture sufficient numbers of 
cells to identify a monoclonal population, b) antibody-free capture, c) capture sites for 
cells in the 8-10 µm size range, d) gaps so that erythrocytes would not be captured, and e) 
suitable build and materials for cellular analysis. 
  Figure 4.1 summarizes the procedure for lymphocyte detection and profiling. First,        
samples are harvested, typically in the range of 1-3 mL. The entire sample is then loaded 
onto the chip, cells are captured in sub-nanoliter traps, and can then be stained. Finally, 
images are analyzed using automatic algorithm to generate cell characterization data. The 
0.75” x 1.5” chip contains a staggered “plinko”-like board with 24,000 staggered, 
butterfly-shaped traps arranged in four bands of 20 x 300 (Figure 4.1b). The capture site 
size was optimized for the size of a single lymphocyte, while a 4-µm gap between the 
butterfly “wings” was incorporated to allow smaller cells, such as erythrocytes, to pass 
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techniques at a cost of <$1 per chip. With tens of thousands capturing sites, the chip 
enables high-throughput analysis. We calculated that even with gentle flow rates, cells 
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Figure 4.1. Process design. a. Summary of overall scheme: paucicellular samples are 
harvested and captured on the chip without preprocessing. Following on-chip fixation, 
permeabilization, and immunostaining, the chip is imaged and cytometry is carried out 
with an in-house image process algorithm. b. Photograph of lymphocyte capture chip 
attached to a microslide, showing inlet, debris filter, and capture area, which contains 
four arrays of 20 x 300 single-cell capture sites. could be captured and stained in well under an hour, important for processing clinical 
samples (Figure 4.1). 
  We performed validation studies and capturing efficiency tests using fixed cells and        
beads. Using 10-µm beads, we found the optimal flow rate for maximum capture 
efficiency to be ~5 mL/hr (Figure 4.2). Interestingly, slower flow rates decreased capture 
efficiency, presumably due to inertial effects. We next tested the capture efficiency of 
cells. DB GCB-type DLBCL and the Daudi Burkitt’s lymphoma cell lines were stained 
with CD45-APC (an extracellular pan-lymphocyte marker) and Hoechst nuclear dye, and 
imaged on the chip (Figure 4.2a). We were able to efficiently capture 10, 100, or 1000 of 
the pre-stained DB and Daudi cells using a 2 mL/hr flow rate to adjust for cellular 
flexibility (Figure 4.2d). The average capture efficiency of >90% is considerably better 
than the 17-30% cell loss attributable to each centrifugation step in traditional sample 
processing for flow cytometry analysis121,122. 
  Once captured, cells were analyzed by multi-color immuno-imaging. As outlined in        
Figure 4.2, the imaging involves three broad approaches: i) the use of CD19 and/or CD20 
to determine B cells; ii) the use of kappa or lambda light chains to identify clonal 
populations and iii) additional phenotypic markers for subtyping and prognostic tasks. 
We validated these markers using a panel of cell lines representing a variety of B-cell 
lymphomas (Figure 4.3). In addition to Daudi and DB, we also profiled SuDHL4, 
DOHH2, and Toledo GCB-type DLBCL lines, the RC-K8 ABC-type DLBCL line, and 
the Rec-1 mantle cell lymphoma line. Hut-78, a T-cell line, was used as a negative 
control, and CD45 indicates the presence of Hut-78 cells in the experiment (Figure 4.3, 
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Figure 4.2. Validation of on-chip capture and imaging. a. DB cells dual-labeled with 
Hoechst and anti-CD45-APC, and captured and imaged on-chip. Capture sites are 
butterfly-shaped, staggered, and customized for lymphocyte size-based capture. Scale 
bar: 25 µm. b. Proposed workflow for clinical diagnosis using image analysis. c. Left, 
optimization of flow rate based on capture efficiency of 10 µm beads; right, capture 
efficiency of DB and Daudi cells is greater than 90% when 10, 100, or 1,000 lymphoma 
cells were introduced to the chip. 
  bottom row). These experiments showed, for example, that it is important to include both 
CD19 and CD20 in identifying B cells. This is also supported by published literature, as 
CD20 has been sometimes found to be decreased either due to cell-of-origin or anti-
CD20 immunotherapy123-125. We also found that some lymphoma cell lines, such as 
Toledo cells, do not express immunoglobulins, which informed choices of cell lines for 
the validation studies of our chip and algorithm. 
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Figure 4.3. Antibody validation and cell line profiling by flow cytometry. Relative 
expression levels of B-cell antigens relevant to diagnosis and prognosis (rows) on 
several lymphoma cell lines (columns). Daudi is a Burkitt’s lymphoma line; DB, 
SuDHL4, DOHH2, and Toledo are GCB-type DLBCL lines, RC-K8 is an ABC-type 
DLBCL line, Rec-1 is a mantle cell lymphoma line, and Hut-78 is a T-cell lymphoma 
control.   Several different lymphomas arise from germinal center B cells, such as Burkitt’s and        
some DLBCLs (GCB-type), but most primary CNS lymphomas are ABC-type 
DLBCLs126. As expected, we found the GCB marker CD10 expressed in all the GCB cell 
lines tested, but not in ABC-type or mantle cell lymphoma. Since ABC-DLBCLs tend to 
be more aggressive, higher-grade lymphomas, we chose Ki-67 as an important marker for 
characterization and prognosis127. Our data suggests that low Ki-67 in a monoclonal 
population would indicate the need for testing additional lymphoma markers, such as for 
GCB-type DLBCL or mantle cell lymphoma. MUM1 may also be important, as it was 
shown to be expressed in over 90% of PCNSLs126. 
  We chose to use Daudi and DB cells as a model system for on-chip analysis, since        
they respectively highly express kappa and lambda light chain. To demonstrate both 
extracellular and intracellular antigen analysis, we performed on-chip staining using 
CD19 and CD20, kappa and lambda, and Ki-67. We prepared cells for on-chip testing by 
diluting DB and Daudi lymphoma cells into artificial CSF. The cells were then fixed and 
stained on the chip, and imaged in four channels in under an hour (Figure 4.4; see Table 2 
for antibody clones and fluorochromes). Figure 4.4a shows the overlay of the four 
imaging channels after a 1:1 mixture of DB and Daudi cells was captured and stained on-
chip, while Figure 4.4b demonstrates our ability to also perform high-resolution imaging 
of individual cells and markers. Although the cell populations appear to be quite 
heterogenous, their restricted kappa/lambda expression can be seen at higher 
magnification (Figure 4.4b). 
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Figure 4.4. On-chip imaging. A 1:1 mixture of DB and Daudi cells were captured and 
stained on-chip using a cocktail of antibodies: anti-CD19-PE, anti-CD20-PE, anti-
Kappa-Brilliant Violet 421, anti-Lambda-Alexa Fluor 647, and anti-Ki-67-Alexa Fluor 
488. a. Low-magnification image shows overall capture site layout and cell 
heterogeneity. Scale bar: 75 µm. b. High-resolution images of differential expression of 
individual markers on the two cell lines. Scale bar: 5 µm. 
    As a proof-of-concept for future analysis of lymphocytes from clinical samples, we        
developed an image processing algorithm for clonality assessment using the spiked CSF 
samples. Following the workflow described in Figure 4.2, we first made a mask around 
cells expressing CD19 and/or CD20 (PE channel), and then quantified the mean 
fluorescence intensity from our target channels in each individual cell (Figure 4.5a). A 
size filter was also included to exclude non-cell debris from analysis (Figure 4.5a, grey 
arrow). After quantification, we were able to clearly distinguish DB (lambda-expressing) 
and Daudi (kappa-expressing) cell populations from samples containing about 1,000 cells 
(Figure 4.5b). 
  Finally, drug sensitivity testing would be clinically useful to guide intrathecal and/or        
systemic chemo and targeted therapies. We hypothesized that primary captured cells 
could be exposed to companion imaging drugs directly on chip. Some of these agents 
have recently been reported, such as Ibrutinib-BFL, an inhibitor of Bruton’s Tyrosine 
Kinase (BTK)128; others include fluorescent rituximab or caged methotrexate. Ibrutinib is 
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Table 4.2. Antibodies 
Antigen Clone Provider Fluorochrome (on chip)
CD10 HI10a BioLegend —
CD19 HIB19 BioLegend R-PE
CD20 2H7 BioLegend R-PE
CD45 HI30 BioLegend —
Ki-67 B56 BD Biosciences Alexa Fluor 488
κ light chain MHK-49 BioLegend Brilliant Violet 421
λ light chain JDC-12 BD Biosciences Alexa Fluor 647                                                                                85
Figure 4.5. Cell profiling for kappa/lambda monoclonality by image analysis. a. Sample 
image analysis using an in-house image processing algorithm. Thresholding in the PE 
channel (CD19, CD20) is used to select B cells, and size-based filtering removes non-
cell debris (grey arrow). Target channels are analyzed within masks created from PE 
channel gating. b. Scatterplots of mean pixel intensities from target imaging channels 
show clear separation of populations based on kappa and lambda light chain expression; 
top, DB cells; middle, Daudi cells; bottom, 1:1 mixture of DB and Daudi cells. 
  approved for several B-cell malignancies, including mantle cell lymphoma, and the Rec-1 
cell line has been shown to be sensitive to the drug129,130. Imaging the Rec-1 cells with 
Ibrutinib-BFL on the chip shows not only the binding of Ibrutinib, but also their cell-to-
cell heterogeneity due to differences in BTK inhibitor sensitivity and BTK protein 
turnover (Figure 4.6). 
 
 
4.3. Materials and Methods 
4.3.1. Fabrication of single cell capturing chip 
  SU-8 based soft-lithography techniques were used for patterning the single cell        
capturing structure. First, photoresist SU-8 2025 (MicroChem Corp, Newton, MA, USA) 
were spin coated on silicon wafer (University Wafer Inc, Boston, MA, USA). The wafer 
                                                                                86
Figure 4.6. Drug testing. On chip imaging of BTK-positive Rec-1 cells or BTK-negative 
Jurkat cells using fluorescent BTK inhibitor (Ibrutinib-BFL), anti-CD20-APC, and 
Hoechst stain. was baked at 65°C and 95°C, and then exposed to UV light through a pattern mask. After 
exposure, the pattern was baked and then developed using SU-8 developer (MicroChem 
Corp, Newton, MA, USA).  
  PDMS channels were made using the SU-8 wafer mold. After patterning, the wafer        
surface was treated by trichlorosilane (Sigma Aldrich, St Louis, MO, USA) under 
vacuum. PDMS (Dow Corning, Midland, MI, USA) was mixed with curing agent at a 
ratio of 10:1. The mixtures was poured over the treated wafer mold and baked at 60°C for 
one hour to cure. After curing, the PDMS layer was lifted from the wafer and bonded to a 
glass slides using surface plasma treatment.  
 
4.3.2. Flow rate optimization 
  Fluorescent 10 µm micro-beads (Bangs Laboratory, Fishers, IN, USA) were used to        
test capture efficiency and to identify the optimal flow rate. First, PDMS channels were 
preconditioned using pluoronic copolymer solution with 0.1% F127 in DI water (Sigma 
Aldrich). The inlet of the channel was connected to a reservoir of beads in solution and 
the outlet to a syringe pump. The syringe pump was programed to control the flow rate of 
the fluid. Bead solutions were diluted to 300 beads per 100 µL and the total bead counts 
were about 300. After capturing, we use fluorescent microscope to image and count the 
total number of beads captured in the chip. 
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  The GCB-type diffuse large B-cell lymphoma (DLBCL) cell lines DB and Toledo        
were generously provided by Dr. Anthony Letai (Dana Farber Cancer Institute, Boston, 
MA, USA). The RC-K8 ABC-type DLBCL cell line was a generous gift from Dr. 
Thomas Gilmore (Boston University, Boston, MA, USA). The GCB-type DLBCL cell 
lines SuDHL4 and DOHH-2 and the mantle cell lymphoma cell line Rec-1 were provided 
by Dr. Russell Ryan (Massachusetts General Hospital, Boston, MA, USA). Daudi 
Burkitt’s lymphoma cell line and Hut-78 T-cell lymphoma lines were from ATCC 
(Manassas, VA, USA). B-cell lymphoma lines were cultured in RPMI 1640 media and 
Hut-78 cells were cultured in Iscove’s Modified Dulbecco’s Medium (both Invitrogen, 
Grand Island, NY, USA), both supplemented with 10% fetal bovine serum at 37°C and 
5% CO2. 
 
4.3.4. Titration of cells 
  Approximately 1.5x106 cells from culture flasks were washed with PBS and stained        
for 30 minutes at room temperature in 1.5 µg/mL Hoechst 33342 (Invitrogen) and APC 
anti-human-CD45 antibody according to manufacturer instructions (Clone HI30, 
BioLegend, San Diego, CA) in PBS containing 2% albumin from bovine serum (BSA) 
(Sigma Aldrich). Following a quick wash with PBS, cells were fixed in 2.6% 
paraformaldehyde (PFA) in PBS (initial 4% PFA in PBS, Affymetrix, Santa Clara, CA, 
USA) at room temperature for 20 minutes. Cells were then washed 3x with PBS and 
counted using a Bright-line hemocytometer (Hausser Scientific, Horsham, PA, USA). The 
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in 1 mL PBS in siliconized microtubes (Clear-view Snap-Cap, Sigma-Aldich). Each 
batch of samples was then introduced to a preconditioned device at a flow rate of 2 mL/
hr. After 30 minutes, the cells were trapped at the capture sites. The cells were then 
counted by eye and showed good agreement with expected cell counts by 
hemocytometer, with an average recovery rate >90%. 
 
4.3.5. Flow cytometry for cell line profiling 
  To measure expression of extracellular markers, cells were washed with PBS, fixed in        
2.6% PFA in PBS (initial 4% PFA in PBS, Affymetrix) for 15 minutes at 37°C, then 
washed 2x with PBS and 1x with PBS containing 2% BSA (staining buffer, SB), and 
allowed to block for ~30 min. Approximately 5x105 cells in were incubated with 4.4 µg 
antibody or mouse IgG control in 42.5 µL (CD10, CD19, CD20, CD45) or with 2.5 µg 
antibody in 50 µL (κ light chain, λ light chain) for 30 minutes at 4°C. For intracellular 
Ki-67 detection, cells were fixed and permeabilized using the eBioscience Foxp3/
Transcription Factor Staining Buffer Set according to manufacturer instructions (San 
Diego, CA, USA) and allowed to block in perm/wash buffer containing 2% BSA 
(permSB) for ~30 min following washout of fix/perm buffer. ~5x105 cells in were 
incubated with 5 µg antibody or mouse IgG control in 50 µL for 30 minutes at 4°C. Cells 
were then washed 1x with SB or permSB and incubated in 20 µL 1:100 R-phycoerythrin 
(PE) goat anti-mouse-IgG (H+L) (1 mg/mL, Invitrogen) secondary antibody reagent for 
30 minutes at 4°C in SB or permSB. Unstained controls were incubated in just SB or 
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NY, USA). Following 1x wash with SB or permSB, cells were resuspended into 200 µL 
PBS containing 0.5% BSA and transferred into Falcon tubes with cell strainer caps (BD 
Biosciences, San Jose, CA, USA) for flow cytometry. Stained and unstained control 
samples were measured on a BD LSRII Flow Cytometer equipped with an Argon 488-nm 
laser using a PE filter set (all BD Biosciences), and analysis was done using FlowJo 
software (Tree Star, Ashland, OR, USA). Mean PE values were found for each cell line / 
antibody combination and normalized to (signal - background)/(IgG - background) for 
CD10, CD19, CD20, CD45, and Ki-67 or (signal - background)/(secondary - 
background) for κ light chain and λ light chain. A heat map was generated using 
MATLAB (MathWorks, Natick, MA, USA) and scaled according to the normalization 
above, with max 50x signal/control for optimum coloration. 
 
4.3.6. Antibodies 
  Several antibodies for each biomarker were tested using combinations of cell lines to        
allow for positive and negative controls, including various clones and manufacturers. 
Purified antibodies for cell profiling were chosen based on a combination of high signal, 
low background in negative control cells, mouse host (for standardized secondary 
reagent), and cost, and are summarized in Table 4.2 (all chosen were obtained from BD 
Biosciences or BioLegend). Fluorescent antibodies from the same clone and 
manufacturer were chosen for on-chip staining. 
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  DB and Daudi cells were prepared by eliminating dead cells (common in suspension        
culture) using Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, UK). 4 mL cells in 
culture media were carefully pipetted onto 4 mL Ficoll, and centrifuged at 400 g, 19°C 
for 30 minutes. The live cells settled at the interface and were collected, diluted 1:1 with 
PBS, and centrifuged at 150 g, 19°C for 10 minutes. The cell pellet was resuspended at a 
concentration of 106/mL in PBS. About 1000 DB, Daudi, or a 1:1 mixture of cells were 
then diluted into 1 mL of artificial cerebrospinal perfusion fluid (aCSF; Harvard 
Apparatus, Holliston, MA, USA). Cells were captured onto the chip at the optimized flow 
velocity for cells of 2 mL/hr. Next, we used the fixation/permeabilization buffer (fix/
perm) and permeabilization/wash buffer (perm/wash) from the eBioscience Foxp3/
Transcription Factor Staining Buffer Set to fix and permeabilize cells on the chip. Fix/
perm was perfused over the cells for 10 minutes, followed by perm/wash containing 2% 
BSA for 5 minutes, and PBS containing 2% FBS (Invitrogen) / 1% BSA for 5 min, all at a 
flow rate of 1 mL/hr. A cocktail of antibodies containing 1 µL of anti-Ki-67, anti-CD19, 
and anti-CD20, and 2 µL of anti-κ light chain and anti-λ light chain (see Table S1 for 
clone,  manufacturer, and fluorochrome information; all were obtained and used without 
prior dilution) was perfused over the cells at 1 mL/hr for 5 minutes. Lastly, to reduce 
background signal from antibodies binding to the PDMS surface, washing buffer (PBS 
with 2% FBS / 1% BSA) was perfused at 1 mL/hr for 5 minutes. Alternatively, cells were 
exposed to Ibrutinib-BFL using conditions recently described prior to imaging128. Images 
were captured on a Nikon Eclipse TE2000S inverted microscope (Nikon, Tokyo, Japan) 
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DAPI/Hoechst/AMCA; 41001 - FITC/ EGFP/ Bodipy Fl/ Fluo3/DiO; 41002b - TRITC 
(Rhodamine)/DiI/Cy3™/AF546 with narrow-band excitation filter; and 41024 - Cy5™ 
Longpass Emission). A CMOS camera (Andor Technology, Belfast, UK) was used to 
capture 10X images in four fluorescent channels corresponding to the antibody-
conjugated fluorochromes listed in Table 4.2. 
 
4.3.8. Image Analysis 
  Images were analyzed using an in-house Matlab (Mathworks, Natick, MA) script.        
Briefly, images from the CD19/20 (PE) channel were thresholded and binarized using 
Otsu’s method with an additional uniform offset to compensate for the specific properties 
of the images. Following thresholding, image regions were analyzed and filtered by 
eliminating any regions greater or less then preset total pixel areas based on the 
magnification of the images. Additional noise was filtered by using “open-close” 
morphological filtering. Boundaries of the remaining regions were then recorded and 
overlaid on target channels where values for the pixels in each mask area for both lambda 
(Alexa Fluor 647) and kappa (Brilliant Violet 421) channels were generated. Final values 
for both lambda and kappa channels for each cell were calculated by averaging the most 
intense 25% of pixels in each region. 
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  CNS lymphoma is difficult to diagnose and characterize at the site of disease, often        
requiring multiple invasive lumbar punctures to retrieve sufficient numbers of cells to 
allow cytopathologic analysis. Due to the paucicellularity and heterogeneity of CSF 
samples, we hypothesized that a PDMS-based capture device would allow 
characterization of populations of lymphoma cells in the CSF on a single-cell level. Here, 
we show that we can indeed image both intracellular and extracellular diagnostic markers 
from lymphoma cells spiked into artificial CSF in under an hour, and further use an 
image processing algorithm to quantitate their expression level. By adding additional 
criteria, differential diagnosis using the Hans algorithm can identify the cell-of-origin of a 
PCNSL, perhaps pointing to an undiagnosed systemic lymphoma if germinal origin is 
found126,131. 
  For secondary CNS lymphoma, it is important to know the extent of metastasis, its        
aggression, and its response to treatment. Methotraxate is currently used intrathecally or 
at very high systemic doses to treat CNS disease, but it has thus far not been possible to 
track response to treatment other than by low resolution MRI or insensitive cytology, 
neither of which would catch minimal disease132-134. By profiling lymphoid cells in CSF 
based on kappa/lambda restriction or proliferative grade, or by customizing antibody 
staining for intracellular or extracellular markers based on particular characteristics of the 
primary tumor (e.g. c-myc rearrangement, CD10, CD5, etc.), CNS lymphoma cell counts 
can be tracked over time and prognostic assessments can be made135,136. Additionally, 
there are several new lymphoma drugs in clinical trials, yet few are tested for CNS 
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brain-blood-barrier drug permeability or look for specific marker inhibition following 
intrathecal administration, such as BTK inhibitors or anti-CD20137-140. To test for such 
drug accumulation (single cell pharmacokinetics) in primary lymphoma cells, we tested 
Ibrutinib-BFL directly on chip. Finally, another approach includes removing CSF after 
intrathecal injection of chemotherapy drugs to track treatment response over time. 
  Additional technologies can be added to front- or back-processing on the chip for        
further improvements and applications. For example, it will be possible to further purify 
B cells by negative selection of other cell types, such as T cells and monocytes. Since the 
capture is passive (i.e. no antibodies on the chip), we can also use optical approaches to 
remove single cells of interest off the chip for further characterization, such as by 
quantitative PCR and sequencing — now possible on a single-cell level 141. Another 
possibility will be to add a CCD or iPhone camera readout to enable the chip to be used 
for lymphoma diagnosis in resource-poor settings. We estimate that in this application a 
1:5 cutoff ratio of kappa-to-lambda fluorescence signal would be enough to establish 
clonality with high specificity. Overall, we believe this new application of single-cell 
molecular profiling on a microfluidic chip for lymphoma will address questions regarding 
the diagnosis and treatment response of the disease not only in CSF, but also in other 
paucicellular samples such as fine needle aspirates, peritoneal fluid samples, pediatric 
applications or vitreous fluid analysis.   
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  The next step in this project is to utilize our microfluidic technology to profile clinical        
samples from lumbar punctures from patients with suspected and/or confirmed CNS 
lymphoma. We plan to start our study with discarded tissue samples, for which half of the 
sample will be sent for pathology, either cytopathology or flow cytometry. It will be 
interesting to compare the performance of the microfluidic chip (i.e. sensitivity and 
specificity) to these more conventional methods. We may also be able to acquire serial 
samples from patients known to be positive for CNS lymphoma who are receiving a 
course of intrathecal treatment, in which we could map whether lymphoma cell count 
decreases or increases over time, as well as any change in molecular markers over the 
course of treatment. This may allow us to hone in on effective treatments for CNS 
lymphoma, whether CSF lymphoma cell counts over time correlate with outcome, 
whether patients are being given drugs via painful lumbar punctures without a need for 
them, and the patient profiles for which the administered treatments are most effective134. 
  In terms of further technology development, we also plan to explore expanding our        
ability to multiplex (beyond 4-5 fluorescent channels) by performing multiple rounds of 
staining using stripping buffers. Finally, we will optimize an optical tweezers method to 
remove single cells from the chip for genomic analysis. Since relatively little is known 
about the incidence and treatment response of CNS lymphomas due to the limited-
information tests currently available, it will be particularly interesting to use these 
microfluidics approaches to investigate the differential biology of lymphoma cells in the 
CSF. 
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Paper-based TCO/Tz Click Chemistry in Low-Cost, Point-of-Care 
Diagnostics 
   
Thomas Reiner, Eunha Kim, and I designed the research, performed chemical synthesis 
and other experiments, and prepared figures. Joshua Dunham assisted with fluorescence 
imaging and David Issadore contributed an introduction to the field and helpful 
discussions. 
 
In the quest for lower cost diagnostics, paper-based tests are a promising solution. 
However, the design of semi-quantitative assays has been largely limited to the 
detection of analytes by color or conductance changes, and it may be helpful to 
introduce other types of chemistries to enable a broader array of tests. Here we 
show that we can perform cellulose chemistry on solid papers, including a synthetic 
route to “clickable” trans-cyclooctene(TCO)-paper for bioorthogonal click 
chemistry reactions. We can then detect the binding of tetrazine(Tz)-modified dyes 
to the paper through the TCO/Tz click reaction using either a spot-based or lateral-
flow approach. Paper-based chemistries can also enable a variety of potential 
applications in drug screening or substrate patterning. 
 
5.1. Introduction 
  Newly realized paper-based microfluidics has recently emerged as a platform and        
opportunity to translate a variety of diagnostics into new formats24,142,143. This method has several key advantages over traditional diagnostics, particularly in resource-poor 
settings in the developing world, including a) ultra-low-cost materials, b) no need for 
external pumps, c) small sample sizes, d) inherent filtration of cells, such as from blood, 
and e) disposable24,143-147. It is interesting to note that paper diagnostics have existed for 
decades in the form of pregnancy and other dipstick tests, but only recently has the 
approach been applied to new problems, and only recently has microfluidics engineering 
been used to move tests into two- and three-dimensional formats148,149. 
  Microfluidics relies on low Reynolds number, laminar flow, typically realized by        
patterning micro-scale channels in silicon wafer molds and casting these molds in 
polymers such as polydimethylsiloxane (PDMS)150. The pores in cellulose are on the 
same scale as these channels, providing a method to achieve laminar flow without the 
need for clean-room micropatterning techniques. Laminar flow is non-turbulent, so the 
flow of liquids can be directed based on pressure from different non-mixing streams; thus 
features from PDMS-based microfluidics such as programmable valves, hydrodynamic 
focusing, and multistep assays can be translated to the paper-based format151-158. Macro-
scale patterning (to create ~1-5 mm in diameter channels or “wells” for ELISA-type 
assays) on paper-based devices has been achieved using wax-printing, laser-cutting, 
origami, photolithography, or “sizing” agents, while materials include chromatography 
paper, filter paper, or glass fiber membrane159-167. Additional patterning can be done with 
nano particles or inkjet printing168,169. These fabrication and patterning techniques, 
combined with microfluidic and other 3-D design principles, have allowed for the 
development of various, multiplexed devices utilizing lateral or vertical flow, for 
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and environmental safety25,26,170-178. 
  Current assays performed on paper devices include ELISAs and other immunoassays,        
nucleic acid hybridization, and color- and electrochemistry-based analyte detection 
177,179-191. However, additional tools are needed to widen the array of possible tests that 
can be developed. By applying traditional chemistry approaches to paper patterning and 
reactions on paper, it will be possible to create new tests involving small-molecule 
detection and patterning. We sought to leverage the [4+2] Diels-Alder cycloaddition 
using TCO/Tz (described in depth in Chapter 2) to create new capabilities on paper-based 
devices. Some chemistries have been recently used to functionalize solid paper 
substrates192-194, but this is the first demonstration of click chemistry for detection during 
paper-based assays. We first confirmed that we could perform standard chemical 
reactions on chromatography and filter papers, and then went on to make “clickable” 
TCO-paper with small-molecule paper sites. The functionality of the TCO-paper was 
then demonstrated in several formats. Although we have not yet applied these methods to 
a diagnostic assay, we believe it could have applications in the detection of a variety of 
drugs and drug-targets. 
 
5.2. Results 
  To test whether we could translate published synthetic chemistry approaches for the        
modification of cellulose in solution to solid-substrate commercial paper fibers (e.g. 
chromatography and filter papers), we first performed an acetylation reaction to make 
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microfluidics work24,142,159, Whatman 1 Chr paper was used for the starting material. Cut 
pieces (about 20 cm2 in size) were submerged in acetic anhydride with 10% pyridine and 
heated to 60°C for 24 hours. After washing the product, it was confirmed that the paper 
was hydrophobic, not allowing water droplets to soak into the fiber (Figure 5.1b). 
  Having confirmed that it was possible to sufficiently modify the hydroxyl groups of        
commercial solid paper fibers to see a change in macro-scale properties, we went on to 
make Amine-Paper, and finally clickable TCO-Paper. We first chose the material for 
reaction, as various manufactured cellulose papers have varying properties195. Whatman 1 
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Figure 5.1. Acetyl-Paper. a. Reaction scheme for acetylation of cellulose to make 
hydrophobic paper. b. When droplets of water are introduced to unmodified paper, they 
soak into the hydrophobic paper. In contrast, droplets sit on top of the more hydrophobic 
acetylated paper.Chr chromatography paper is 180 µm thick with 11 µm average pore size, while 
Whatman #4 filter paper is 205 µm thick with 20-25 µm average pore size. In testing the 
two papers, better reaction efficiency was found for the #4 filter paper, perhaps due to the 
larger pore size, which allows for greater interaction between molecules in solution and 
on the fiber. The reaction scheme to make TCO-Paper is shown in Figure 5.2. In brief, 
cellulose paper was first reacted with 4-Toluenesulfonyl chloride (TsCl) to yield Tosyl-
Paper. After a washing and an in vacuo drying step, Tosyl-Paper was reacted with 
diaminoethylene in DMSO to make the amine functionalized Amine-Paper. Finally, the 
Amine-Paper was reacted with TCO-NHS or TCO-PEG4-NHS to yield TCO-Paper or 
TCO-PEG-Paper, respectively. TCO-PEG4-NHS was tested since we thought the longer 
linker may lead to different positioning of the functional group within the paper fibers. 
  The paper products were characterized at two stages of synthesis: Amine-Paper and        
TCO-Paper / TCO-PEG-Paper. To test for primary amine functional groups, a ninhydrin 
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Figure 5.2. TCO-Paper synthetic scheme. Clickable TCO-Paper is synthesized in three 
steps from cellulose filter paper. In the case of TCO-PEG-Paper, a PEG4 linker separates 
the TCO from the sugar.
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Bioorthogonal Small-Molecule Ligands for PARP1 Imaging in Living Cells
Thomas Reiner, Sarah Earley, Anna Turetsky, and Ralph Weissleder*
[a]
Poly(ADP-ribose) polymerase 1 (PARP1) is an important cellular
protein that senses DNA damage and initiates the base exci-
sion repair pathway.
[1] DNA damage (strand breaks) occurs
during each cell cycle and must be repaired for a cell to sur-
vive. In the absence of functional BRCA (another class of com-
plementary DNA repair enzymes), cells depend primarily on
the PARP repair mechanism. Thus, PARP inhibitors
(PARPi) are emerging as a useful option for cancer
therapy, either as single agents or in combination
with other DNA-damaging molecules.
[2,3,4] In view of
their encouraging results in breast cancer trials, there
is now considerable interest in expanding PARPi to
other primary tumors. However, despite the increas-
ing body of literature on PARP, many questions
remain unanswered, not only regarding its basic biol-
ogy, regulation, heterogeneity, and role in individual
tumor types, but also regarding the efficacy of new
PARPi, optimum dosing, timing and combination of
treatment, among other factors.
[2,5] For example,
PARP1 has a number of additional roles,
[2] including
the restarting of stalled replication forks, the inhibi-
tion of nonhomologous end-joining repair, the regu-
lation of transcription, the initiation of a unique cell-
death pathway, and the modulation of cellular bio-
energetics.
[2] Thus, to gain more insight into these ad-
ditional roles and to better understand PARP1 regula-
tion in vivo, it would be an enormous advantage to
be able to image PARP1 in live cells and ultimately in
whole living organisms. Whilst green fluorescent pro-
tein (GFP) fusion proteins remain valuable tools for
imaging at the cellular level, labeled affinity ligands,
which are cell permeable, will ultimately be required
for whole-body preclinical and clinical imaging.
To date, a variety of small-molecule PARPi have been devel-
oped. These include the lead group 1(2H)-phthalazinones, such
as AZD2281 (1) and its derivatives.
[2,5,6] It has been shown that
the 4-NH-piperazine of AZD2281 tolerates a diverse range of
capping groups without significantly decreasing PARP1 bind-
ing affinity.
[6] We therefore used this anchor point to attach
bioorthogonally reactive groups and/or different fluorophores
to the phthalazinone. We hypothesized that these modifica-
tions would still result in low nanomolar affinity ligands and
that conjugates would retain their cell permeability, particularly
with the use of bioorthogonal linkers.
As a precursor for the synthesized AZD2281 inhibitors
(Scheme 1), 4-[[4-Fluoro-3-(piperazine-1-carbonyl)phenyl]meth-
yl]-2H-phthalazin-1-one (2) was obtained according to known
literature procedures.
[6] For the synthesis of the bioorthogonal-
ly reactive derivatives AZD2281-NOB (6) and AZD2281-TCO (7),
compound 2 was first reacted with glutaric acid anhydride to
produce the glutaric acid-modified 4-(5-oxopentanamide)piper-
azine (3) in 72% yield. Subsequently, an ethylene diamine
spacer was attached to precursor 3, yielding the amine-func-
tionalized AZD2281 derivative 4. Norbornene-functionalized
AZD2281-NOB (6) was obtained by amide-bond formation with
5-norbornene-2-carboxylic acid in the presence of polymer-
supported dicyclohexylcarbodiimide (DCC) beads. In the case
of AZD2281-trans-cyclooctene (AZD2281-TCO; 7), precursor 3
was reacted with (E)-cyclooct-4-enyl 2,5-dioxopyrrolidin-1-yl
carbonate (5) in the presence of triethylamine.
[7] The identities
of all 1(2H)-phthalazinone-based bioorthogonal probes and
their precursors were confirmed using HPLC-MS, high-resolu-
tion MS and NMR spectroscopy.
The fast reaction kinetics of trans-cyclooctenes (TCO) and
tetrazines (Tz)
[7–10] make AZD2281-TCO (7) a potential candi-
date for live-cell imaging using fluorophore-tetrazine deriva-
Scheme 1. Synthesis of bifunctional 1(2H)-phthalazinone-based targeted probes. Re-
agents and conditions: a) Polystyrene-bound DCC, Et3N, CH2Cl2, RT, overnight; b) Et3N,
CH2Cl2, RT, overnight; For detailed synthetic descriptions, see the Supporting Informa-
tion.
[a] Dr. T. Reiner, Dr. S. Earley, A. Turetsky, Prof. R. Weissleder
Center for Systems Biology, Massachusetts General Hospital, Richard B.
Simches Research Center
185 Cambridge Street, Suite 5.210, Boston, MA 02114 (USA)
Fax: (+1)617-643-6133
E-mail: rweissleder@mgh.harvard.edu
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/cbic.201000477.
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Figure 5.3. Characterization. a. Amine-Paper testing. Ninhydrin solution changes color 
in the presence of primary amines when heated; Bodipy 650/665-X, SE binds to Amine-
Paper, but not to unmodified cellulose. b. TCO-Paper testing. Texas Red-Tz and Bodipy 
FL-Tz dyes bind to TCO-Papers, but not to unmodified cellulose. Dye was pipetted into 
the center of each circle, and the reaction is so quick that white edges are visible where 
dye did not wick any further. Dyes are shown under white light and UV light; paper 
circles are 4 mm in diameter.test was performed on Amine-Paper and starting material (unmodified Whatman #4 filter 
paper) (Figure 5.3a, top). In addition, we tested the reaction of the primary amine groups 
with a Bodipy 650//665-X succinimidyl ester (SE) dye under the same conditions as the 
Amine-Paper-to-TCO-Paper synthetic step. After washing with DMSO, the dye remained 
covalently bound to Amine-Paper, yielding a colored, fluorescent paper, while the dye 
was cleanly washed away from unmodified paper (Figure 5.3a, bottom). The TCO-
Papers’ clickability was characterized using two tetrazine-conjugated dyes, Texas Red-Tz 
(2.8) and Bodipy FL-Tz. Notably, when the dyes were pipetted into the center of 4 mm-
circular cutouts of TCO-Paper or TCO-PEG-Paper, the click reaction occurred so quickly 
that the dye could not wick to the perimeter of the circle. After washing, Tz-dyes were 
washed away from unmodified paper, but remained covalently bound to TCO-
functionalized papers, visible under white or UV light (Figure 5.3b). No difference was 
noticeable between the reactivities of TCO-Paper and TCO-PEG-Paper. 
  To begin to build paper-based microfluidic devices for small molecule assays, we        
wax-printed test devices using a wax printer and a hot plate to melt the wax into 
hydrophobic barriers permeating the paper. Several organic solvents were tested against 
the wax barriers for their potential to transport organic small molecules in a lateral flow 
assay. We found that the wax channels withstand DMSO better than DMF, ethanol, or 
methanol (Figure 5.4a). Since 100% DMSO was nevertheless able to dissolve the wax, 
we next tested the ability of 50% and 75% DMSO in water to transport a model small 
molecule drug, AZD2281-Tz (2.17). 75% DMSO was found to be the optimal solvent for 
balancing the needs to solubilize and transport organic small molecules, yet not bleed into  
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the wax channels (Figure 5.4b). 
  One application of TCO-Paper is as a capture site for a tetrazine-conjugated dye or        
drug molecule. To test it in a lateral flow assay format, the TCO-Paper was first “grafted" 
onto a wax-printed channel by using a biopsy punch to punch a hole out of the channel 
and replace it with a circle of TCO-Paper (Figure 5.5a; photographs in Appendix C). A 
paper-based, lateral-flow click chemistry reaction was then performed and imaged on a 
fluorescence macroscope. Texas Red-Tz was spotted onto a paper device and 75% 
DMSO was introduced upstream to flow down the device, carrying the Texas Red-Tz 
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Figure 5.4. Solvent optimization. a. Hydrophobic wax channels are able to withstand 
DMSO better than ethanol, methanol, or DMF; DMSO traveled down the channel from 
the top, whereas other solvents formed rings where they were added to the paper. b. In a 
race down wax-printed lanes, 75% DMSO transports AZD2281-Tz (pink) the farthest 
down the channel. AZD2281 was initially spotted where shown in the control (—).over the TCO-Paper capture site. Upon contact with the TCO-paper, Texas Red-Tz was 
clearly visible bound to the capture site (Figure 5.5b). The Texas Red-Tz reaction with 
TCO-Paper can be blocked by co-spotting 19F-TCO (2.15), demonstrating the specificity 
of the reaction (Figure 5.5b, far left). 
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Figure 5.5. Lateral flow test. a. Schematic of paper device shows wax-printed channel in 
a 10-cm petri dish; blue is a cigarette filter for solvent-loading and yellow represents the 
TCO-paper that was cut and replaced part of the channel as the capture site. b. 
Brightfield (left) and fluorescent images of a lateral flow test. At the solid white arrows, 
1 µL of Texas Red-Tz dye was spotted prior to lateral flow; at the dotted arrow, 19F-TCO 
was co-spotted to block binding of the dye to the TCO-paper. Scale bar: 0.5 cm.5.3. Materials and Methods 
Unless otherwise noted, all reagents were purchased from Sigma-Aldrich (St. Louis, MO, 
USA) and used without further purification. 
 
5.3.1. Synthesis and Characterization of Acetylated Paper 
  Acetylation of paper was adapted from previously published procedures196. Six        
1.5x2” cutouts of Whatman 1 Chr cellulose chromatography paper (1; GE Healthcare, 
Piscataway, NJ, USA) and a magnetic stirrer were dried in a 150°C oven for two hours, 
giving a final dry paper mass of 1.12 g (~7.4 mmol cellulose units). 10% pyridine in 
acetic anhydride were added to submerge the paper and the resulting mixture was heated 
to 60°C under reflux for 24 hours, giving acetyl-cellulose, a white paper. The paper was 
then washed on a Büchner funnel sequentially with 250 mL each of water, EtOH, 
methanol, diethyl ether, water, and acetone, and then dried in vacuo overnight. The 
hydrophobicity of acetylated paper was tested against control unmodified 1 Chr paper by 
introducing water droplets onto paper strips. Results were photographed using an iPhone 
camera (Apple Inc., Cupertino, CA, USA). 
 
5.3.2. Synthesis of TCO-Paper 
  Tosylation of paper, followed by amination, was adapted from previously published        
procedures197-201. All modified papers were stored in vials at -80°C. 
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  ~200 mg (~1.2 mmol) Whatman #4 cellulose filter paper (GE Healthcare) was dried        
in a 150°C oven for two hours (resulting in ~9% loss of mass due to water evaporation) 
prior to submerging it in 3 mL triethylamine. 9% (by weight) LiCl in dimethylacetamide 
(DMAc) was made by adding 1.68 g LiCl into 20 mL DMAc (18.74 g), and 10 mL of this 
was added to paper while stirring. To the other 10 mL of LiCl/DMAc, 4-Toluenesulfonyl 
chloride (TsCl, 1.7 g, 8.9 mmol) was added, and this solution was added to the paper 
mixture dropwise while stirring. The mixture was then allowed to stir at room 
temperature, covered, for 24-36 hours (mixture became brown and turbid), to give Tosyl-
paper, which was yellowish. The paper was then washed on a Büchner funnel 
sequentially with water, ethanol, and acetone, and dried in vacuo overnight.   
 
Amine-Paper 
  Tosyl-Paper was submerged in 50 mL DMSO and 0.875 mL 1,2-diaminoethane (0.79        
g, 13 mmol) and refluxed at 100°C for 24 hours, yielding Amine-Paper, which was white. 
The paper was then washed on a Büchner funnel sequentially with tetrahydrofuran and 
EtOH, and dried in vacuo overnight. A second wash was conducted by shaking the paper 
in DMSO for 10 minutes on a vortexer, rinsing with acetone on a Büchner funnel, 
followed by drying. 
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  TCO-succinimidyl ester (TCO-NHS; Chapter 2, compound 5; synthesized as        
described previously 5) and TCO-PEG4-NHS (Click Chemistry Tools, Scottsdale, AZ, 
USA) solutions were prepared for reaction with Amine-Paper. 2 mg (0.0039 mmol) of 
TCO-PEG4-NHS in 389 µL of DMSO and 2.28 mg (.00853 mmol) of TCO-NHS in 853 
µL of DMSO yielded 10 mM stock solutions. Amine-paper was submerged in 5% (by 
volume) triethylamine in DMSO (TEA), then TCO-NHS or TCO-PEG4-NHS (TCO) 
stock solutions were added for a final ratio of 1:2 TCO:TEA. The resulting mixtures were 
gently tumbled at room temperature for 30 minutes to yield TCO-Paper and TCO-PEG-
Paper. The papers were then washed with DMSO, EtOH and acetone, and dried in vacuo. 
 
5.3.3. Characterization of Amine-Paper 
  For ninhydrin test, 1.5 µL of 2% ninhydrin solution was spotted onto a 4 mm-       
diameter circle of washed Amine-Paper or control unmodified Whatman #4 paper, 
followed by drying in a 150°C oven for 10 minutes. For N-hydroxysuccinimide coupling 
test, Bodipy 650/665-X, SE (Thermo Fisher Scientific, Waltham, MA, USA) was 
prepared as a 10 mM stock in DMSO, and then combined 1:2 by volume with 5% (by 
volume) triethylamine in DMSO. 1.5 µL of dye solution was spotted onto a 4 mm-
diameter circle of washed Amine-Paper or control unmodified Whatman #4 paper and 
allowed to sit for 15 minutes. The paper was then washed by shaking submerged in 
DMSO. Results were photographed with a DSLR camera under ambient light for visual 
readout or under a UV lamp at 365-nm irradiation for fluorescence images. 
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5.3.4. Testing and imaging of TCO-Paper using dyes 
  Bodipy FL-Tz, synthesized as described earlier202, and Texas Red-Tz (2.8) were        
prepared as 5 mM stocks in DMSO, and then combined 3:1 with water for final 3.75 mM 
dye in 75% DMSO / 25% H2O. 1.5 µL of dye solution was spotted onto a 4 mm-diameter 
circle of washed TCO-PEG-Paper, TCO-Paper or control unmodified Whatman #4 paper. 
The paper was immediately washed for 10-20 minutes by shaking submerged in 75% 
DMSO / 25% H2O. Results were photographed with a DSLR camera under ambient light 
for visual readout or under a UV lamp at 365-nm irradiation for fluorescence images. 
 
5.3.5. Printing and characterizing paper devices 
  Designs were made in Adobe Illustrator (Adobe, San Jose, CA, USA) and devices        
were printed using Yellow, Cyan, Magenta, and/or Black wax inks on a Xerox Phaser 
8560 wax printer (both Xerox Corporation, Norwalk, CT, USA). The wax was then 
melted into the paper on a hot plate to create hydrophobic barriers as described 
previously159. Papers were cut with scissors or with biopsy punch (Miltex, York, PA, 
USA). Solvents were introduced to the paper devices either by direct pipetting or by 
using a soaked cigarette filter (Premier brand filter tips) as the source. The wax channels 
were testing on 1 Chr paper against several hydrophobic solvents: EtOH, CH3OH, 
DMSO, and DMF, by adding 15 µL each to the end of wax-printed channels. 
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  1 µL of 125 µM Texas Red-Tz or 1 µL of 125 µM Texas Red-Tz and 1 µL of 63 µM        
19F-TCO were spotted onto wax-printed paper devices on which a 4-mm hole had been 
punched out with a biopsy punch and replaced with a 4-mm circle of TCO-Paper*. The 
channel portion of the device was suspended over a petri dish by using pieces of plastic 
(cut Disposable Micro Slides; VWR International, Radnor, PA, USA) as raisers around 
the edge of the paper, glued with rubber cement. An additional piece of plastic was placed 
over the TCO-Paper circle to hold it in place and attached to the waxed portions of the 
device using rubber cement. (See Appendix C for front and back view of device.) 75% 
DMSO in water was introduced to the device by placing a soaked cigarette filter at the 
top, and it was allowed to flow through the channel until the solvent front reached the end 
of the device. The device was then imaged on an Olympus OV110 imaging system 
(Olympus America) using brightfield and RFP imaging channels. 
*TCO-Paper for this experiment was acquired using a different synthetic approach than 
described above (somewhere deep in the lab notebooks of Thomas Reiner), and was 
adapted from previously published literature203. 
 
5.4. Discussion and Conclusions 
  Herein we show that we can perform cellulose chemistry on commercially available        
sheets of paper, including synthesizing clickable TCO-Paper. We then validated the 
chemistry using reactive dyes and performed click chemistry reactions in paper-based 
microfluidics lateral flow format. TCO-Paper has several potential applications, owing to 
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functionalized molecules. These include precise patterning of paper with biomolecules 
(including small molecules with Tz moieties) for detection or cell experiments (e.g. 
chemoattractants), as well as cheaper companion diagnostics tests. 
  One potential approach is to perform a competitive binding assay in which a clickable        
version of a drug (say, Ibrutinib-TCO) reacts with and blocks binding of a clickable dye 
(say, Texas Red-Tz) to a TCO spot in a lateral flow test. The amount of Texas Red in the 
binding spot would be inversely correlated with the amount of Ibrutinib-TCO. The 
amount of Ibrutinib-TCO available for the blocking would depend on the assay design, 
but could depend on either BTK target abundance or blocking of BTK target by 
unlabeled drug (e.g. occupancy test). Similar work was previously done using a 
nanoparticle-based approach204. The design of a dual-moiety clickable/fluorescent ligand 
would also be possible depending on the application. Visible or turn-on probes could 
cheapen this type of test so that a microscope is not needed for detection; alternatively, 
new technologies, such as portable fluorescence microscope could lower the cost of 
readout. 
  Overall, the ability to perform chemical assays on paper could lower the cost and        
increase the portability of drug sensitivity, compliance, and efficacy screening for 
resource-poor settings and home healthcare, bringing more complex diagnostics to the 
point-of-care. 
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Conclusion 
   
  BTK imaging with Ibrutinib-BFL and microfluidics-enabled CNS lymphoma 
profiling were technologies developed in parallel, as applications of effective, novel 
companion diagnostic approaches for B-cell lymphomas, but their potential intersection 
may be particularly beneficial for improving clinical trials and patient care. Since it is 
currently difficult in the clinic to determine which patients are at risk for CNS 
involvement, it is in standard practice to protect against it with prophylactic intrathecal 
injections of chemotherapy drugs, typically methotrexate205. While methotrexate has been 
used for decades, a recent clinical trial evaluated the efficacy of intrathecal Rituximab as 
a novel alternative206. To evaluate these therapeutics and still-newer drugs like BTK 
inhibitors, we can expand upon the use of the technologies developed herein. 
  We have already shown that the microfluidic chip can be potentially useful in drug 
imaging; it also has possible applications for on-chip drug screening and 
pharmacodynamic testing. This can include correlating dose and cell death, testing cell 
uptake of nanoparticle-carried drugs, screening for drug resistance (e.g. for resistance to 
covalent BTK inhibitor binding207), evaluating combinations of drugs, and plotting drug 
uptake and effects across populations of cells to look at cell-to-cell heterogeneity83. These 
studies are not limited to CNS lymphoma, and on chip drug imaging could be a useful 
tool for investigating biomarkers and target engagement for other suspension cell 
populations. The discrete cell capture sites provide a convenient platform for large-scale 
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benchmarks for drug efficacy in lymphoma subtypes13. 
   Additionally, drug-based imaging agents may be useful for targeted CNS lymphoma 
PET. Ibrutinib's consistently strong performance thus far in clinical trials for other B-cell 
malignancies 208, as well as previous cell studies of sensitivity to BTK inhibition, suggest 
that it is likely to be found to be effective for treating ABC-type DLBCLs14. Since the 
ABC molecular signature is a hallmark of primary CNS lymphomas, Ibrutinib may 
indeed emerge as a potential therapeutic for delivery by intrathecal injection or perhaps a 
nanoparticle formulation to bypass the blood-brain-barrier (BBB). Using new mouse 
models of CNS lymphoma209, it may be possible to test targeted PET imaging across the 
BBB using an Ibrutinib probe. Although Ibrutinib-BFL is unlikely to be BBB-permeable, 
perhaps a two-step click chemistry approach would allow for imaging. Recently, it was 
shown that 18F-TCO can be delivered to the brain210. It is therefore reasonable that 
following intrathecal administration of Ibrutinib-Tz to lymphoma cells in the CNS, 
uptake and drug levels could be measured at various time-points using 18F-TCO delivered 
intravenously via PET imaging. This approach for tracking novel intrathecal treatments 
non-invasively could be expanded to additional CNS lymphoma therapeutics or other 
non-therapeutic targeted imaging agents. 
  In all, targeted companion diagnostics and B-cell lymphoma treatment profiling either 
in vitro or through imaging will improve our understanding of drug efficacy across 
therapeutic classes and specific patient subgroups, enabling effective drug development 
and personalized, precise treatment strategies for these diseases. 
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Appendix A 
Additional methods for Section 2.6 
 
 
 
Compound name 
in Chapter 2
Compound name 
in Appendix A
2.10 1
2.11 2
2.12 3
2.13 4
2.14 5
2.15 6
2.3 7
2.16 8
2.17 9
2.18 10
2.19 11
2.20 12
2.21 13
2.22 14
2.23 15
2.24 16
2.25 17
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Appendix B 
NMR spectra of compounds in Chapter 3 
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Appendix C 
Images of paper-based device in Chapter 5 
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